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ABSTRACT
DETERMINA nON OF IN SILICa RULES FOR PREDICTING SMALL MOLECULE
BINDING BEHAVIOR TO NUCLEIC ACIDS IN VITRO
Patrick Andrew Holt
May 21,2010

The vast knowledge of nucleic acids is evolving and it is now known that DNA
can adopt highly complex, heterogeneous structures. Among the most intriguing are the
G-quadruplex structures, which are thought to playa pivotal role in cancer pathogenesis.
Efforts to find new small molecules for these and other physiologically relevant nucleic
acid structures have generally been limited to isolation from natural sources or rationale
synthesis of promising lead compounds.

However, with the rapid growth in

computational power that is increasingly becoming available, virtual screening and
computational approaches are quickly becoming a reality in academia and industry as an
efficient and economical way to discover new lead compounds. These computational
efforts have historically almost entirely focused on proteins as targets and have neglected
DNA.

We present research here showing that not only can software be utilized for

targeting DNA, but that selectivity metrics can be developed to predict the binding
mechanism of a small molecule to a DNA target. The software Surflex and Autodock
were chosen for evaluation and were demonstrated to be able to accurately reproduce the
known crystal structures of several small molecules that bind by the most common
nucleic acid interacting mechanisms of groove binding and intercalation. These software

IV

were further used to rationalize known affinity and selectivity data of a 67 compound
library of compounds for a library of nucleic acid structures including duplex, triplex and
quadruplexes. Based upon the known binding behavior of these compounds, in silica
metrics were developed to classify compounds as either groove binders or intercalators.
These rules were subsequently used to identify new triplex and quadruplex binding small
molecules by structure and ligand-based virtual screening approaches using a virtual
library consisting of millions of commercially available small molecules. The binding
behavior of the newly discovered triplex and quadruplex binding compounds was
empirically validated using a number of spectroscopic, fluorescent and thermodynamic
equilibrium techniques. In total, this research predicted the binding behavior of these test
compounds in silica and subsequently validated these findings in vitro. This research
presents a novel approach to discover lead compounds that target multiple nucleic acid
morphologies.
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CHAPTER I

INTRODUCTION AND BACKGROUND

Modem day drug discovery has focused almost exclusively on targeting proteins.
While these efforts have resulted in many therapeutic successes, other classes of targets
such as nucleic acids have largely been ignored. In fact, fewer than 2% of currently
marketed drugs and biologicals target nucleic acids [1]. This is most unfortunate as
nucleic acids represent promising targets for indications ranging from microbial
infections to cancer [2-5].

In the past, this lack of focus on nucleic acids as small

molecule targets may be partly ascribed to limited knowledge of the diversity of nucleic
acid structure and function. Recently, much scientific progress has been made in the
understanding of the physiological relevance of duplex, triplex and G-quadruplex
morphologies of nucleic acids and these structures are becoming increasingly attractive
small molecule targets [2, 6-8]. Furthermore, various classes of small molecules have
been shown to bind to unique nucleic acids in a sequence and structurally specific
manner, as has been elegantly demonstrated by Dervan with the hairpin polyamides and
Chaires with multiple small molecule families [9-10]. This research has paved the way
for the approach of discovering novel small molecules that specifically target newly
discovered nucleic acids that may have particular therapeutic or clinical relevance.

1

Nucleic Acid Structures are Promising Small Molecule Targets

Nucleic acids have long escaped therapeutic targeting because of a lack of
knowledge and appreciation of the structural and functional diversity of these
macromolecules. It is now known that DNA can have tremendous diversity with respect
to structure, conformation and sequence. For example, DNA can exist as a single strand
or as duplex, triplex and quadruplex structures.

DNA can adopt a large number of

secondary and higher order structures in vivo, including the standard B-form duplex DNA
as well as other duplex structures such as the Z-form duplex DNA.

The sequence

composition also adds a unique dimension of diversity to DNA. Small molecules have
been discovered that may bind to particular DNA structures with moderate selectivity and
modulate biological activity in vivo. One example is the small molecule telomestatin,
which has been shown to bind to G-quadruplex structures with a greater than 70 fold
preference compared to duplex DNA and has possible anti-cancer cell activity [11]. This
suggests that it is possible to identify small molecules with a preference for specific
nucleic acid structures. The discovery of novel small molecules to date appears to be
mostly limited to isolation from natural sources and chemical synthesis and sorely
overlooks the capability of in silico virtual screening and computational approaches.

Virtual Screening Approaches for Discovering New Drugs

In silico virtual screening techniques are valuable computational tools for the
discovery of new small molecules that can bind to a target of interest [12]. Indeed,
computational methods have been integrated into the discovery process for over 50
compounds that are in clinical trials as well as marketed drugs [13]. Table 1 shows

2

Table 1. A sampling of the various target classes for which ligands have been
successfully identified by computational approaches.
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Table 1. A sampling of the various target classes for which ligands have been
successfully identified by computational approaches. Adapted from [14].

Target Family

Target Name

Manuscript
Reference

Enzyme

Renin

[15]

Drug Metabolizing Enzymes

Cytochrome P450s

[16]

Kinases

Protein Kinase C

[17]

Transporter

Na+/D-glucose co-transporter

[18]

Receptor

AMP A receptor

[19]

Channels

Potassium and Sodium Channels

[20]

Transcription Factors

AP-l transcription Factor

[21 ]

Antibacterial

Mycobacterium tuberculosis thymidine

[22]

monophosphosphate kinase
Antivirual

N euroamidase

4

[23]

compounds that have been discovered using various computational methods against a
wide array of target classes emphasizing the importance of in silico approaches in
discovering new compounds in many research areas.
The benefits of virtual screening are its speed, accuracy, hit rates and
affordability, which circumvent the often laborious, slow and expensive process of
synthesis of novel small molecules for testing purposes. These benefits have accelerated
the adoption of virtual screening in the drug discovery process and it is estimated that up
to 20% of new drugs will be found by virtual screening methods in the year 2010 [24].
There are multiple ways to perform in silico virtual screening experiments as well as
many small molecule databases that can be used for in silico screening that will be
described in detail below.
Virtual screening experiments are typically considered to be either structure-based
or ligand-based [25]. Structure-based virtual screening methods require the availability
of an in silico structure of the target. This structure is usually obtained through highresolution X-Ray crystallography techniques or by NMR methods. Some of the most
widespread resources for many in silico solved structures are the RSCB protein data bank
(PDB) and the Nucleic Acid Database (NDB).

These databases are popular as the

structures can be visualized through a web interface and downloaded directly for virtual
screening experiments. Structure-based virtual screening uses various software packages
to screen millions of compounds to determine how well each compound can fit into a site
on the three dimensional target of interest [26]. This approach involves both "docking"
the compounds to the target as well as "scoring" the poses and determining which pose is
"correct" [27]. The "scoring" and ranking of the top poses of each ligand in the binding
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pocket of the target is one of the most challenging aspects of docking [12]. Molecular
docking using programs such as DOCK, Autodock, Ludi, FlexX and Surflex-Dock have
been used to find many lead molecules against a variety of targets, of which the vast
majority are proteins such as thymidylate synthase, retinoic acid receptor, kinases,
estrogen receptor and thrombin [14, 28-30]. The use of molecular docking appears well
entrenched in academia and industry and its use will likely increase as virtual databases
of small molecules and drug targets continue to expand.
A second type of virtual screening approach is referred to as ligand-based virtual
screening which requires knowledge of the structure of a biologically active ligand. The
structure of the active compound is compared to millions of other chemical compounds to
check for chemical and morphological similarity. The premise is that if the structure of
the test compound is similar to that of the known active compound, then the test
compound may possess similar biological activity [27]. If multiple small molecules are
known to possess similar biological activity, a "pharmacophore" can be constructed
which describes the ligand chemical properties that are necessary for a ligand to interact
with its target. This "pharmacophore" modeling can be particularly useful to detect a
wide number of compounds with diverse chemical features [25]. One consideration with
ligand-based virtual screening that it does not require knowledge of the structure of the
target. This can be advantageous because it can be difficult and sometimes controversial
to actually use the "correct" structure of the target for docking studies. However, it is
also disadvantageous in that critical interactions of the active compound with the target
such as hydrogen bonding and steric interactions may not be effectively visualized and
assessed. Ligand-based virtual screening is a popular approach to look for derivatives of

6

known biologically active compounds.

This approach has also been used to enrich

databases for possible selection of lead compounds [27]. Programs such as FlexS, fFlash
and Surflex-Sim have been previously used with success for ligand-similarity based
searches [25].
A final aspect of virtual screening is the importance of the repository of small
molecules that are used for screening experiments.

The database of compounds for

virtual screening has increased dramatically in recent years, with tens of millions of
compounds currently available in multiple databases [27]. In our own experience, one of
the ZINC databases that we use for virtual screening experiments has increased from
approximately 2.7 million compounds in 2007 to over 10.6 million compounds in 2009,
the vast majority of which are purchaseable from vendors world-wide. The value in
having large databases is the large chemical space that these compounds encompass.
This vastly increases the number of small molecules considered as possible lead
candidates which is favorable compared to the relatively few molecules that are evaluated
by actual chemical synthesis and other drug discovery techniques. Additionally many of
the in silica libraries have been filtered based on specific criteria (for example, Lipinski's
Rule of 5) to increase the chance that the molecules are "Drug-Like" in behavior. In the
case of Lipinski's Rule of 5, a structural analysis was performed on a large library of
drugs that are either currently marketed or in clinical trials. The following rules were
developed (coined "Lipinski's Rule of 5") to characterize a small molecule as "DrugLike" as the vast majority of compounds that were in the library possessed these
properties:

~5

hydrogen bond donors,

~1 0

hydrogen bond acceptors,

~500

daltons

molecular weight and ~5 octanol-water partition coefficient (Log P) [31]. Taken in total,
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virtual screening against large databases of compounds rationally explores a much larger
chemical space than using other approaches such as chemical synthesis and represents a
novel way to discover new lead candidate small molecules against a target of interest.

Virtual screening targeting DNA forms has been largely ignored
While the use of virtual screening for the discovery of new ligands that target
proteins has been well established, very few studies have been performed with nucleic
acids [2, 32]. This may be partly because almost all virtual screening software has been
designed for proteins, and may not account for characteristics that are particularly
important to nucleic acids such as their distinct geometrical symmetry and the
electrostatic effects of the phosphate backbone.

Moreover, there are few published

reports of the use of these programs to target nucleic acids [33-34]. Perhaps the greatest
gap in knowledge in this area is the lack of a systematic study to determine whether
docking software can accurately reproduce known crystal structures of ligands bound to
nucleic acids and also predict the binding mechanisms of small molecules to nucleic
acids, which we address here.
Small molecules typically interact with duplex nucleic acids by binding to the
minor groove or by intercalation between existing base pairs [4, 10, 35]. The geometry
of the grooves of triplex and quadruplex structures may have structural features that make
these nucleic acids unique compared to the major and minor grooves of duplex B-DNA.
The quadruplex structures in particular have diverse loop regions that may be functional
targets for small molecule binding. It is of primary interest to develop virtual screening
metrics that can differentiate small molecules that bind by either minor groove binding or
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intercalation. This is important because correctly predicting the nucleic acid structural
selectivity and binding mechanism of small molecules is critical for understanding the
therapeutic potential and non-specificity of a ligand. It remains of paramount importance
to first, ascertain whether molecular docking software can be used to target nucleic acids
and second, if novel rules can be developed to predict nucleic acid structural selectivity
and the binding mechanism of a given small molecule. This will serve dual roles in
filling a major basic science knowledge gap in predicting how small molecules bind to
nucleic acids and also provide potentially enormous opportunities for translating this
knowledge into the discovery of new therapeutic small molecules.

Limitations in Previous Virtual Screening Studies

A limited number of virtual screening studies against nucleic acids suggest that it
is possible to successfully target these structures for small molecule discovery. The
DOCK program in particular was used by Grootenhuis and Chen to target duplex DNA
and RNA, respectively [33, 36-37]. Rohs et al. used a Monte Carlo algorithm to assess
binding of methylene blue to DNA [38]. Shafer and Kuntz discovered a carbocyanine
dye (DODC) that binds to G-quadruplexes [39]. Finally, Evans et al. appears to have one
of the most comprehensive studies assessing minor groove binders to DNA using
Autodock [34]. However, the Evans study was limited and did not assess ligands that
bind by intercalation and did not exhaustively explore the Autodock parameters, which
can significantly affect docking performance and outcome. While all of these studies
suggest it is possible to use virtual screening to target nucleic acids, none of the studies
comprehensively compared the ability of the software to reproduce mUltiple minor
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groove binder and intercalator crystal structures or assessed the software for large scale
virtual screening feasibility. A major deficiency of the studies is a lack of a knowledge
base for in silica prediction of the mechanism of action of a ligand.

Experimental Validation of Predicted In silico "Hits"

A necessary complementary technique to any virtual screenmg approach is
empirical testing of the "hits" that are identified from the in silica virtual screen. This is
important to distinguish the false from true positive hits from the in silica screening data
[27]. There is much debate about which techniques are appropriate for assessing the
interaction of a small molecule with an array of nucleic acids.

Several methods include

ESI-MS (Electro spray Ionization Mass Spectroscopy), FRET-melting (Flourescence
Resonance Energy Transfer), SPR (Surface Plasmon Resonance), Fluorescence
Intercalation Displacement Assay (FID) and competition dialysis [40]. The method of
competition dialysis is preferred as it has distinct advantages over the others, although the
methods of FID has advantages as well and is complementary to competition dialysis.
For example, ESI-MS requires changing the salt condition of the nucleic acid out of
sodium and potassium and typically into ammonium acetate, which may dramatically
impact the structure of nucleic acid morphologies, particularly the therapeutically
relevant quadruplex structures [40-43]. FRET-melting suffers from having to modify the
oligonucleotides with a fluorescent probe and possible ligand-probe fluorescence
interference [40]. Finally, while SPR has the advantage of high sensitivity in assessing
small molecule-nucleic acid interactions, either the ligand or nucleic acid must typically
be covalently modified and bound to a chip for analyzing the interaction, as opposed to
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allowing the interaction to occur free in solution [40]. Additionally, great expertise is
required in choosing the appropriate chip for assessing the interactions as well as
significant capital expenditure in purchasing the instrument. For these reasons, ESI-MS,
FRET -melting and SPR techniques have substantial limitations for assessing the ligandnucleic interactions as described here. FID is complementary to competition dialysis and
may have particular utility if a small molecule lacks a suitable chromophore for
competition dialysis testing. The assay relies upon the known intercalation of a reporter
dye such as ethidium bromide or thiazole orange into a DNA of interest.

The

fluorescence of such reporter molecules is markedly increased upon binding to the
nucleic acid and quenched when free in solution.

Thus, the assay can be used for

competition experiments where small molecule can be added to a solution containing
DNA and thiazole orange and the fluorescence of thiazole orange can be monitored to
determine if it is bound or displaced from the DNA. We describe in more detail the use
of this assay for characterizing the binding mode of some newly discovered compounds
in Chapter V.
On the other hand, competition dialysis is a simple, rapid technique that has
gained world-wide acceptance as a way to quantitatively and rigorously assess the
binding of small molecules to nucleic acids [10]. The assay can determine the sequence
and structural selectivity of a single ligand for any nucleic acid of interest. The setup
involves dialyzing a set of nucleic acids at identical concentration against a common
dialysate containing the ligand of interest. As the system reaches equilibrium, the ligand
will accumulate in the dialysis cassette containing the nucleic acid to which the ligand
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Figure 1. A drawing of the competition dialysis assay setup.
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Figure 1. A drawing of the competition dialysis assay setup. Adapted from [44].
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binds the tightest [10]. The ligand is then dissociated from the nucleic acid usmg
detergents and quantified by either absorbance or fluorescence. The current version of the
assay typically consists of 19 nucleic acid species including duplex, triplex and Gquadruplex morphologies. However, the original 19 structures is but a starting point for
the assay. The power of this assay is the customizability and freedom of choice of the
nucleic acid structures; essentially any unique nucleic acid sequence or morphology can
be added to the array of nucleic acids and tested for ligand binding. Additionally, the
technique allows for a comparison of the ligand binding properties for many nucleic acids
that are simultaneously free in solution. This highlights the substantial benefit of this
technique compared to the previously mentioned methods.

Competition dialysis has

proven valuable in assessing ligand affinity and selectivity for any nucleic acid species
and has particular utility as described here for testing the binding behavior of a small
molecule that is predicted from virtual screening metrics.

In sitico Discovery of Novel Small Molecules with Therapeutic Potential
The ultimate goal in our research is to combine our in silica research with actual
testing by competition dialysis and other techniques to provide an integrated platform to
discover new small molecules that bind to physiologically important nucleic acids. The
determination of predictive metrics for the purposes of discovering novel small molecules
that can bind nucleic acids could have substantial therapeutic benefit in many areas of
disease, most notably cancer. The CDC estimates from 2006 placed cancer as the second
leading cause of death in the United States, second only to cardiovascular disease. Most
recently in 2008 in the United States alone, an estimated 565,650 people succumbed to
cancer [45] which can affect many different organ systems (Figure 2). In fact, the
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Figure 2. Most Common Anatomical Sites for Cancer Deaths for Males (Top Figure) and
Females (Bottom Figure). Adapted from [46].
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Figure 2. Most Common Anatomical Sites for Cancer Deaths for Males (Top Figure) and
Females (Bottom Figure). Adapted from [46] . '
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Other

lifetime probability of a male developing cancer is 1 in 2 and I in 3 for females [47]. As
Figure 2 shows, cancer can arise in many anatomical positions and is a major cause of
morbidity and mortality in the United States. In recent years, the scientific and medical
community has developed new cancer drugs in response to the demand for new
treatments. A substantial number of cancer drugs have been approved that are now
considered essential for treating various forms of cancer. In particular, biologicals such
as monoclonal antibodies have become attractive treatments for specific cancers because
of their remarkable specificity and minimal adverse effects [48]. An example is
Cetuximab, an Epidermal Growth Factor Receptor (EGFR) Inhibitor, which is approved
for the treatment of locoregionally advanced squamous-cell carcinoma of the head and
neck (LASCCHN) [49].

While biologicals such as Cetuximab have undoubtedly

benefited patients, these large molecules are costly and time-consuming to manufacture
and the cost is prohibitive for many patients.
Even though the vast majority of new cancer treatments are focused on protein
targets, there are some existing therapeutics that work by targeting nucleic acids. The
anthracylines, for example, have been a key class of drugs that target DNA for cancer
chemotherapy for over 40 years, despite suffering from severe side effects [50-51]. An
example is cisplatin which is a chemotherapy drug that induces cross linking of DNA and
is indicated for the treatment of various sarcomas and head and neck cancers.
Unfortunately, the major limitation of current nucleic-acid based therapies such as
cisplatin is target non-specificity and toxic side effects, which include in the case of
cisplatin, severe ototoxicity and neurotoxicity [52]. The development of new anti-cancer
drugs based on nucleic acid targets has stagnated until recently.
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A new area of cancer drug development is in the area of G-quadruplex nucleic
acid structures. These quadruplexes have been observed in the human telomeric region
of chromosomes and have a novel mechanism of possibly inhibiting cancer cells
replication [53]. Since over 85% of cancer cells overexpress the reverse transcriptase
enzyme telomerase, cancer cells are able to maintain the human telomere sequence
(TTAGGG)n which is responsible for cancer cell immortality [54].

G-quadruplex

structures have been shown to destabilize telomerase from the telomere, resulting in
decreasing cancer cell life [55]. Thus, these quadruplexes have become a source of great
interest for the identification of highly selective, small molecules that may bind and
stabilize the structures in vivo, and inhibit telomerase activity. In fact, there are several
G-quadruplex interacting small molecules currently in clinical trials including Quarfloxin
(Cylene Pharmaceuticals). This area is one of the most promising areas of current antineoplastic small molecule development. As we will describe next in the Dissertation
Overview, we target tetraplex nucleic acids to test the therapeutic utility of these novel,
predictive, virtual screening metrics. Additionally, the morphologically distinct triplex
nucleic acids are targeted because of their ability to potentially modulate gene expression
[56-58]. Targeting of triplex and tetraplex nucleic acid structures will demonstrate the
power and utility of this new scientific knowledge for the identification of small
molecules that can selectively bind to these targets.

Dissertation Overview

In silico virtual screening approaches have been under-utilized for small molecule
discovery because of the inability to predict how small molecules interact with nucleic
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acids. There is a clear need to detennine if this behavior can be predicted in silica and
validated in vitro. To meet this need, the goal of this research is to detennine if rules can
be developed to predict the binding behavior of novel small molecules to therapeutically
relevant nucleic acids.
The first goal of this research as detailed in Chapter II is detennining if virtual
screening methods can be used for targeting nucleic acid structures. Two software
packages Surflex and Autodock, are selected for the purposes of validating nucleic acids
as feasible targets.

Autodock is selected because it is one of the most widely cited

molecular docking software [59]. Surflex is chosen since it has the proven advantage of
rapid docking which may have particular utility for large scale virtual screening
applications [60]. This is a key initial step in this research, as it must be detennined if the
currently available software is appropriate for evaluating small molecule interactions with
nucleic acids. Four nucleic acid-ligand structures were chosen that represent the two
major mechanisms (minor groove binding and intercalation) that small molecules use to
bind to nucleic acids.

The anti-malarial drug pentamidine and the antiviral drug

distamycin are two well known drugs that bind to the minor groove of duplex nucleic
acids [5, 61]. Daunorubicin and ellipticine are anti-neoplastic drugs that were selected as
prototypical nucleic acid intercalators [62]. We demonstrate that both Autodock and
Surflex are able to accurately reproduce the in silica structures of these ligand-nucleic
acid complexes. Interestingly, the docking results change dramatically with the various
paramaters that can be customized with the software.

The "optimal" parameters for

balancing docking accuracy and ranking were detennined and serve as the basis for the
software operation for the remaining chapters of this dissertation. The results of the work
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support the use of Surflex in particular for virtual screening applications as the software
was found to be approximately 10 fold faster than Autodock with comparable docking
accuracy and ranking.

Some considerations and limitations of the software are also

detailed. The results of this work are published in P.A. Holt et al [63].
After demonstrating that molecular docking software can reproduce multiple
known ligand-nucleic acid crystal structures, the focus of Chapter III is on whether rules
can be developed to predict the nucleic acid structural specificity and binding mechanism
of a ligand. This is significant as a major hurdle to current drug development is small
molecule non-specificity, which can result in drug toxicity and significant adverse
effects. An in silica nucleic acid library with 10 structures was constructed including
duplex, triplex and quadruplex morphologies of nucleic acids with appropriate groove
binding and intercalation sites for docking the ligand. The small molecules from Chapter
II (daunorubicin, distamycin, ellipticine and pentamidine) were docked to the compounds
and in silica rules were developed to classify the binding mechanism and sequence
selectivity of these molecules, based on their known binding behavior. The rules were
tested on several triplex and quadruplex binding ligands that our lab has recently
discovered as well as on a set of 67 minor groove binder and intercalator compounds that
have been previously tested by competition dialysis [10]. The results showed that the
metrics were able to generally accurately predict whether the compounds were groove
binders or intercalators, but predicting sequence specificity was more challenging. In
general, Surflex appeared to outperform Autodock and appears more appropriate for large
scale virtual screening efforts.
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The knowledge gained from Chapters II and III is utilized for the discovery of
new ligands that can bind to a specific nucleic acid and this work is described in Chapter
IV.

In this chapter, both ligand and structure based virtual screening techniques are

combined as well as utilizing the established in silica selectivity metrics to discover new
triplex nucleic acid binding small molecules. Chaires et al. have previously identified a
set of napthylquinoline ligands that were demonstrated by competition dialysis to be
highly selective triplex poly(dA)-[poly(dT)h intercalators [44].

One of these

napthlyquinolines in particular, MHQ-12, was used as the parental ligand in a similarity
search against millions of in silica compounds. For the top similarity hits, additional
structure-based docking studies were performed and in silica selectivity metrics were
applied. Two novel compounds were discovered that were tested by competition dialysis,
UV/Vis thermal melting and circular dichroism and were demonstrated to be highly
selective intercalators into the targeted triplex DNA.

This demonstrated the practical

application of the in silica metrics that were discovered in the previous chapter and shows
that novel small molecules can be discovered using an integrated in silica and biophysical
testing platform. The results of this work are published in P.A. Holt et at [64].
Chapter V focuses on the structure-based targeting of G-quadruplex nucleic acids
for the purposes of discovering new small molecules. The work details the targeting of
the AGGG(TTAGGG)3 G-quadruplex which is found with increasing frequency in the
single stranded overhang of the human telomeric region of chromosomes. Using the
previously optimized software parameters, Surflex and Autodock were used to screen
over 6.6 million compounds that may interact with the G-quadruplex. Ligands that bind
by intercalation or at the end of quadruplexes (by "end pasting") are particularly
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appealing as they may stabilize the quadruplex structure by interactions with the guanine
quartets. Stabilization of G-quadruplexes can dissociate telomerase and result in
decreased cancer cell proliferation [55].

A consensus scoring approach was applied

which combines the top scoring results for Surflex and Autodock and re-ranks the results.
The top compounds were tested by spectroscopic and fluorescent methods and a
compound was discovered that interacts with the G-quadruplex DNA by the hypothesized
binding mechanism.
literature.

Moreover, the scaffold is unlike any reported to date in the

The work in this chapter is a practical application of the knowledge

discovered in previous chapters and demonstrates that the software and approach as
developed in this work, is capable of discovering new small molecules that bind to a
nucleic acid by a specific mechanism.

Summary

While nucleic acids represent a viable class of drug targets for in silico virtual
screening, progress has been hampered by the lack of virtual screening rules that can
predict the binding mechanism of a ligand to a nucleic acid target. The development of
predictive rules is an essential step to discover novel small molecules to fight disease. It
is also a critical part in an integrated virtual and actual screening platform that can screen
millions of compounds in silico and biophysically test the most promising compounds
identified from the initial computational screen. While there has been much progress in
the research and understanding of nucleic acids, the therapeutic development of targeting
nucleic acids lags behind. This appears to be due to a lack of a rapid, efficient and
economical approach to identify selective small molecules that can bind to nucleic acids.
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Determination of predictive rules, as described herein, addresses this knowledge gap by
making it possible to better understand and predict the interaction of small molecules
with nucleic acids. We believe this new information will ultimately facilitate the
discovery of novel ligands that target therapeutically relevant nucleic acids.
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CHAPTER II
MOLECULAR DOCKING OF INTERCALATORS AND GROOVE BINDERS TO
NUCLEIC ACIDS USING AUTODOCK AND SURFLEX

This chapter describes the validation of selected virtual screening software for the
purposes of targeting nucleic acids. We demonstrate here that the molecular docking
tools Autodock and Surflex accurately reproduce the crystallographic structures of a
collection of small molecule ligands that have been shown to bind nucleic acids. Docking
studies were performed with the intercalators Daunorubicin and Ellipticine and the minor
groove binders Distamycin and Pentamidine. Autodock and Surflex dock Daunorubicin
and Distamycin to their nucleic acid targets within a resolution of approximately 2

A,

which is similar to the limit of the crystal structure resolution. However, for the top
ranked poses, Autodock and Surflex both dock Ellipticine into the correct site but in a
different orientation compared to the crystal structure. This appears to be partly related to
the symmetry of the target nucleic acid, as Ellipticine is able to dock from either side of
intercalation site but also due to the shape of the ligand and docking accuracy. Surflex
docks Pentamidine in a symmetrically equivalent orientation relative to the crystal
structure, while Autodock was able to dock this molecule in the original orientation. In
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the case of the Surflex docking of Pentamidine, the initial RMSD is misleading, given the
symmetrical structure of Pentamidine. Importantly, the ranking functions of both of the
programs are able to return a top pose within approximately 2 A RMSD for
Daunorubicin, Distamycin and Pentamidine and approximately 3 A RMSD for Ellipticine
compared to their respective crystal structures.
Finally, we also discuss some docking challenges and potential pitfalls when
using these software tools, such as the importance of hydrogen treatment on ligands as
well as the scoring functions of Autodock and Surflex. Overall for this set of complexes,
Surflex is preferred over Autodock for virtual screening, as although the results are
comparable, Surflex has significantly faster performance and ease of use under the
optimal software conditions tested. These experiments show that the molecular docking
techniques can be successfully extended to include nucleic acid targets, a finding which
has important implications for virtual screening applications and in the design of new
small molecules to target therapeutically relevant morphologies of nucleic acids. The
results and conclusions of this scientific research were published by P.A. Holt et al [63].
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Introduction
Molecular docking techniques have shown great promise as a new tool in the
discovery of novel small molecule drugs for targeting proteins [60, 65-67].

Fewer

molecular docking studies have been performed targeting nucleic acids structures, despite
advances in the understanding of the functional importance and the unique structural
features of duplex, triplex and G-quadruplex morphologies [2, 6-8, 32]. This is
unfortunate since not only are there clinically used drugs that target nucleic acids, but
many forms of nucleic acids are becoming an increasingly attractive target for antineoplastic and anti-microbial agents [2-5, 10, 44, 61, 68-70]. The few docking studies in
which nucleic acids are targeted have focused on such sites as the minor groove of DNA,
a tetraloop structure of RNA and the major groove of an RNA duplex, while rarely
targeting intercalation sites which also hold therapeutic potential [33-34, 36-37, 71-72].
The use of molecular docking has important implications for the synthesis and
development of small molecule drugs that selectively target nucleic acids since these
techniques have the potential to shed light on the interaction and mechanism ofaction of
these ligands with targets that may have medicinal value.
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Small molecules can interact with nucleic acids at multiple sites to alter nucleic acid
function [71, 73-74]. In the case of duplex DNA, one drug class binds within the minor
groove and a second class intercalates between existing base pairs of the nucleic acid
structure [4, 10, 35]. Intercalators and groove binders have distinct thermodynamic
signatures that indicate different driving forces for binding [75]. The minor groove is an
attractive target for small molecules since this site has less competition from proteins and
polymerases, which typically interact with the major groove [5]. An exeption are histone
tails which can bind in the minor groove of DNA. The closer proximity of the strands in
the minor groove compared to the major groove allows more contact surface area for a
small molecule to bind tightly [76]. The unfavorable geometry of the major groove is
another reason why few drugs target this groove [71]. Two well-known minor groove
binders are the anti-malarial drug Pentamidine and the antiviral drug Distamycin, which
we selected for our studies [5, 61, 77-78]. While only limited docking studies have been
performed with minor groove binders, even fewer studies have tested whether drugs that
act through intercalation can be modeled successfully using docking methods [4, 66]. We
selected two prototypical intercalators, Daunorubicin, a drug commonly used to treat
certain forms of leukemia, and Ellipticine, another anti-neoplastic drug, for docking
experiments using Autodock (4) [79] and Surflex (2.11) (Figure 3) [80].
Autodock 4 and Surflex 2.11 have been used previously for protein-ligand
docking, but very few studies have been performed using nucleic acids as targets [2].
Autodock is a logical selection for further exploration as it has been shown in some cases
to be superior to DOCK, FlexX and GOLD at reproducing the crystallographic pose of
ligand-protein complexes [81]. Surflex was chosen because it has rapid computational
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Figure 3. Chemical structures of the four test ligands used in the Autodock and Surflex
docking studies. (A) Daunorubicin, (B) Distamycin, (C) Ellipticine and (D) Pentamidine.
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Figure 3. Chemical structures of the four test ligands used in the Autodock and Surflex
docking studies.
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speed with protein-ligand docking which could prove useful for virtual screening [60].
Autodock and Surflex have important differences in search algorithms and scoring
functions. A search algorithm is initially used for conformationally sampling the ligand
and target interactions, and scoring functions are used for evaluating and ranking the final
poses of the ligand to determine the "correct" pose [82].
Autodock performs molecular dockings by pre-calculating energy grids around a
site of interest on the target [83]. A stochastic search algorithm utilizing the Lamarkian
Genetic Algorithm (LGA) for exploring the grid space is used to perform energy
evaluations of the position of the ligand with respect to the target energy grids [83]. This
algorithm explores the various orientations and conformations of the whole ligand
relative to the energy grids for the defined number of energy evaluations and returns the
lowest energy conformation in the target site [83]. The LGA has found particular utility
in modeling systems with large numbers of rotatable bonds and possible numbers of
conformations [83].

Surflex uses a so-called "whole" molecule alignment algorithm

based on morphological similarity between the ligand and target [60]. This docking
approach aligns the ligand to a "protomol" or idealized ligand in the active site of the
target [60]. The protomol is composed of a collection of fragments or probe molecules
that characterize the surface morphology of the binding site [84]. These probe molecules
consist of CH4 ,

c=o and N-H fragments that model steric effects in the binding pocket,

hydrogen bond acceptor groups and hydrogen bond donor groups, respectively [60, 84].
The docking ligand fragments are checked for alignment and similarity against the
protomol probes [60]. This is referred to as a "whole" molecule approach because after
the initial ligand fragmentation, both the small fragment and the rest of the "whole"
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ligand are carried into the protomol binding site [60]. However, only the small fragment
is checked for similarity and alignment against the protomol, while the rest of the
"whole" ligand is assessed for steric interactions in the target site after optimal alignment
of the fragment [60). This "whole" molecule approach is powerful because it considers
the subsequent position of the rest of the "whole" molecule with respect to the target after
the small fragment is optimally aligned with the protomol [60].

This is an important

difference between Autodock and Surflex, since Autodock involves evaluation of the
conformations of the whole ligand without ligand fragmentation [83).
The scoring functions for Autodock and Surflex are partially empirically based,
with Autodock incorporating an Amber type force field and Surflex calculating atom to
atom pairwise interactions between the ligand and target [60, 83, 85]. Autodock evaluates
pairwise interactions based on van der Waals radii of the atoms to determine the free
energy of binding and returns the optimal lowest energy docked conformation as the best
docked pose [82). The Surflex scoring function is parameterized by calculating van der
Waals distances between protein and ligand and parameterization of the scoring function
was based on 34 protein-ligand complexes [86). Surflex assigns the atoms as either polar
or non-polar and then calculates a score based on hydrophobic and polar contacts
between the two atoms [67). The docked poses are then ranked according to the maximal
Surflex Overall score.
Aside from the algorithmic differences in Surflex and Autodock, there are several
other aspects of molecular docking in general and these programs specifically that present
challenges to successful docking of ligands to nucleic acids. First, because proteins have
attracted the most interest as drug targets, proteins have also been the focus of most
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docking efforts compared to nucleic acids [82]. This leads to the question of whether
these protein-configured docking programs will work for nucleic acids because of the
unique structural features of nucleic acids including their high charge density, exposed
binding sites, and distinct geometrical symmetry [82, 87].

Another challenge is the

dependence on crystal structures for visualizing how ligands interact with their targets
and for assessing the accuracy of docking software. This approach relies on both the
availability and resolution of the crystal structure. For nucleic acids, there are few crystal
structures of ligand-nucleic acid complexes available and even small variations in the
resolution of the atomic positions of the crystals can significantly affect the modeling of
important forces between the ligand and target such as hydrogen bonding [88].
Differences in scoring functions also present a challenge for docking, as ranking of the
poses is typically the most difficult aspect of docking [24, 89]. The coefficients and
weighting for the scoring function terms are calibrated based on ligand-protein
complexes, and it is unknown how well Autodock and Surflex would perform with
ligand-nucleic acid complexes [85]. Autodock and Surflex include entropic contributions
by accounting for conformational and tortional changes as well as a term for solvation
[60, 85]. However, the entropic contribution of solvation terms for most docking
programs has been difficult to incorporate accurately in scoring functions and could
contribute to erroneous pose ranking [82]. Another traditionally challenging area for
docking programs is accounting for target flexibility, since even small conformational
changes of the ligand in the binding pocket can cause dramatic changes in the scoring
function [67]. While Autodock has the option to explore side chain flexibility for protein
receptors, this function has not been extensively explored in the published literature for
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nucleic acids. Moreover, Surflex does not take target flexibility into account during
molecular docking [60]. To fairly compare the performance of these two programs, target
flexibility was not considered in these experiments. These are important considerations
when performing docking of ligands to nucleic acids using Autodock and Surflex, and
could significantly impact docking performance.

In spite of these challenges, however, we demonstrate that Autodock and Surflex
can accurately dock small molecules with different binding modes to nucleic acid targets.
More importantly, the ranking of the poses is also evaluated, which has been the more
challenging aspect for many docking programs [24, 89]. The minor groove binders
Distamycin and Pentamidine, and the intercalators, Daunorubicin and Ellipticine were
selected for docking studies since these small molecules have crystal structures that are
available in the Protein Data Bank (PDB). Autodock and Surflex software operating
parameters were evaluated to determine which parameters increase docking accuracy and
the successful ranking of the poses. Given the challenge of docking to nucleic acids,
some reasons for suboptimal docking are detailed, including the importance of hydrogens
on ligands, the scoring functions of the programs, and the quality of the crystal structure.
This collection of experiments demonstrate the utility of these programs for molecular
docking of ligands to target nucleic acids.

Experimental and Computational Methods

Virtual Library Preparation.

Ligand-nucleic acid complex crystal structures for

Daunorubicin, Distamycin, Ellipticine and Pentamidine were obtained from the Protein
Data Bank with identification numbers of 152d, 2dnd, lz3f and Id64, respectively. The
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resolutions of these structures are 1.4

A, 2.2 A, 1.5 A and 2.1 A, respectively.

Distamycin and Pentamidine are bound to the minor groove of DNA duplex dodecamers
d(CGCAAATTTGCG)z and d(CGCGAATTCGCG)z, respectively.

Daunorubicin and

Ellipticine intercalate between the Cytosine and Guanine nucleotides in the sequence
d(CGATCG)2. For the Ellipticine intercalation PDB structure, Maestro (8.0) [90] was
used to construct the symmetrical strand to form a complete, complementary, double
stranded DNA. For the intercalator nucleic acid targets, there were two intercalation sites
on the target. Thus, the 3' terminal Guanine residue was removed from the 6 base pair
sequence so that there would only be a single intercalation site in the target nucleic acid
structure. The ligand and nucleic acid targets were saved as separate files for docking
purposes.
The PDB files were visually inspected using Macromodel (7.0) [91] and all water
molecules were removed. Amber ligand atom types were assigned using Sybyl (7.3) [92]
and hydrogen atoms were added as appropriate. The program Antechamber in the
software suite Amber (8) [93] was used to assign AMI-BCC charges to the atoms in each
of the ligands and to also convert the files from PDB format to MOL2. Python scripts
were used to prepare the nucleic acid structures in PDBQT format with Gasteiger charges
for use in Autodock experiments while MOL2 files were used for Surflex experiments.
Autodock 4 Methods. Autodock 4 and the graphical user interface Autodock Tools

(1.4.6) [94] were compiled for a Macintosh OS X PowerMac G5 and Linux workstations.
Autodock Tools 1.4.6 was used for establishing the Autogrid points as well as
visualization of docked ligand-nucleic acid structures. The target site on the nucleic acid
was specified to encompass either the entire minor groove or the intercalation target site.
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Table 2. Autodock Grid Map Coordinate Dimensions and Grid Center Information
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Table 2. Autodock Grid Map Coordinate Dimensions and Grid Center Information

Test Ligand

Grid Point Characteristics

Grid Center Characteristics

(Dimensions)

(Dimensions)

X

y

Z

Total

X

Y

Z

Number of
Points
Daunorubicin

52

42

28

66091

14.332

13.212

5.489

Distamycin

34

50

64

98175

9.776

21.55

76.162

Ellipticine

58

32

40

79827

0.992

19.28

46.762

Pentamidine

34

54

52

102025

10.298

20.854

8.457
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The grid center was also established by centering the grid box on either the minor groove
or the intercalation site. The grid maps had a spacing of 0.375

A (Table 2).

Several available docking parameter options in Autodock 4 were systematically
varied to determine the optimal conditions for ligand-nucleic acid docking. These factors
include the number of total energy evaluations per docking run and also the total number
of docking runs performed. The total number of energy evaluations is the total number of
ligand-target energy interaction evaluations before the lowest energy conformation is
selected. These factors are suggested as logical starting areas of optimization as they
have previously been shown to impact ligand-protein docking studies [95]. The number
of energy evaluations per docking run was varied as 200,000 (2E5), 2,000,000 (2E6) or
20,000,000 (2E7). Docking runs were varied as 5, 10 or 20 runs. Thus, a total of nine
experiments were performed with varying numbers of energy evaluations and dockings to
determine if these factors would impact docking accuracy and ranking. All other docking
parameters were left at the default values. For the Autodock parameterization testing
experiment with 50 docks and 5E7 energy evaluations, the "ga_num_generations" was set
at

100,000.

Normally,

the

docking

run

will

terminate

when

either

the

"ga_num_generations" or the number of energy evaluations is reached, so the
ga_num_generations was increased to from 27,000 to 100,000 to ensure that 5E7 energy
evaluations was reached for these docking experiments [59].
SurJlex 2.11 Methods. Surflex 2.11 was compiled for a Macintosh OS X PowerMac

G5 and Linux workstations. The protomol was generated using a ligand-based approach,
where a small molecule is selected that fits into the site of interest. The structure of the
molecule in the site is then used for protomol generation. The protomol represents a set of
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Figure 4. Chemical structure of Furamidine, the ligand used to generate Surflex 2.11
protomols.
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Figure 4. Chemical structure of Furamidine, the ligand used to generate Surflex 2.11
protomols.
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molecular fragments that characterizes the active site and to which the ligand of interest
is fragmented and checked for both similarity and alignment [67]. Furamidine was
chosen as the ligand for protomol generation, as it has been previously shown to be a
minor groove binder and is small enough to fit into the intercalation site to ensure
adequate protomol generation (Figure 4) [4, 61, 96]. Importantly, this also reduces the
bias of the evaluation by not using the actual ligands to be docked and is a more realistic,
generalized docking approach. Two important factors that can significantly effect the size
and extent of the proto mol generated are "proto_thresh" and "proto_bloat" options.
"Proto_thresh" determines how far the protomol extends into the concavity of the target
site while "proto_bloat" impacts how far the protomol extends outside of the concavity
[97]. For the purposes of these experiments, "proto_thresh" was set to 0.2 and
"proto bloat" was left at the default (0) for all protomols generated except for
Daunorubicin, where a "proto_bloat" of 0.5 was used. Protomols were visualized with
Sybyl 7.3 to ensure proper coverage of the desired target area.
Surflex 2.11 offers many parameters that can be customized to help optimize
ligand targeted docking. An investigation of all of the combinations of these factors is
beyond the scope of this paper. Instead, two factors, the "Multistart 5" and "Random 5"
options, were selected as these are thought to have the potential to most significantly
impact the accuracy of the docked poses. The "Multi start 5" designation enables docking
to begin from 5 different initial starting positions around the designated target.
Previously, Jain et al. had observed little increase in successful docks with protein targets
beginning at a value of 5 ("Multi start 5"), relative to the additional computational
resources required for docking these extra conformations [97]. A "Random 5" option
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ensures that the ligand adopts 5 random X,Y,Z coordinate conformations prior to
initiating docking calculations. These options are both thought to be important since it
minimizes the chance that the ligand may be randomly assigned to an energetically or
conformationally unfavorable position from which it cannot recover during the docking.
A total of three experiments were subsequently performed, with the first having default
Surflex 2.11 options ("No Multistart", "No Random"), the second with implementation of
"Multi start 5" and the last experiment with implementation of both "Multi start 5" and
"Random 5" to test for a potential synergistic effect between these two options. All other
parameters were left at the default values.

RMSD Calculations. One metric for evaluation of the quality of docking results is the
difference in the X, Y ,Z coordinates between the docked pose and the known crystal
structure which can be used to calculate the Root Mean Square Deviation (RMSD)
between the two poses. For consistency in evaluation of docked poses, the Surflex 2.11
software RMSD method was used for calculation of the RMSD differences for both
Autodock and Surflex results based on only the heavy atoms. This method determines
the RMSD between the docked pose and the crystallographic structure using a direct
atom to atom comparison of the two structures. An additional Surflex RMSD function
(Actual RMSD ISO) was used to account for internal ligand symmetry. This function is
independent of atom numbering and computes isomorphisms between the crystal and
docked poses, returning the lowest symmetrical RMSD value [98].

The practice of

accounting for ligand symmetry is fairly universal and has been documented in previous
papers [99]. To address nucleic acid target symmetry, Macromodel 7.0 was used to flip
and superimpose the docked pose on the crystallographic pose. This involves copying
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the complex consisting of the ligand docked to the target nucleic acid and then selecting
to superimpose DNA bases from the copied structure onto the opposite DNA base of the
original structure.

Molecular superposition was performed using the "Superimpose

Atoms" (SuprA) function followed by the "Rigid Superposition" (RigSA) function. In all
cases, the resolution of the superposition was less than 0.15 A.

The superimposed

structures were saved and the coordinates were used for RMSD calculations. Surflex
docked poses are in a MOL2 file format which can be used directly by the Surflex
program for RMSD calculations. Autodock docked poses are in a PDB file format and
were converted to a MOL2 file format using Open Babel (2.1.1) [100] or iBabel [101]
(2.0) prior to RMSD calculations. Docked poses of Autodock and Surflex in the target
binding site were visualized using Autodock Tools.
Autodock and Surflex Scoring Function Methods.

Rescoring of all top ranked

Autodock and Surflex poses and the crystal structure poses was performed using the
Autodock and Surflex scoring functions. To rescore all of the poses using the Autodock
scoring function, the files were converted to Autodock PDBQT file format by merging all
of the non-polar hydrogens. The Autodock epdb command was used to calculate a free
energy of binding (kcallmol) for each of the poses. The Surflex "score list" command
was used to rescore the top ranked poses using the Surflex scoring function. Macromodel
was used to add hydrogens to the crystal structures and to the top ranked Autodock poses
which normally only has polar hydrogens added for docking purposes. The Surflex
scoring function ranks poses by an affinity score, pKd [97].

To fairly compare the

docking poses for these two programs, the Surflex pKd results were converted to free
energy of binding (kcallmol), as previously described, where RT = 0.59 kcallmol [102]:
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Free Energy of Binding = RT loge(10-pKd)

Macromodel Energy of Binding Methods.

(1)

Macromodel was used as a third,

independent software to calculate the energy of binding of the poses using different force
fields and solvation. All hydrogens were added, as previously described. The energy of
binding was determined in structures with and without energy minimization of the
hydrogens, as follows:
(2)

Energy of Binding = Ecomplex - Eligand - Enuc1eic acid

Where: Ecomplex is the energy of the docked ligand in the target and the Eligand and Enuc1eic
acid represent the individually calculated energies. Energy minimization was performed
by the Polak-Ribier Conjugate Gradient (PRCG) method for 1000 iterations with a
convergence threshold of 0.05. The force fields were set at either Amber* or OPLS2005,
with and without implicit water solvation to show the effects of these factors on the
energy of binding. The experiments with no implicit water solvation were performed
with distant dependent electrostatic treatment with a dielectric constant of 4.0 and an
extended cutoff. The experiments with water solvation were performed with a constant
dielectric electrostatic treatment with a dielectric constant of 1.0 and a normal cutoff.

Results and Discussion
Few studies have been performed to determine if molecular docking techniques
such as Autodock and Surflex can dock ligands accurately to nucleic acids. We compare
two poses derived from the docking calculations, the lowest RMSD pose for accuracy
comparisons, and the top ranked pose for ranking comparison. A common metric for
evaluation of accurate doc kings is to calculate the RMSD between the crystallographic
pose and the docked conformation. A level of significance of 2
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A will

be evaluated to

facilitate a comparison of these data to docking data in other reports [2, 86, 89, 99, 103].
When evaluating the ranking functions of the programs under different software
conditions, only the single top ranking pose was used for comparing software conditions,
as this is typically the mostly likely and facilitating pose that would be evaluated across
large libraries of ligands that are used for virtual screening. The top pose was also
inspected visually to determine the goodness of the ligand fit within the expected target
site. Using these metrics, the optimal software conditions to maximize docking accuracy
and ranking were "S docks" and "2E7 energy evaluations" for Autodock and either the
"Multi start S" and "No Random" or the "Multi start S" and "Random S" for Surflex.
Autodock 4 Docking Accuracy. Close examination of the dock with the lowest RMSD

for each software parameterization shows that Autodock is able to accurately reproduce
the crystal structure of several ligand-nucleic acid complexes to a resolution of less than 2

A (Figure

SA). Taking ligand and nucleic acid target symmetry into account results in

even lower RMSD poses for Pentamidine (ligand symmetry) and Ellipticine (nucleic acid
target symmetry).

Of the four ligands tested, Pentamidine is the only chemically

symmetrical ligand. Accounting for this symmetry results in lower RMSD results since
several of the poses that are docked in a flipped orientation relative to the crystal
structure can be recalculated (Figure SB). At first glance, the higher overall RMSD
results for the optimal Ellipticine pose can be misleading as this appears to be a relatively
poor docking. Visualization of the dockings reveals that the ligand is actually docked
successfully into the intercalation site but lies in a flipped orientation rotated 180 degrees
relative to the crystal pose. This flipped orientation of Ellipticine occurs for all of the
lowest RMSD poses (Figure SA) as well as the top ranked poses (Figure 6A). The
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Figure 5. Autodock and Surflex accuracy: The dock with the lowest RMSD is presented,
regardless of ranking. Figures A and C present the RMSD calculated without taking into
account ligand or nucleic acid symmetry, for Autodock and Surflex, respectively. Figures
Band D includes ligand and nucleic acid symmetry, for Autodock and Surflex,
respectively.

Black

=

Daunorubicin, Blue

=

Pentamidine.

45

Distamycin, Red

=

Ellipticine, Green

=

Figure 5. Autodock and Surflex accuracy: The dock with the lowest RMSD is presented,
regardless of ranking.
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Figure 6. The top ranked pose by Autodock and Surflex. Figures A and C present the
RMSD calculated without taking into account ligand or nucleic acid symmetry, for
Autodock and Surflex, respectively. Figures Band 0 include ligand and nucleic acid
symmetry, for Autodock and Surflex, respectively. Black
Distamycin, Red = Ellipticine, Green = Pentamidine.

47

=

Daunorubicin, Blue

=

Figure 6. The top ranked pose by Autodock and Surflex.
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orientation and quality of the docked Ellipticine pose is partially explained by the
symmetrical nature of the nucleic acid target, Slllce Ellipticine can dock into the
intercalation site not only from the orientation observed in the crystal structure but also
from a flipped orientation with intercalation from the opposite side of the nucleic acid.
Given that the Surflex RMSD calculator is based solely on the ligand poses and is
irrespective of the nucleic acid target structure symmetry, the RMSD for Ellipticine is
unusually high, even though Ellipticine is positioned well inside the intercalation site
compared to the crystal structure. Thus, flipping and superposition of the docked pose on
the crystallographic pose using Macromodel was necessary for an accurate comparison to
the crystal structure. The fact that Ellipticine is docked in the intercalation site is
encouraging, especially given the steric hindrance and tight fit typically associated with
intercalation sites. Note that the Autodock grid is also large enough to allow for potential
docking into the groove sites located near the intercalation site, so the intercalation dock
is the preferred site.

This emphasizes that RMSD values are only one metric for

evaluating quality of docking poses and that the top poses should be visually inspected to
check for ligand-target symmetry.
The lowest RMSD docking pose for Daunorubicin and Pentamidine are close to
the resolution of the crystal structures, especially at the software conditions of "5 docks"
and "2E7 energy evaluations".

In particular, the RMSD for Daunorubicin is almost

always lower than 1 A. The RMSD values for Distamycin appear to be the most variable
over the different software conditions, which is not surprising given that Distamycin has
the highest number of rotatable bonds (14) compared to Daunorubicin (9), Pentamidine
(12) and Ellipticine (0). The number of rotatable bonds for each molecule was defined by
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AutoDockTools usmg a united-atom representation that merges non-polar hydrogens
[94]. AutoDockTools is used to automatically select the rigid "root" section of the ligand
and the "branches" off of the "root" are subsequently defined as rotatable bonds [59].
Molecules with larger numbers of rotatable bonds are expected to take a larger number of
energy evaluations to converge to an energy minimum due to a larger number of degrees
of freedom and conformational states [59, 99]. The docking results for Distamycin are
especially encouraging considering that most small molecules that are tested for
therapeutic utility typically have less than 12 rotatable bonds [103]. The number of
energy evaluations appears to be most important when the fewest number of docks (5) is
used, and the accuracy of the Distamycin docking increases significantly with increasing
number of energy evaluations. Moreover, once the number of energy evaluations used
reaches 2E7, there appears to be no increase in docking accuracy when the number of
docks is increased from 5 to 10 or 20.

This finding is consistent with previous

observations from ligand-protein studies that tested the effects of varying energy
evaluations and number of dockings on docking accuracy [95]. Visualization of the
Distamycin docking poses that have a resolution of greater than 2

A show

that even

though the RMSD is higher than the cutoff, the ligand still occupies a similar space in the
minor groove relative to the crystal structure.

These results suggest that a software

parameterization of "5 docks" combined with "2E7 energy evaluations" is acceptable, as
the resolution of all of these docks with the exception of Ellipticine is less than 2 A.

Autodock 4 Pose Ranking.

The ability of Autodock to correctly rank the lowest

RMSD docks must also be assessed as a particularly challenging aspect of molecular
docking is scoring the docked poses correctly. The rank of the lowest RMSD pose out of
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all dockings for either Autodock and Surflex is shown in Figure 7. Autodock ranks the
docked conformation by calculating a binding energy and sorting the results from lowest
to highest energy.

Ideally, the docked pose with the lowest binding energy would

correspond to the docked pose with the lowest RMSD. In all software conditions, the top
ranked dock for Daunorubicin achieves the RMSD cutoff of 2 A. (Figure 6).
A number of poses with RMSD values less than 2

A are produced for Distamycin and

Pentamidine using several different software conditions. However, there are a number of
top ranked poses for Distamycin, Ellipticine and Pentamidine in several software
conditions that merit further discussion as these had higher RMSD values. It is critical to
ascertain whether the high RMSD values associated with these poses is due to lack of
consideration of either ligand or target symmetry or if the pose itself is of marginal
quality. Visual inspection of the four top ranked poses for Distamycin with a resolution
of greater than 12

A RMSD suggests that the flipped orientation of the ligand relative to

the crystal structure is the main cause of the high RMSD. However, the high RMSD
cannot be ascribed solely to nucleic acid target symmetry, as the crystal structure shows
that Distamycin is not centered around the minor groove and superposition of the docked
pose results in poor visual overlap with the crystal structure. Instead there appears to be
poor docking that is localized to the multiple terminal nitrogen groups, which float freely
outside of the minor groove instead of the expected tight binding within the minor groove
that is observed with the crystallographic structure. The marginal accuracy of these
dockings may be influenced by the large number of rotatable bonds observed with
Distamycin. This significantly increases the degrees of freedom and number of possible
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Figure 7. The rank of the lowest RMSD pose out of all dockings. Figures A and C present
the rank without taking into account ligand or nucleic acid symmetry, for Autodock and
Surflex, respectively. Figures Band D includes ligand and nucleic acid symmetry, for
Autodock and Surflex, respectively. Black

=

Ellipticine, Green = Pentamidine.
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Figure 7. The rank of the lowest RMSD pose out of all dockings.
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conformations of the ligand, making it challenging to dock to the target [59, 99]. With
respect to Ellipticine, the high RMSD values appear to be due to a combination of the
flipped orientation of the ligand which can be reassessed by accounting for nucleic acid
target symmetry, and also by marginal overall alignment of the docked pose relative to
the crystal structure.

Pentamidine is a unique case where consideration of ligand

symmetry into the RMSD calculations dramatically reduces the RMSD values for several
top ranking poses (Figures 6B). This shows that the high RMSD is ascribed to ligand
symmetry rather than to marginal docking quality and atom overlap.
In summary, there are several software conditions that appear promising with
respect to ranking of the poses including "5 docks" with "2E7 energy evaluations" and
"10 docks" with "2E5 energy evaluations".

However, the real value in assessing

Autodock performance lies in combining both docking accuracy and ranking of the
docked results. A software parameterization of "5 docks" and "2E7 energy evaluations"
appears best able to balance docking accuracy and ranking.

By using this

parameterization, docking of Daunorubicin, Distamycin and Pentamidine was achieved to
a resolution of approximately 2

A, while the intercalator Ellipticine was the most

challenging dock, with a top pose resolution of approximately 3 A. These docked
conformations are also visually in close agreement with the observed crystal structure
(Figure 8).
Surflex 2.11 Docking Accuracy.

The Surflex docking results generally show that

crystal structures are accurately reproduced (Figure 5). In all experiments, Daunorubicin
and Distamycin are docked accurately to a resolution of less than 2 A. Visualization of
the lowest RMSD Ellipticine pose demonstrates that Ellipticine is docked in the correct
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Figure 8. Comparison of the top ranked Autodock pose (magenta) to the PDB
crystallographic pose (yellow) for the experiment with a software conditions of "5 docks"
and "2E7 energy evaluations." (A) Daunorubicin, (B) Distamycin, (C) Ellipticine and
(D) Pentamidine.
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Figure 8. Comparison of the top ranked Autodock pose to the PDB crystallographic pose
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orientation relative to the crystal structure. The higher RMSD for the top Ellipticine pose
relative to the other compounds appears to be due to the marginal alignment of the ligand
structure with the crystal structure.

A similar marginal overlap was observed for the

Autodock Ellipticine poses, as described previously. Importantly, Ellipticine is located
well inside the intercalation site. For Pentamidine, incorporation ofligand symmetry into
the RMSD calculation results in significant increases in the docking accuracy for all
software conditions, with the lowest RMSD structures occurring with the "Multi start 5"
only experiment, and the "Multistart 5" and "Random 5" combination experiment. This
is attributed to inclusion of poses that were docked in a flipped orientation that initially
had RMSD values greater than 12

A,

but subsequently have significantly lower RMSD

values after taking into account ligand symmetry. With respect to docking accuracy,
addition of the "Multi start 5" option produces a better docked pose for Pentamidine. This
supports the hypothesis that initiating the docking of the ligand from multiple points
surrounding the nucleic acid target increases the accuracy of the dockings. Interestingly,
the addition of the "Random 5" option in combination with the "Multi start 5" option did
not significantly impact the lowest RMSD dock produced for these test ligands. The
"Random 5" option generates 5 randomized X,Y,Z coordinate positions of the atoms at
the initial starting position of the ligand [97]. Most importantly, Surflex is able to dock
the ligands to the nucleic acid targets and produce docking results with RMSD values
close to the resolution of the observed crystal structure.

Surflex 2.11 Pose Ranking. Ranking of Surflex results is performed by maximizing
the Surflex Overall Score, which consists of an affinity score of the ligand for the target.
Ideally, a maximal Surflex Overall Score would correspond with the lowest RMSD pose.
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Figure 9. Comparison of the top ranked Surflex pose (magenta) to the PDB
crystallographic pose (yellow) for the experiment with a software parameterization of
"Multistart 5" and "Random 5." (A) Daunorubicin, (B) Distamycin, (C) Ellipticine and
(D) Pentamidine.
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Figure 9. Comparison of the top ranked Surflex pose (magenta) to the PDB
crystallographic pose (yellow) for the experiment with a software parameterization of
"Multi start 5" and "Random 5."
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Inspection of the RMSD values for the top Surflex docks ranked by maximal Surflex
Overall Score are at first glance misleading (Figure 7). In particular, the experiment that
included the "Multi start 5" and "No Random" options and the experiment with the
"Multi start 5" and "Random 5" options initially appear to have a poor docking pose for
Pentamidine. However, closer visual inspection of the docked conformation relative to
the crystal structure pose again emphasizes the use of symmetry for RMSD calculations
where appropriate (Figure 9), which reduces the RMSD to under 2 A.
For all of the experiments, Ellipticine is docked in a flipped orientation in the
intercalation site, which was initially thought to be the major factor influencing the high
calculated RMSD value.

However, even after accounting for nucleic acid target

symmetry, Ellipticine has still only minimal overlap with the crystal structure.
Inspection of the top ranked dock for Daunorubicin for the software parameterization
with "No Multistart" and "No Random" and the software parameterization with
"Multistart 5" and "No Random" options appears to show Daunorubicin in a flipped
orientation relative to the crystal structure. The Daunosamine ring occupies the minor
groove, which is similar to the ring location in the crystal structure. After taking into
account the nucleic acid target symmetry, the docking pose RMSD values for both the
"Multi start 5" and "No Random" experiment and the "Multi start 5" and "Random 5"
experiment are dramatically improved, to a resolution of 3.4

A and 2.3 A,

respectively.

Finally, all Surflex software conditions docked Distamycin to the target at a resolution of
less than 2 A. These results emphasize the importance of not only calculating RMSD
values for docked poses, but also visualizing results to check for reasonable docking
conformations.
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The software parameterization with "Multi start 5" alone and the software
parameterization with both "Multi start 5" and "Random 5" appear to produce the top
ranked results with the lowest RMSD structures, compared to the software
parameterization of "No Multistart" and "No Random" options. The top ranked pose for
Daunorubicin using the "Multi start 5" and "Random 5" software parameterization has an
RMSD of 1.3

A and is superior to the top ranked dock for the other Surflex experiments.

Both software conditions dock Distamycin and Ellipticine comparably with respect to the
RMSD of the top ranked Surflex pose. For Pentamidine, the top ranked pose for the
"Multi start 5" and "No Random" option experiment has a marginally better RMSD for
the top pose compared to the top pose from the "Multistart 5" and "Random 5"
experiment. Overall, the performance of the "Multi start 5" and "No Random" experiment
and the "Multistart 5" and "Random 5" experiments are comparable.

Extended Parameter Optimization for Autodock and Surflex.

While the overall

docking results for Surflex and Autodock generally show the ability to accurately
reproduce the crystal structure and rank the results, it is important to determine the reason
for some of the more challenging dockings such as Ellipticine and Distamycin. One
possibility for the marginal docking accuracy could be an inadequate number of iterations
(number of docks and energy evaluations for Autodock, and multistart number and
random parameters for Surflex) of the software. If this is the case, it would be expected
that increased docking accuracy and ranking could be obtained by increasing the
exploration of the Autodock and Surflex parameters.
To investigate this possibility for Autodock, the docking experiments with the
four ligands were repeated after increasing the number of dockings from 5 to 50 and the
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number of energy evaluations from 2E7 to 5E7. The number of dockings were selected
based on previous applications of the software [59]. The number of energy evaluations
was increased to 5E7, which is consistent with the number of energy evaluations used in
previous protein docking experiments [95]. A similar approach was taken with Surflex by
increasing the Multistart parameter from 5 to 10 and the Random parameter from 5 to 10.
However, Jain et al. had previously seen only marginal improvement in increasing the
Multistart parameter greater than 5 with protein docking [97].
Evaluation of the docking accuracy (Figure 10) and ranking (Figure 11) results
show that there is no benefit in docking accuracy or ranking for either Autodock or
Surflex by extending dockings and evaluations of software parameters. Moreover, the
Autodock experiments took approximately 25 fold longer under conditions of 50 docks
and 5E7 energy evaluations compared to conditions of 5 docks and 2E7 energy
evaluations. Surflex took approximately 5 times longer under conditions of Multistart 10
and Random 10 compared to Multistart 5 and Random 5.

Even if the extended

experiments showed improved docking accuracy and ranking, the increase

III

computational time could be a limiting factor for use in virtual screening applications. In
summary, the results suggest that the originally optimized Autodock conditions of 5
docks and 2E7 energy evaluations and Surflex conditions of Multistart 5 and Random 5
are optimized for molecular docking to nucleic acids.

Evaluation of the Autodock and Surflex Scoring Functions. As the docking
accuracy and ranking does not appear to be related to suboptimal software
parameterization, another possible contribution to marginal docking may be from the
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Figure 10. Autodock and Surflex Parameterization Accuracy. The dock with the lowest
RMSD is presented, regardless of ranking.

Figures A and C present the RMSD

calculated without taking into account ligand or nucleic acid symmetry, for Autodock and
Surflex, respectively. Figures Band D includes ligand and nucleic acid symmetry, for
Autodock and Surflex, respectively. Black

=

Ellipticine, Green = Pentamidine.
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Figure 10. Autodock and Surflex Parameterization Accuracy.
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Figure 11. Autodock and Surflex Parameterization Ranking. Figures A and C present
the RMSD calculated without taking into account ligand or nucleic acid symmetry, for
Autodock and Surflex, respectively. Figures Band D include ligand and nucleic acid
symmetry, for Autodock and Surflex, respectively. Black
Distamycin, Red = Ellipticine, Green = Pentamidine.
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Figure 11. Autodock and Surflex Parameterization Ranking.
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scoring functions of these programs. This is possible given that scoring functions are one
of the major challenges of current docking programs [104]. To investigate this possibility,
the crystal structure and the top ranked poses for each method were rescored using both
the Surflex and Autodock scoring functions.
according to the lowest free energy of binding.

The poses were scored and ranked
An additional molecular mechanics

method was selected to calculate the energy of binding of the crystal pose, Autodock, and
Surflex poses.

This was useful as the added hydrogens could also be selectively

energetically minimized, which highlighted the hydrogen atom treatment as a potential
pitfall. Macromodel 9.S was used to determine the effects on the energy of binding of
using either the OPLS200S or Amber* force field with and without water as an implicit
solvent. These experiments investigated if the limitations in the ranking of the software
were related to the scoring functions for these programs.
Scoring of Poses by Autodock and Surjlex. The direct comparison of the Surflex and

Autodock Scoring Functions is shown in Figure 12. Unsurprisingly, the Surflex scoring
function tends to score the Surflex poses the best while the Autodock scoring function
tends to score the Autodock poses the best. The Surflex scoring function scores the
Autodock poses reasonably well, with a low free energy of binding. In general, the
Autodock scoring function produces results with the lowest free energy of binding. Both
Autodock and Surflex appear to typically score either the Autodock or Surflex poses as
having lower free energy of binding compared to the crystal pose. The Surflex scoring
function produces a "Static" score (red, Figure 12) and an "Optimized" score (green
Figure 12) when scoring an individual pose. The "Static" score applies the Surflex
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Figure 12. Comparison of the Free Energy of Binding for the Crystal pose, Autodock top
ranked pose and Surflex top ranked pose for various ligands using the Autodock and
Surflex Scoring Functions. Blue
Scoring Function. Green

=

=

Autodock Scoring Function. Red

=

Surflex Static

Surflex Optimized Scoring Function. (A) Daunorubicin, (B)

Distamycin, (C) Ellipticine and (D) Pentamidine.
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Figure 12. Comparison of the Free Energy of Binding for various ligands.
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SCOrIng function directly to the input pose, with no energy minimization.

The

"Optimized" score performs a gradient energy minimization and subsequently scores the
pose.

Scoring of the Surflex poses using the Surflex scoring function reveals little

difference between the Static score and Optimized score. On the other hand, Autodock
and the crystal structure scores are significantly improved when comparing the "Static"
score to the "Optimized" score. One possible explanation for this difference is how the
hydrogens are accounted for by these docking programs.

Hydrogen Atom Treatment of Poses Can Significantly Effect Free Energy of Binding.
It appears from Figure 12 that the significant difference in the "Static" and "Optimized"

Surflex scoring function scores for Autodock and the crystal poses could be influenced
by the way hydrogen atoms are added to these structures. In order to determine if this is
the case, it is important to first address the way hydrogens are normally accounted for by
these programs. Surflex adds all hydrogens on the ligand prior to docking so all of the
hydrogens are present during scoring. The crystal structure does not have any hydrogens
added.

Autodock uses a United Atom force field which takes into account "polar"

hydrogens that are attached to electronegative atoms [59]. "Non-polar" hydrogens
attached to carbon atoms are merged and the charge is added to the nearby carbon atom
[85].

To evaluate whether the trends in Figure 12 could be influenced by the way

hydrogens are handled by the docking programs, Macromodel was used to add all
hydrogens to the ligands and their binding energies were recalculated both before and
after energy minimization of the hydrogens (Figure 13). Comparing the binding energy
of the poses before and after minimization of the hydrogens shows that the most
significant decrease in energy after minimization is seen with the crystal structure.
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Figure 13. Calculated Energy of Binding by Macromodel for the Crystal pose, Autodock
top ranked pose and Surflex top ranked pose for various ligands using the Amber* and
OPLS2005 Force Fields with and without implicit water solvation.

Solid Blue

=OPLS2005, no implicit water solvation. Blue with Hatches = OPLS2005, with implicit
water solvation. Solid Gray = Amber*, no implicit water solvation. Gray with Hatches =
Amber*, with implicit water solvation.

(A) and (B): Daunorubicin, before and after

hydrogen minimization, respectively.

(C) and (D): Distamycin, before and after

hydrogen minimization, respectively. (E) and (F): Ellipticine, before and after hydrogen
minimization, respectively.

(G) and (H): Pentamidine, before and after hydrogen

minimization, respectively.
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Figure 13. Calculated Energy of Binding by Macromodel for the various ligands.
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However, there is also a substantial reduction in the energy of binding for Autodock. The
Surflex binding energies appear to be the least affected presumably because all hydrogens
were accounted for during docking and scoring. The results in Figure 13 are important
because a molecular mechanics approach was used to assess each of the poses for the
docking programs with two force fields and two solvation approaches. These results
show that Surflex appears to consistently produce the docked poses with the lowest
energy of binding.

This suggests the hydrogen atom treatment is an important

consideration when scoring docked poses and can substantially influence scoring and
energy calculations. It is interesting to note that Ellipticine, which has the fewest number
of rotatable bonds and hydrogen atoms is least effected by hydrogen atom treatment.

Effects of Force Field Choice and Solvation on Energy of Binding. A series of
experiments was performed to test the effects of using either the Amber* and OPLS2005
force fields, with and without implicit water solvation, on the energy minimization and
the calculated energy of binding of the ligands to the targets. The Amber* force field
was selected because the Autodock force field is parameterized based on the Amber force
field [59, 85]. OPLS2005 was chosen because it is an updated general force field from
the original OPLSAA force field that has demonstrated utility in evaluating protein
structures [105]. The calculated energy of binding of the top ranked ligand poses, before
and after energy minimization of the added hydrogens are shown in Figure 13.

The

force field choice and solvation effects can substantially influence the calculated energy
of binding. For the structures where the hydrogens were energetically minimized, the use
of the Amber* force field with inclusion of water solvation appears to produce energy of
binding results that are most consistent with the results in Figure 12 that were obtained
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usmg the Autodock and Surflex SCOrIng functions.

The energy of binding of the

Autodock and Surflex poses appears substantially lower than the crystal structures, with
the exception of Ellipticine. It appears in these cases that for the Autodock and Surflex
poses, the addition of implicit solvation in just the energy minimization is not
advantageous and not indicative of a favorable binding event. In total, this shows that
force field selection and solvation factors can contribute substantially to scoring and
ranking docked poses and this could be one of the main challenge of docking ligands to
nucleic acids.

Crystal Structure Energies are not necessarily the "Minima". The free energy of
binding for the crystal structure and top ranked Autodock and Surflex poses, determined
by either the Autodock or Surflex scoring function is shown in Figure 12. The top ranked
Autodock or Surflex pose almost universally has a comparable or lower free energy of
binding compared to the reference crystal structure.

This is true irrespective of the

scoring function. These results are supported by the molecular mechanics results in
Figure 13, where the calculated energy of binding for all ligands, apart from Ellipticine,
is comparable to or lower than the crystal structure. These results are important for
several reasons. First, the crystal structures should not be assumed to be the energetically
minimized conformation in the nucleic acid target, as the structure is a product of
experimental data and the original force field it is fitted to. Interestingly, the energy of
the lower resolution crystals, Distamycin (2.2 A) (Figure 13D) and Pentamidine (2.1 A)
(Figure 13H), appear to have more variability between the energy of the top ranked poses
and the crystal structure compared to the higher resolution crystal structures
Daunorubicin (1.4 A) (Figure 13B) and Ellipticine (1.5 A) (Figure 13F). This suggests
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that the quality and resolution of the crystal structure may be a consideration when
performing docking studies and evaluating poses.

However, it is also a function of

flexibility of the ligand as Distamycin and Pentamidine are the most flexible. Another
reason these results are important is that the docked poses such as Distamycin that
initially appeared to be of only marginal accuracy by RMSD compared to the crystal
structure are better than initially thought with respect to the energy of binding, which
implies that the crystal structure ligand pose may not be optimal to start with.
Overall Comparison of Autodock and Surflex Performance. In assessing the overall

performance of Autodock and Surflex, several facets of docking must be compared
including docking accuracy, docking ranking, computational speed, and even ease of use.
Both Autodock and Surflex have comparable performance in accurately reproducing the
crystal structure and ranking the poses, particularly with software conditions of "5 docks"
with "2E7 energy evaluations" and "Multi start 5" and "Random 5" respectively.
However, one important factor where performance differs substantially are the
computational resources required for docking.

Using 2.0 GHz AMD Opteron 246

processors, Surflex performed the dockings significantly faster than Autodock for all
ligands tested.

The average time to complete each Surflex docking with a software

parameterization of "Multi start 5" and "Random 5" was just under 8 minutes while
Autodock with a software parameterization of "5 docks" with "2E7 energy evaluations"
took approximately 76 minutes. Given that the docking accuracy and ranking results
were comparable, the significantly faster docking speed of Surflex makes it particularly
well suited for virtual screening applications where large numbers of ligands are
screened. Surflex is also superior with ease of use, as it is a single executable application
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with direct input from a MOL2 file format. Autodock requires file conversion from a
MOL2 into a PDBQT file format prior to performing molecular dockings. For these
reasons, under the tested software conditions, we show Surflex is a superior software
package for virtual screening of nucleic acids in the system reported here.

Comparison of Results to Previous Studies. Relatively few molecular docking studies
have been performed with nucleic acids. In comparing the data presented in this paper to
other docking papers, we placed particular emphasis on the evaluation of the accuracy of
the top ranked pose returned by either Surflex or Autodock. This is a logical approach
for assessing docking software performance for virtual screening applications, since
when screening a large ligand database, only the evaluation of the top ranked pose may
be computationally feasible. Several previous studies have focused on utilization of the
DOCK program for molecular docking of ligands to nucleic acids. Grootenhuis et al.
used DOCK to target the minor groove, major groove and an intercalation site on duplex
DNA while more recently, Chen et al. successfully targeted the major groove of RNA
[33,36-37]. Van et al. targeted an RNA tetraloop structure and demonstrated docking at a
similar resolution to what was observed in our study of docking ligands to DNA targets
[72]. Rohs et al. recently developed a molecular docking approach utilizing a Monte
Carlo algorithm that successfully demonstrated the binding of methylene blue to DNA by
minor groove and intercalation binding modes [38]. However, methylene blue has only
four rotatable methyl groups with fewer degrees of freedom than several of the more
conformationally complex ligands tested in this study [38].
One report of docking studies to nucleic acids using Autodock was performed by
Evans et al., who demonstrated the ability of a previous version of Autodock to
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accurately predict binding of minor groove binders to their respective nucleic acid targets
[34]. A direct comparison of all of the results from the Evans paper and this study is
difficult due to different operating conditions and software versions for Autodock;
however, some differences are noteworthy. One limitation of the previous study is that
while the number of energy evaluations was varied, the maximum number of evaluations
performed was only 2.5E6. Based on our studies, we found that 2E7 energy evaluations
was optimal for docking accuracy and pose ranking. Another consideration is that in this
previous study the number of dockings was kept constant. We evaluated the parameters
by varying both the number of docks and energy evaluations to determine which
combination of software parameters is best for virtual screening applications. Similar to
the results in this paper, Evans did find that in general, increasing the number of energy
evaluations increased the accuracy of the predicted pose, with respect to the crystal
structure [34]. However, we also found that using fewer numbers of dockings while
concurrently increasing the number of energy evaluations increases both pose accuracy
and ranking. This is presumably due to a more complete exploration of the energetic
landscape surrounding the ligand-target interaction. This has important implications for
virtual screening where of crucial importance is the accuracy of the top ranked pose.
Generally, the results of Evans et at. are consistent with results in this paper, and show
that Autodock is able to successfully predict the binding of multiple minor groove
binders to their targets at a resolution of approximately 2 A [34]. However, based on the
data herein, we recommend using more energy evaluations and fewer numbers of docks
for virtual screening applications to produce the best top ranked dock. While the results
in this paper expand and add value to previous Autodock work targeting nucleic acids,
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importantly, we show that the results with Surflex in particular are very useful,
applicable, and the first published study to demonstrate successful molecular docking of
intercalators or minor groove binders to nucleic acid targets using this software.

Conclusions
The results reported here support the primary objective of this work, which is to
test Autodock 4 and Surflex 2.11 for accurately reproducing ligand-bound nucleic acid
structures.

This is a critical first step in validating these software for future use in

targeting specific nucleic acid structures. Even given the aforementioned limitations and
uncertainties of using Autodock 4 and Surflex 2.11 with nucleic acids, these results show
that these software can accurately reproduce the crystal structures of both groove binders
and intercalators. Ours is one of only a few studies to date to have shown that nucleic
acids can be successfully targeted using these docking methods. Our results show that an
Autodock 4 software condition of "5 docks" and "2E7 energy evaluations" is the best for
The Surflex 2.11 software conditions of

combined docking accuracy and ranking.

"Multistart 5" and "No Random" and "Multi start 5" and "Random 5" appear equally good
at producing top ranked structures with low RMSD values relative to the crystal structure.
Extended experiments testing further increases in Autodock and Surflex parameterization
did not improve docking accuracy or ranking.

The most challenging ligand to dock

accurately was Ellipticine, which was no surprise given the small pocket in the nucleic
acid and tight fit associated with the binding of ligands into the intercalation site. Given
that the Autodock and Surflex scoring functions for ranking the docked poses were
parameterized based on protein-ligand structures, the ranking results are particularly
encouraging [2, 86].

Both programs are able to return a top ranked pose with
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approximately 2

A RMSD for Daunorubicin, Distamycin and Pentamidine and a pose

with approximately 3 A RMSD for Ellipticine. It is important to consider that while the
docking accuracy and pose ranking of these programs is comparable, Surflex performs
docking much faster than Autodock under the optimized software conditions in this
paper. Surflex also requires less manipulation of input files, suggesting that Surflex is
preferred for virtual screening applications for systems similar to presented here.
Based on these docking studies, several points should be strongly considered when
performing molecular docking with nucleic acids and evaluating docked poses. Docking
parameters should be explored in detail since suboptimal software conditions can
significantly impact the accuracy and ranking of the docked poses. When evaluating
docked poses, visualization of the most promising docking poses should be performed as
well as calculation of RMSD values. It is crucial to also account for both ligand and
target symmetry by either including ligand symmetry in RMSD calculations or
performing molecular superposition to account for nucleic acid target symmetry. Given
the conformation and structural heterogeneity of proteins, target symmetry is less likely
with respect to docking. However, nucleic acid targets are much more likely to exhibit
symmetry due to the simple base pair composition and the nature and geometry of the
nucleic acid strand associations. Another consideration when performing docking is the
hydrogen atom treatment of the software, as this can significantly impact the free energy
of binding. These studies also demonstrated that force field and solvation selection can
dramatically effect the binding energy.

Finally, selection of high quality and high

resolution crystal structures is especially important when using these structures as
reference conformations to evaluate docking poses. Based on the results in this paper, it
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is important to consider that the crystal structure does not necessarily represent the
energetically minimized pose with respect to the poses generated by docking software.
These findings have important implications not only in the field of chemistry and
computational biology, but also in the area of organic small molecule synthesis using
structure-based drug design. Many previous efforts at rational drug design have focused
on time-consuming and expensive small molecule synthesis methods. If reliable,
molecular docking allows for the construction of virtual libraries of molecules that can be
docked against any nucleic acid target of interest.

One of the logical next steps in

molecular docking to nucleic acids is the development of rules to select ligands that may
bind nucleic acid targets with affinity and specificity. These experiments suggest that
molecular docking techniques may have particular value as a virtual screening precursor
step to full chemical synthesis of drug candidates.
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CHAPTER III

DEVELOPMENT OF IN SILICO PREDICTIVE METRICS THAT GOVERN
SMALL MOLECULE - NUCLEIC ACID INTERACTIONS

Work in our previous chapter described the validation of the molecular docking
software Surflex and Autodock for the purposes of reproducing the crystal structure of
the minor groove binder and intercalator small molecules bound to nucleic acid targets.
The results were significant as they demonstrated that these software can be used for
molecular docking to nucleic acids.

However, this work involved rationalization of

known crystal structure data by docking the small molecules to a single nucleic acid
target.

The question remains whether a compound can be screened against multiple

nucleic acids in silico for the purposes of predicting binding mechanism and sequence
and structural selectivity. Determining if predictive in silico metrics can be developed to
answer this question is the focus of this chapter.
This chapter details a novel approach to predict the binding mechanism and
sequence and structural selectivity of small molecules for nucleic acids. We describe the
construction of an in silico nucleic acid library and the docking of the small molecules
from Chapter II (daunorubicin, distamycin, ellipticine and pentamidine) to the array of
nucleic acids. Metrics were developed that successfully classify these compounds as
either groove binders and intercalators, with moderate success at predicting sequence and
structural selectivity. The metrics were further tested on several new triplex and
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quadruplex binding small molecules that our lab has recently discovered. Finally, using
the in silica metrics, an extensive 67 member small molecule library for which in vitra
nucleic acid sequence and structural binding data exists, was classified on the basis of
binding mechanism and sequence selectivity. This was the most robust test of the metrics
as the compound library was highly heterogeneous with respect to binding mechanism of
action and sequence preference. In total, we demonstrate that the metrics as described
here can generally successfully predict the mechanism of binding of a ligand to a nucleic
acid in silica although it was generally more challenging to predict sequence and
structural selectivity. A summary comparison of the performance and limitations of
Surflex and Autodock is also detailed. The new information described here can facilitate
large scale virtual screening efforts that can be used to discover new small molecules in
silica that bind to a specific site on a nucleic acid structure and with a desired binding
mechanism.
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DEVELOPMENT OF IN SILleD PREDICTIVE METRICS THAT GOVERN
SMALL MOLECULE - NUCLEIC ACID INTERACTIONS
Patrick A. Holt, Jonathan B. Chaires, John O. Trent.
Introduction
Knowledge about the structure and function of nucleic acids has increased
dramatically in recent years. It is now known that nucleic acids are highly polymorphic
and can adopt physiologically relevant structures in vivo that are promising targets for
drug development. There is increasing evidence suggesting that DNA is altered in many
neoplastic conditions and there are many nucleic acid structures that are intriguing targets
for small molecule drug discovery [106]. G-quadruplex structures are but one example.
These structures are found in increased prevalence in the single stranded telomeric ends
of chromosomes. Stabilization of G-quadruplexes through small molecule targeting has
been shown to inhibit cancer cell life by inhibiting telomerase association with the
chromosome. As telomerase is overexpressed by cancer cells and not normal cells, this is
a potentially effective strategy for selectively targeting tumor cells [53-55].
There are multiple known small molecules that bind to G-quadruplexes. One
example is the porphyrin TmPyP4 which has potential anti-cancer properties in vivo
[107-108]. Unfortunately, many of these molecules, TmPyP4 included, suffer from poor
selectivity and are known to bind to many other nucleic acid structures and sequences in
vitro, which is a major concern for further clinical development [10, 109]. This poor
selectivity may be in large part because many small molecules are designed or
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synthesized only considering the binding to a single target of interest and may not take
into account binding and interactions with other potential targets in vitro and in vivo.
There is a critical need to determine if the mechanism of action and sequence and
structural selectivity of small molecules for nucleic acids can be predicted in silica. This
would allow for the virtual screening of millions of molecules in silica for the best "hit."
We describe here a novel computational strategy here to address this unmet need.
Before detailing our in silica approach for predicting small molecule-nucleic acid
interactions, we briefly review the important binding mechanisms of compounds to
nucleic acids. Small molecules can interact with nucleic acids by two main modes of
binding; groove binding and intercalation [110]. The minor groove of DNA provides a
site for many small molecules to bind because of the favorable geometry of the groove
and because there is less competition from polymerases and proteins that typically target
the major groove of duplex DNA [5]. Small molecules that bind to the minor groove
typically have intrinsic curvature present or have the capability of existing as a stable,
low energy conformation that is compatible with the geometry of the minor groove [111].
This compound curvature or "crescent shape" is an important property of many minor
groove binding small molecules as this allows the compound to bind between the walls of
the minor groove [111-112]. However, compound curvature is not an absolute
requirement for compounds that bind to the minor groove, as some linear diamidine
compounds have been identified that possess minor groove binding activity [113]. A few
examples of small molecules that bind to the minor groove are DAPI, pentamidine and
distamycin.
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The second mam binding mechanism of small molecules to nucleic acids is
intercalation which occurs by insertion of the molecule between adjacent base pairs in the
nucleic acid. Intercalation of a small molecule into DNA exerts a profound change on the
structure of DNA. In order for the intercalator to stack between the adjacent bases, the
nucleic acid must unwind partially and increase in length [110]. "Classical" intercalators
typically possess a fused, planar aromatic ring system which allows a small molecule to
insert between adjacent base pairs. In almost all cases, the small molecules also possess a
cationic external charge and many times bind cooperatively to DNA [110]. Molecules
that intercalate into DNA include ethidium bromide and acridine based molecules.
Compounds can also interact by hybrid methods where contributions of both
intercalation and groove binding are involved. Additionally, in some cases, molecules
can stack onto the ends of specific DNA structures ("end-stacking") such as Gquadruplexes, which involves interaction of the ligand with the guanine quartet on the
one side and the flanking DNA loops on the other side. This is in contrast to intercalation
into G-quadruplexes which occurs when a compound inserts between two adjacent
guanine tetrads. Finally, molecules can have chemical properties that allow intercalation
of part of the molecule with concomitant groove binding of substituents which is referred
to as "threading" intercalation. Generally, however, small molecules are divided along
the main categories of minor groove binding and intercalation.
We focus here on determining if predictive in silico rules can be developed to
predict the nucleic acid binding mechanism and sequence specificity of a small molecule
in silico.

This would provide valuable information as the rules could be applied to

virtually screen large numbers of small molecules to identify ones that bind with a known
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mechanism of action to a specific nucleic acid target. Large scale in silica molecular
docking of small molecules to a target of interest is becoming an accepted approach for
discovering novel small molecules for drug development. This field has largely focused
on proteins until recently as many of the software have been designed with proteins in
mind. However, validation of various software with nucleic acids has been successful
and recent evidence suggests that the molecular docking software, Surflex and Autodock
has particular utility for the virtual screening of large numbers of compounds to
We previously reported (as described in

promising nucleic acid targets [34, 63].

Chapter II) the use of Surflex and Autodock to successfully reproduce the known crystal
structure pose of a collection of small molecules that bind by groove binding and
intercalation to nucleic acid targets [63]. While these studies were successful, they relied
on the presence of a single in silica structure of a small molecule with nucleic acid and
did not determine if the docking software can predict sequence or structural selectivity.
The question remains whether rules can be developed for Surflex and Autodock that can
predict whether small molecules will groove bind or intercalate and to which sequences
and DNA morphologies that the small molecules prefer.
We report here the development of in silica rules that can be used to predict the
mechanism of action and the sequence specificity of an array of small molecules. An
initial set of four small molecules (daunorubicin, distamycin, ellipticine and pentamidine-the so-called "Positive Control" set of ligands) were selected because Surflex and
Autodock can successfully reproduce the known crystal structures of these groove
binders and intercalators [63]. These compounds were docked to an array of 10 nucleic
acids that were constructed in silica. The array of nucleic acids are highly diverse and
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consist of duplex, triplex, and quadruplex DNA and RNA as well as groove and
intercalation sites and sequence heterogeneity. Based on the docking results, in silica
rules were developed to classify the compounds on the basis of their binding mechanism
and to assess the sequence and structural selectivity of the compounds. The rules were
further tested on several novel triplex and quadruplex binding small molecules (the
"Validation" set) that our laboratory has discovered. Finally, the rules were also tested
on a 67 set of compounds (the "67 Compound Library" set) for which nucleic acid
sequence and structural data for the 10 array of nucleic acid structures was previously
acquired by competition dialysis.

In summary, we present the development of in silica

metrics that rationalizes existing data and can predict critical binding information about
small molecules in silica.
The development of in silica rules for predicting small molecule-nucleic acid
binding behavior has significant implications for the field of drug discovery. This is a
vastly unexplored area of research and there have been almost no efforts to predict the
binding mechanisms of small molecules by in silica approaches [114]. The development
of predictive rules to govern small molecule-nucleic acid interactions will facilitate
screening of many small molecules to the in silica array of targets to determine binding
mode and sequence specificity.

This will be a valuable tool to discover new small

molecules by virtual screening or alternatively, preempt chemical synthesis of derivatives
of known small molecules which is an often expensive and laborious undertaking.
Another consideration is that the in silica array of 10 nucleic acids is but an initial point
for testing. The power of this approach is that the in silica screen and library can be
expanded or customized as more structures become available in silica. In total, we
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believe this information will allow for the virtual screenmg of millions of small
molecules in silico to discover compounds that can bind to a nucleic acid target of
interest by a known binding mechanism and sequence specificity. This will provide an
essential tool for novel lead compound discovery.
Experimental and Computational Methods
Construction of the In silico Nucleic Acid Library. The first challenge was to build a
structurally equivalent in silico nucleic acid library compared to the library that was used
for competition dialysis for the 67 Compound Set. This array could also be used for the
Positive Control and Validation sets as nucleic acids were included in the array that were
known to interact with these small molecules. A representative 10 nucleic acid in silico
library was built and serves as the basis for the docking experiments described here
(Table 3). The nucleic acids exhibit a wide variety of structural and sequence diversity.
Duplex, triplex and quadruplex nucleic acids are represented as well as an array of
binding sites including grooves, intercalation and end-pasting sites (Figure 14).
All of the nucleic acids were either built using Sybyl 8.1 or by direct download
from the Protein Data Bank (PDB) database [115]. Unless otherwise noted, all nucleic
acids were 12 nucleotides in length. Additionally, the nomenclature used herein for
nucleic acids is the following: polydA: polydT consists of one strand Adenine and one
strand Thymine while poly( dAdT) consists of alternating Adenine and Thymine
nucleotides on each strand. Pure duplex DNAs (poly(dAdT), polydA : polydT, polydG :
polydC and poly(dGC» were built in the B-Form while the RNA-DNA hybrid (polyrA :
polydT) and pure RNA (polyrA : polyrU) were built in the A-Form as these are the
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Table 3. The following table describes the nucleic acid morphologies, sequences and
sites targeted for molecular docking and are identical to those used in competition
dialysis. The nomenclature for each nucleic acid will be the nucleic acid identifier in
remaining figures and tables in this chapter.
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Table 3. The following table describes the nucleic acid morphologies, sequences and
sites targeted for molecular docking and are identical to those used in competition
dialysis. The nomenclature for each nucleic acid will be the nucleic acid identifier in
remaining figures and tables in this chapter.

Nomenclature
Nucleic Acid
Sequence
Targeted Site
Morphology
Duplex A form
polyrA : polydT
Major groove
ar2
po lyrA : polyrU
Duplex A form
Major groove
au2
jJolydA : po!ydT
DUl!lex B form
Minor groove
tal
Duplex B form
poly(dAdT)
Minor groove
at2
Duplex B form
polydG : polydC
Minor groove
cg2
poly(dGC)
Duplex B form
Minor groove
Zc1
poly(dGC)
Duplex B form
Intercalation
gcit
Duplex Z form 1 poly(dGC)
zdl
Groove I
Duplex Z form I
poly(dGC)
Groove 2
zd2
poly(dGC)
Intercalation
Duplex Z form
zint
Triplex DNA
dal
poly(dA)-[poly(dT)b
Minor groove
Triplex RNA
poly(A)-[poly(U)b
Minor groove
ra2
Triplex DNA
poly(dA)-[poly(dT)h
Intercalation
dadtdtint
Triplex RNA
poly(A)-[poly(U)b
Intercalation
raruruint
Imotif1
(AACCCC)4
Groove I
iml
Imotifl
Groove 2
im2
lAACCCC14
Quadruplex
Groove I
lhl
A3GGG(TTAGGG)3A 2
Quadruplex
Groove 2
Ih2
A3GGG(TTAGGG)3A2
Quadruplex
Groove 3
Ih3
A 3GGG(TTAGGG)3A2
Groove 4
Quadruplex
A3GGG(TTAGGG)3A 2
Ih4
Quadruplex
A3GGG(TTAGGG)3A 2
Groove 5
Ih5
Quadruplex
Intercalation Site I
lhintl
A 3GGG(TTAGGG)3A2
Quadruplex
Intercalation Site 2
Ihint2
A3GGG(TTAGGG)3A2
End Pasting Site I
Quadruplex
I hend I
A 3GGG(TTAGGG)3A2
Quadruplex
End Pasting Site 2
Ihend2
A3GGG(TTAGGG)3A 2
I: Due to the structural dIversIty of these DNA, both grooves were targeted
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Figure 14.

Some of the nucleic acid structures used for the molecular docking

experiments: (A) poly(dGC) B Form DNA; (B) poly(dAdT) B Form DNA; (C)
poly(dGC) Z Form DNA; (D) polyrA : polydT A Form RNA-DNA hybrid; (E) polyrA :
polyrU A Form RNA; (F) poly(dA)-[poly(dT)h triplex DNA; (G) poly(A)-[poly(U)h
triplex RNA; (H) I-Motif and (I) Hybrid-l Quadruplex DNA. The color scheme is red

=

Adenine, dark blue

=

=

Thymine, green

=

Guanine, yellow

Uracil.
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=

Cytosine and light blue

Figure 14. Some of the nucleic acid structures used for the molecular docking
experiments.
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typical fonns for these structures in vivo [116]. Poly (dGC) was built in the Z-Fonn and
brominated by atom replacement of 50% of the deoxycytosines with 5 bromodeoxycytosine at alternating positions. The DNA and RNA triplexes, poly(dA)[poly(dT)]z and poly(A)-[poly(U)]z, respectively, were constructed using B-type parallel
triplex with and without an X-ray structural intercalation site backbone fragments [(PDB)
entry Ip20.ent] and minimized holding the heavy atoms fixed. The I-Motif structure of
the sequence (AACCCC)4 was downloaded from the PDB [(PDB) entry lybl.ent]. The
Hybrid-l quadruplex consisting of the sequence A3GGG(TT AGGG)3A2 was downloaded
from the PDB [(PDB) entry 2hy9.ent]. Intercalation sites and end-pasting sites for the
Hybrid-l quadruplex were using methods that will be further described in Chapter V.
Briefly, a ligand consisting of four connected purines (a "quaterpurine" ligand) was
placed at the site of interest and the nucleic acid was energetically minimized using
sequential steepest descent and Polak Ribier Conjugate Gradient Methods iterations,
allowing the nucleotides adjacent to the ligand to remain flexible but the remaining
structure to be rigid. For all structures, AMBER atom types were assigned using Sybyl
8.1.

Preparation of the In silico Compound Libraries. Three sets of small molecules were
built for the in silico molecular docking studies; the "Positive Control" set, the
"Validation" set and the "67 Compound Library" set. The Positive Control set consists
of the four small molecules which bind to nucleic acids by either groove binding
(distamycin and pentamidine) or intercalation (daunorubicin and ellipticine) and were
initially used for validation of the molecular docking software Autodock and Surflex for
targeting nucleic acid structures (Figure 15) [63, 79-80]. This Positive Control set will be
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Figure 15. The Positive Control Set of Ligands used for the molecular docking
experiments
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Figure 15. The Positive Control Set of Ligands used for the molecular docking
experiments

Daunorubicin

Distamycin

Ellipticine

Pentamidine
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used to develop the preliminary virtual screening metrics for characterizing the binding
mechanism and specificity of small molecules for nucleic acid targets.

The second

testing set is the Validation set and consists of three novel compounds that we initially
discovered in silico and demonstrated in vitro to bind to either triplex or quadruplex
nucleic acid structures. These compounds are referred to as triplex compounds I and 2
and the quadruplex compound [64]. The in silico rules developed on the Positive Control
set were tested on the Validation set to determine if the metrics are predictive of the
known binding activity of the compounds in the Validation set. Finally, the third set is
the 67 Compound library which were subdivided into 11 smaller sets grouped by
chemical similarity (Table 4). These clustered sets possess a range of chemical diversity
and contain small molecules that interact with nucleic acids by groove binding,
intercalation and end-pasting mechanisms.

The 67 Compound set were used for

robustness testing of the metrics on an expanded set of small molecules with different
binding mechanisms and sequence and structural selectivity. The 67 Compound set was
the best data set because we have competition dialysis data on these compounds which
will be used as a reference to assess the accuracy of the in silico rules for predicting small
molecule binding to various sequences and structural nucleic acids. All compounds in
these experiments were built using Sybyl 8.1. Charges of the AMI-BCC type were
added using the antechamber suite from Amber 8.
Docking of Small Molecule Sets to Nucleic Acid Targets. One of the greatest challenges
of molecular docking is that no single program is superior in all facets of a virtual screen.
We had previously identified Surflex-Dock 2.4 as superior software for molecular
docking and appropriate for large scale virtual screening [63]. To add robustness to our
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Table 4. The classification of compounds from the 67 Compound library set grouped by
chemical similarity.
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Table 4. The classification of compounds from the 67 Compound library set grouped by
chemical similarity.

Compound
Class Number
1

2
3
4

5
6

7
8
9
10

11

Compound
Classification
Ethidium Bromide Derivatives
Acridine Derivatives
Aromatic Diamidine Derivatives
Cyclic Aromatic Derivatives
Dibenzop_henanthroline Derivatives
Bis-quinoline Derivatives
Amidoanthraquinones (aromatic side chains)
Amidoanthraquinones (non-aromatic side chains)
Naphthoflavones
Amidofluorenone Derivatives
Other Compounds

98

Number of
Compounds
9
6

3
6

5
8
9

4
2
4
11

screen; however, we also pursued the development of in silico metrics using Autodock
4.0. Autodock is a logical choice for several reasons. First, it is one of the few virtual
screening programs with a force field (AMBER) that is parameterized for nucleic acids.
We have also previously found Autodock to be comparable to Surflex-Dock at accurately
reproducing both groove binding and intercalation crystal structures [63]. Autodock also
adds versatility to the virtual screening platform as it is complementary to Surflex with
respect to both docking and scoring functions [60]. Finally, Autodock is the most widely
cited molecular docking program in the literature, making our findings relevant to the
research that is on-going in many laboratories. Importantly, in our previous work, we
optimized the docking parameters for these software for docking both minor groove
binding and intercalating ligands to nucleic acids. Thus, the same docking parameters
used for those experiments were used here. Specifically, for Surflex, the "Multi start 5"
option was employed for each ligand and for Autodock, the "Number of Runs" was set to
5 and the "Number of Energy Evaluations" was set to 20,000,000 (2E7). These docking
parameters were described in detail in our previous report and were found to reproduce
with a high degree of accuracy the crystal structures of a set of small molecule groove
binders and intercalators in the Positive control set (Figure 15) [63].
The details of how Surflex and Autodock perform molecular docking have been
described in detail in previously [60].

Briefly, Surflex uses protomols that characterize

the chemical and spatial properties of the binding site and guides the docking of each
small molecule to that site. Protomols were prepared using ligand-based methods against
35 possible binding sites on the 10 nucleic acids, as previously described [63]. The
various sites represent groove, intercalation or end-pasting sites that are all possible sites
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of interaction for each of the docking small molecules. All files were saved in MOL2
format using Sybyl 8.1 prior to molecular docking. Autodock precomputes energy grids
around the nucleic acid to characterize the properties of the target [117]. Each ligand is
docked and evaluated against the target using a Lamarkian Genetic Algorithm and the top
pose was selected as the most energetically stable pose of the ligand with respect to the
target. PERL scripts were written to center the Autodock docking energy grids on the
center of the Surflex protomol for each site, to best compare the performance of the two
programs.

Targets were visualized in AutoDockTools to ensure the grid center was

centered on the Surflex-Dock protomol. All files were saved in PDBQT format using
AutoDockTools. The Autodock grid center and extent of the grid maps for each of the
targets can be found in Table 5. For each docking compound, the score for the top
ranked pose (the highest docking score) was used for subsequent data analysis.

All

preparation procedures and docking experiments were performed on a 440 computer IBM
server with 2.66GHz Intel(R) Xeon(R) E5430 processors.
Results and Discussion

Initial Docking of the Positive Control Set to the In silico Nucleic Acid Targets.
The initial objective in these studies was to dock the four ligands of the Positive Control
set to the array of nucleic acids and determine if the scores would yield insights as to the
preferential binding mode (groove binding versus intercalation) and the sequence
selectivity of the small molecules.

In order to perform docking to these structures,

typically a site on the target must be specified to guide the docking.

This required

generalizing which specific site on each nucleic acid target are "relevant" for small
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Table 5. Autodock Grid Properties used for Docking Experiments
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Table 5. Autodock Grid Properties used for Docking Experiments
Autodock Target
at1
at2
tal
ta2
zd1
zd2
cg1
cg2
gel
gc2
arl
ar2
au1
au2
da1
da2
da3
ra1
ra2
ra3
im1
im2
1h1
1h2
1h3
1h4
1h5
gcit
zint
dadtdtint
raruruint
1hint1
1hint2
1hend 1
1hend2

Gridcenter (X, Y,Z)
1.463 -0.0503.149
-0.541 0.8954.139
4.842 2.005 0.299
1.506 -0.1594.317
2.467 -4.137 -1.358
5.371 -3.340 -3.319
1.100 -3.746 -1.423
1.807 1.431 4.152
-3.929 -3.230 1.876
-2.5760.5704.061
-1.827 -1.902 0.880
-0.4120.4668.713
1.048 -0.070 -0.115
7.6292.534 1.076
-1.574 -1.340 6.844
9.3992.7365.313
5.451 5.0880.048
6.2372.560 -1.739
5.3142.801 -0.509
-1.385 -1.390 11.110
5.814 1.4982.134
7.521 2.221 0.992
5.9907.1520.890
-2.6476.861 5.388
5.9670.905 6.972
3.016 -0.706 10.441
-8.534 -3.914 1.367
0.339 -0.334 -2.261
0.4450.145 1.473
0.214 1.929 -0.129
-0.165 1.302 0.030
0.4022.6980.144
1.928 -0.579 -0.217
-1.6446.950 -0.460
-0.491 5.057 -0.484
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Number of Grid Points
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40X40X40
40 X 40 X 40
40X40 X40
40 X 40 X 40
40X40X40
40 X 40 X 40
40X40X40
40X40X40
40 X 40 X 40
40 X 40 X 40
40 X 40 X 40
40X40X40

molecule interactions. For example, in the case of distamycin and pentamidine for the
Positive Control set, we would expect the highest reported docking scores to be for the
minor groove of AT rich B-DNA, as these compounds are known minor groove binders
to this sequence [118-119].
Applying this rationale to the other nucleic acid targets, for the RNA and RNADNA hybrid structures, the major groove was the target while for triplexes, the minor
groove was the initial target. For the quadruplex structure, all grooves were targeted, as
the most likely binding sites for compounds with the quadruplex are less clear. Finally,
in order to select for molecules in the Positive Control Set that bind by intercalation
(daunorubicin and ellipticine), we included multiple intercalation sites in duplex, triplex
and quadruplex structures in the nucleic acid library.

In total, each of the four

compounds in the Positive Control set were docked using both Surflex and Autodock
against a total of 25 groove, intercalation and end pasting sites on all 10 nucleic acids
(Table 6-highlighted in green). The data were evaluated to determine if the ligands in
the Positive Control set could be classified by binding mechanism and sequence
specificity based solely on the in silico screening results.
The initial docking results for the Positive Control Set are shown in Figures 16
(groove site scores) and 17 (intercalation site scores). In both figures, more positive
docking scores for Surflex and Autodock are generally indicative of better binding to the
nucleic acid site of interest. Surprisingly, both docking programs appear to dock all of the
Positive Control small molecules to all of the sites of interest, regardless of whether the
targets are grooves or intercalation sites.

Generally, Surflex appears to have higher

groove binding scores for distamycin and pentamidine compared to the intercalators
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Table 6. The nucleic acids targeted for docking experiments. The targets highlighted in
green were used in the original molecular docking experiments while the targets
highlighted in yellow were added later to augment the initial experimental design.

104

Table 6. The nucleic acids targeted for docking experiments. The targets highlighted in
green were used in the original molecular docking experiments while the targets
highlighted in yellow were added later to augment the initial experimental design.

Nucleic Acid

Sequence

Targeted Site

I: Due to the structural diversity of these DNA, both grooves were targeted
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Nomenclature

Figure 16. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive
Control set of compounds, before application of the groove binding metrics. The results
shown are for the groove binding sites in the nucleic acid library.
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Figure 16. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive
Control set of compounds, before application of the groove binding metrics. The results
shown are for the groove binding sites in the nucleic acid library.
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Figure 17. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive
Control set of compounds, before application of the intercalation metrics. The results
shown are for the intercalation sites in the nucleic acid library.
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Figure 17. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive
Control set of compounds, before application of the intercalation metrics. The results
shown are for the intercalation sites in the nucleic acid library.
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daunorubicin and ellipticine, which supports the known preferential groove binding
mechanism of these small molecules. However, distamycin and pentamidine also obtain
higher Surflex-Dock scores for the intercalation sites than the known intercalators
daunorubicin and ellipticine (Figure 17). The trend is less clear with Autodock, and few
definitive conclusions can be drawn from these data. Overall, the data as seen in Figures
16 and 17 make it difficult to discern either the "real" binding mechanism or sequence
selectivity of the Positive Control Set.

This suggests that the initial experimental

approach must be augmented and refined to try to elucidate this information from the
docking experiments.
Augmentation of the Initial Positive Control Docking Experiments. The initial docking

data for the Positive Control set reveal an important consideration when performing in
silica docking.

The docking software appear to dock compounds to almost any site

"successfully" and return some positive value, suggesting that the compound may have
some interaction with that site. This suggests that our initial strategy of limiting the
initial docking to just the most likely binding site (for example, the minor groove for
distamycin) is an over-simplification of what actually occurs in vitro in competition
dialysis. The positive scores observed at almost all sites suggest that metrics must be
developed based on the docking scores to separate the true positive "real" binding data
from the "false positives." We briefly revisit how competition dialysis is performed in the
hopes of redesigning our strategy to more closely mimic in silica what is occurring in
competition dialysis in vitro.
In competition dialysis, each nucleic acid resides in the retentate of individual
dialysis cassettes and is exposed to a ligand that exists in a common dialysate. The
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ligand has the potential to interact with multiple sites on each nucleic acid in the assay,
including both grooves and intercalation sites. The idea of the small molecule having
access to multiple sites on a single target led us to hypothesize that multiple sites on a
target may non-specifically bind a ligand, so the interaction of a ligand with all of the
sites on a target must be taken into account when considering the overall binding of the
ligand to the site of interest. Our initial experiments oversimplified this concept as we
targeted only the most likely site of interaction of the ligand with the nucleic acid. An
example is illustrative. In the case of the triplex DNA, poly(dA)-[poly(dT)h, we believe
it is insufficient to target just an intercalation site to try to identify ligands that act by
intercalation (Figure 18A). Instead, all possible binding sites on the triplex must be
considered (Figure 18B), including the major grove, minor grove and minor-minor
groove. "Non-specific" binding of small molecules to sites other than the one of interest
must be accounted for by developing in silico metrics to subtract out non-specific
interactions. With this in mind, the number of docking sites was expanded from the
original 25 (highlighted in green in Table 6) to a total of 35 (including the targets
highlighted in yellow in Table 6) to take into account other possible binding sites for
ligands on the nucleic acids.
Re-Docking and Metric Development for the Positive Control Set. The Positive Control
Set was docked against the expanded library of nucleic acid targets and separate metrics
were developed based on the resulting data to classify the compounds in the Positive
Control set as either groove binders or intercalators.
intercalation metrics will be described in detail below.
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These groove binding and

Figure 18. (A) The triplex DNA poly(dA)-[poly(dT)h with an intercalation site that is
designated as the target site by the Surflex-Dock protomol. (B) The same DNA with a
protomol covering all available binding sites including the intercalation site, major
groove, minor groove and minor-minor groove. Yellow
Thymine. Red = Adenine.
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=

Surflex protomol. Blue

=

Figure 18. (A) The triplex DNA poly(dA)-[poly(dT)h with an intercalation site that is
designated as the target site by the Surflex-Dock protomol. (B) The same DNA with a
protomol covering all available binding sites including the intercalation site, major
groove, minor groove and minor-minor groove. Yellow = Surflex protomol. Blue =
Thymine. Red = Adenine.
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Groove Binding Metric Development.

The metrics developed to determine which

compounds bind by groove binding as opposed to intercalation were developed as
follows.

The metrics seek to take into account "non-specific" binding of a ligand to

multiple possible grooves that may exist on a single target.

The hypothesis is that

intercalators will likely bind with similarly low scores to all grooves while groove
binders should bind with much higher scores to their respective minor grooves compared
to the other grooves. The difference in scores should allow for discrimination between
intercalators and minor groove binders. We have created a Surflex or Autodock "metric
score" that takes into account the "non-specific" binding to each nucleic acid target. For
example, for duplex B-DNA where we target the minor groove, the raw score for the
major groove is subtracted as a "non-specific" interaction, as the minor groove is the
typical interaction site for small molecules. The metric for this would therefore be:

Metric score

=

Scoreminorgroove - Scoremajorgroove - CF (Correction Factor)

(3)

In this example, the compound would be docked against both sites and the metric score
would be computed from (3). Note that we still had to include a numerical correction
factor (CF) (Surflex: 2.8 and Autodock: 3.0) to differentiate groove binders from
intercalators, as we will show later.

U sing a similar rationale, metrics could be

determined for duplex RNA and RNA-DNA hybrids, except in this case, the major
groove is where small molecules typically bind, so the smaller minor groove score is
subtracted as follows [120]:

Metric score = ScoremajOrgroove - Scoreminorgroove - CF
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(4)

For triplex nucleic acids and quadruplex structures, the situation is more complicated as
multiple grooves are present, but a similar rationale applies. In this case, since the minor
groove ofpoly(dA)-[poly(dT)]z is of interest, the maximum score from either of the other
grooves (major or minor-minor) is subtracted as follows:

Metric score = Scoreminorgroove - MAX (Scoremajorgroove, Scoreminor-minorgroove) - CF (5)
The principal idea here is the metric corrects for the docking software's attempt to always
find a suitable dock for a small molecule on a target. A complete listing of the groove
binding metrics for all sites can be found in Table 7.

Intercalation and End Pasting Metric Development.

The metrics developed to

discriminate intercalators from groove binders were developed as follows. One lesson
learned from our initial docking experiments was that while intercalators had fairly high
positive docking scores to in silico intercalation sites, unfortunately so did many groove
binders. However, we did also find that the true positive groove binders possessed higher
groove binding scores to the groove sites than the intercalator ligands. This led us to
hypothesize that the true intercalators could be discriminated from the groove binders by
subtracting the maximal groove binding score observed across the nucleic acid library
from each individual intercalation site score. This would effectively "penalize" groove
binders more than intercalators and leave the intercalators with a higher overall net
positive score. As we performed with the groove binding metrics, we have created an
intercalator metric score. For example, with the triplex DNA poly(dA)-[poly(dT)]z, the
metric score for the intercalation site is determined by subtracting the maximal groove
site score observed for that compound across all of the grooves (27 groove sites in total)
from the intercalation site score. This formula is as follows:
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Table 7. The following table describes the groove binding and intercalation metrics that
were developed for Surflex and Autodock.
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Table 7. The following table describes the groove binding and intercalation metrics that
were developed for Surflex and Autodock.
Nucleic Acid
Targeted Site
Metric Score (MS) Formulae'
Seauence / Nomenclature
polyrA : polydT I ar2
Maior groove
MS = Scoremaor - SCOreminor - CF
polyrA : polyrU I au2
Maior groove
MS = Score maor - SCoreminor - CF
polydA : polydT I tal
Minor groove
MS = SCOreminor - Scoremaor - CF
poly( dAdT) I at2
Minor groove
MS = SCOreminor - Scoremaor - CF
polydG : polydC I cg2
Minor groove
MS = SCOreminor - Scoremaor - CF
poly(dGC) I gel
Minor groove
MS = SCOreminor - Scoremaor - CF
poly( dGC) I gcit
Intercalation
MS = Scoreintercalation site- MAX (Scoreall grooves) - CF
poly(dGC) I I zdl
Groove 1
MS = ScoregrOovel- Scoregroove2 - CF
poly(dGC)1 I zd2
Groove 2
MS = Scoregroove2- Scoregroovel - CF
poly( dGC) I zint
Intercalation
MS = Scoreintercalation site- MAX (Scoreall ~ooves) - CF
poly(dAHpoly(dT)12 /dal
Minor groove
MS = SCOreminor - MAX(Score maor , SCoreminor.minor)- CF
polY(A)-[poly(U)h I ra2
Minor groove
MS = Scoreminor - MAX(Score maor , SCOreminor.minor)- CF
poly(dA)-[poly(dT)h I dadtdtint
Intercalation
MS = Scoreintercalation site- MAX (Scoreall ~ooves) - CF
poly(A)-[poly(U)h I raruruint
Intercalation
MS = Scoreintercalation site- MAX (Scoreall .rooves) - CF
(AACCCC)4' I iml
Groove 1
MS = Scor~oovel- ScoreJ<foove2 - CF
(AACCCC)4' I im2
Groove 2
MS = Scor~oover Scor~oovel - CF
A3GGG(TTAGGGhA2 I Ihl
Groove I
MS = Scor~oovel - MA~Scor~ooves2 345) - CF
Groove 2
A3GGG(TTAGGGhA2 I Ih2
MS = Scoregroove2 - MAXJScor~oovesl 345) - CF
A3GGG(TTAGGGhA 2 I Ih3
Groove 3
MS = Scoregroove3 - MAX(ScoregrOOveSI 245) - CF
A3GGG(TTAGGGhA2 I Ih4
Groove 4
MS = ScoregrOOve4 - MAX(Scoregroovesl 235) - CF
A3GGG(TTAGGGhA2 Ilh5
Groove 5
MS = Scoregroove5 - MAX(Scoregroovesl 234) - CF
Intercalation Site I
A3GGG(TTAGGGhA2 I Ihintl
MS = Scoreintercalation site- MAX (Scoreall grooves) - CF
A3GGG(TTAGGGhA2 I Ihint2
Intercalation Site 2
MS = Scoreintercalation site- MAX (Scoreall grooves) - CF
A3GGG(TTAGGGhA2 I Ihendl
End Pasting Site I
MS = Scoreendoasting site- MAX (Scoreall grooves) - CF
End Pasting Site 2
A3GGG(TTAGGGhA2 I Ihend2
MS = Scoreendoasting site- MAX (Scoreall grooves) - CF
I: Due to the structural diverSity of these DNA, both grooves were targeted
2: A correction factor (CF) of 2.8 and 3.0 was used for Surflex groove binding and intercalation/end pasting metrics, respectively. A CF of 3.0 and 0.0 was used for Autodock groove binding and
intercalation/end-pasting, metrics, respectively.
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Metric score

=

Scoreintercalation_site - MAX (Scoreall_nucleicacidJJrooves) - CF

(6)

This formula is applied to all intercalation and end-pasting sites in the nucleic acid library
to yield a metric score for these sites. A correction factor of 2.8 was necessary for
Surflex to discriminate between groove binders and intercalators, while no correction
factor was necessary for Autodock. A detailed list of the metric score formulae can be
found in Table 7.
Classification of the Positive Control Library after Metric Application. After
completing the re-docking experiments of the Positive Control ligand set to the
augmented nucleic acid library containing 35 sites, the groove binder and intercalator
metrics were applied to the resulting docking data. The development and application of
these in silico metrics greatly enhances the trends in the data and makes it possible to
classify ligands as groove binders or intercalators, based solely on the transformed in
silico data. A comparison of the groove binding data prior to metric application (Figure

16) and after application (Figure 19) and intercalation data prior to metric application
(Figure 17) and after application (Figure 20) particularly emphasizes this point. It is
readily apparent that Surflex has only positive scores for the groove binders pentamidine
and distamycin with no scores seen for the intercalators daunorubicin and ellipticine,
which is what is expected for the groove sites (Figure 19). A similar general trend is seen
with Autodock.

While the groove binding metrics can discern groove binders from

intercalators, the data show that predicting sequence selectivity is less clear. Surflex
appears to do an overall better job compared to Autodock in this area, as Surflex has
more positive scores for both the "at" and "ta" sites (AT rich B-DNA) which pentamidine
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Figure 19. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive
Control set of compounds, after application of the groove binding metrics. The results
shown are for the groove binding sites in the nucleic acid library.
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Figure 19. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive
Control set of compounds, after application of the groove binding metrics. The results
shown are for the groove binding sites in the nucleic acid library.
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and distamycin are known to bind (Figure 19) [118-119]. It is interesting to observe that
the minor groove of triplex DNA and RNA appears to have high scores, even after metric
application for both Surflex and Autodock. This suggests that more subtle differences in
structure are perhaps difficult to discriminate with the software and groove binding
metrics that have been developed here. With the success of the groove binding metrics at
preferably identifying groove binders over intercalators, the next question is whether the
intercalator metrics could select out the intercalating ligands, daunorubicin and
ellipticine. The intercalator metrics were developed and applied to the Positive Control
set and the results are shown in Figure 20.

For both Surflex and Autodock, after

application of these metrics, only positive scores are seen for the intercalation sites with
the intercalators daunorubicin and ellipticine, while no scores are seen for the groove
binding ligands, distamycin and pentamidine.

Surflex appears to have more overall

positive scores for different types of intercalation sites, suggesting that prediction of in
silico sequence selectivity may be more problematic. Surprisingly, for Surflex, neither

daunorubicin nor ellipticine were predicted to bind to the "gcit" duplex intercalation site
after application of the metrics.

This is significant as the "gcit" target represents a

"typical" intercalation site consisting of duplex B-DNA with a GC flanking sequence.
We believe that this could be in part due to the way Surflex scores docked poses which is
predominately shape and contact based. With triplex and quadruplex intercalation sites,
there is more surface area present which could artificially elevate the Surflex score and
unfairly penalize smaller intercalation sites such as "gcit."

Interestingly, Autodock

appears to predict intercalation of the intercalator Daunorubicin to "gcit." (Figure 20).
The fact that Autodock does appear more sequence selective may be because Autodock
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---------------------------------

Figure 20. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive
Control set of compounds, after application of the intercalation metrics. The results
shown are for the intercalation sites in the nucleic acid library.

122

Figure 20. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive
Control set of compounds, after application of the intercalation metrics. The results
shown are for the intercalation sites in the nucleic acid library.
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operates usmg a semi-empirical Amber Force Field which has been appropriately
parameterized for DNA and thus may be more appropriate for our uses here.
In summary, the newly developed groove binding and intercalation metrics appear
capable of generally predicting the binding mechanism of the Positive Control set of
ligands. The question remains whether the metrics that were developed here would also
be predictive for the binding mechanism of other small molecules that we have
discovered as well as when larger and more diverse chemical compound sets are tested,
such as the 67 compound set. Additionally, the question of whether the metrics can
predict sequence selectivity will be further evaluated by looking at the 67 Compound
Library.
Application of Metrics to the Validation Set. The Validation Set consists of two triplex

DNA and one G-quadruplex DNA binding compound that our lab discovered using in
silica based methods, as we will describe in detail in the next two chapters (Figure 21)

[64].

Using the same metrics developed on the Positive Control Set, we sought to

determine how the metrics would classify the mechanism of binding (groove binding
versus intercalation) of these compounds as well as the predicted sequence selectivity of
the compounds. This test of the metrics was valuable as we have already biophysically
characterized the binding behavior of these compounds and can compare the predicted in
silica behavior with the known binding behavior in vitro. The triplex compounds were

found to intercalate selectively into the triplex poly(dA)-[poly(dT)h by Induced Circular
Dichroism (lCD) experiments [64].

As we will show in Chapter V, the quadruplex

compound binds to the human telomeric quadruplex AG 3(TTAGGG)3 by end pasting and
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Figure 21. The Validation Set of Ligands used for the molecular docking experiments

125

Figure 21. The Validation Set of Ligands used for the molecular docking experiments
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possibly intercalation as shown by ICD and a Thiazole Orange Fluorescent Intercalation
Displacement Assay (TO-FID).
The Surflex and Autodock results before application of the groove binder and
intercalator metrics can be seen in Figures 22 and 23, respectively. As with the Positive
Control ligands, the raw data make it difficult to determine whether the triplex and
quadruplex compounds are groove binders or intercalators. After applying the groove
binding metrics, there are very few positive scores observed for any of the groove
interaction sites (Figure 24), particularly for Surflex, which is expected, as the
compounds are known intercalators. The Autodock data is somewhat less clear, but
generally there are few groove binding scores overall, suggesting that groove binding is
not the primary mechanism of action (Figure 24). After application of the intercalator
metrics, the Surflex data show prominent positive scores in multiple intercalation sites for
the triplex and quadruplex compounds (Figure 25). This suggests that intercalation is the
primary mechanism of action of these compounds, which is also consistent with the
known binding properties of these compounds. Autodock also shows positive scores
particularly in the triplex intercalation sites for the triplex and quadruplex compounds
except for triplex compound 1, for which no scores are present. Additionally, Autodock
predicts that the quadruplex binding ligand will preferably intercalate into the triplex
structure, but this binding behavior has not been biophysically determined.

Overall,

however, the application of the metrics to the Validation set suggests that the metrics
(particularly with Surflex) are able to generally classify known intercalators correctly, but
it remains a challenge to also predict sequence selectivity of these ligands.
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The next

Figure 22. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation
set of compounds, before application of the groove binding metrics. The results shown
are for the groove binding sites in the nucleic acid library.
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Figure 22. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation
set of compounds, before application of the groove binding metrics. The results shown
are for the groove binding sites in the nucleic acid library.
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Figure 23. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation
set of compounds, before application of the intercalation metrics. The results shown are
for the intercalation sites in the nucleic acid library.
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Figure 23. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation
set of compounds, before application of the intercalation metrics. The results shown are
for the intercalation sites in the nucleic acid library.
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Figure 24. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation
set of compounds, after application of the groove binding metrics. The results shown are
for the groove binding sites in the nucleic acid library.
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Figure 24. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation
set of compounds, after application of the groove binding metrics. The results shown are
for the groove binding sites in the nucleic acid library.
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Figure 25. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation
set of compounds, after application of the intercalation metrics. The results shown are for
the intercalation sites in the nucleic acid library.
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Figure 25. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation
set of compounds, after application of the intercalation metrics. The results shown are for
the intercalation sites in the nucleic acid library.

<$

1!!

8

(/)

u

SQ)
~

"'0u"

Q

.9
;:,

«

135

question is whether these metrics can be applied to the 67 Compound set to correctly
classify the mechanism of action of these ligands. Moreover, the 67 compound set is
particularly valuable here to assess the sequence selectivity, as competition dialysis data
exists for each compound against the array of nucleic acids that was used for the in silica
studies.
Application of Metrics to the 67 Compound Set.

The 67 Compound Set of ligands

consists of both groove binders and intercalators with unique nucleic acid sequence
selectivity determined by competition dialysis.

The ligands have varying length,

aromaticity and chemical features that make this diverse set of compounds appropriate
for testing the metrics that have been developed on the Positive Control set and tested on
the Validation set. For ease of comparison, the compounds have been grouped into sets
of chemically similar compounds as shown in Table 4. The structures of the compounds
can be found in Figure 26. For each class of compounds, the known binding mechanism
and sequence selectivity as reported in the literature and determined by competition
dialysis will be briefly discussed below. The metrics that were developed will then be
applied to each class of compounds to determine if the compounds act as groove binders
or intercalators. Finally, the molecular docking data after application of the metrics will
then be compared to the known sequence selectivity data determined by competition
dialysis to assess the accuracy of the metrics for predicting sequence selectivity.
Ethidium Bromide Derivatives. Ethidium Bromide is the quintessential DNA "classical"

intercalating small molecule that binds non-specifically to many types of DNA and RNA
[10, 112, 121-124]. It possesses the "typical" structure of the known nucleic acid
intercalators; a flat, planar aromatic surface that can facilitate stacking between adjacent
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Figure 26. The Subsets of the 67 Compound Set of Ligands used for the molecular
docking experiments.
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Figure 26. The Subsets of the 67 Compound Set of Ligands used for the molecular
docking experiments.
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base pairs. The ethidium bromide derivatives (Figure 26) may act by both intercalation
and groove binding, as the primary aromatic system may intercalate and the substituents
may subsequently interact with the grooves, but generally they act primarily by
intercalation [122]. The competition dialysis data (Figure 27) demonstrates this type of
promiscuous binding of ethidium bromide to almost all of the structures in the
competition dialysis assay.
The Surflex and Autodock in silica data, after application of the metrics, show
very few positive scores for groove sites (Figure 28) while many positive scores for the
intercalation sites (Figure 29).

This suggests that the in silica screen classifies the

ethidium bromide derivatives as predominantly intercalators, which is their known
mechanism of action. The in silica results for sequence specificity are more variable.
Surflex generally has higher scores for the compounds binding to the various quadruplex
intercalation and end-pasting sites while Autodock has higher scores for the triplex DNA
intercalation sites (Figure 29). This data is consistent with the competition dialysis data
that shows many of these compounds binding to both of the triplex and quadruplex DNA
forms (Figure 27). However, there is almost a complete absence of predicted binding to
duplex DNA, which is in contrast to the binding data from competition dialysis. Overall,
the metrics can generally successfully classify the ethidium bromide derivatives as
intercalators and but it is generally more challenging to predict sequence preference.
Acridine Derivatives. The acridine derivatives (Figure 26) are another group of classical
DNA intercalating agents [124].

Compounds in this chemical family are of interest

because of their potent anti-bacterial and anti-neoplastic activity [125-126]. The potent
intercalation activity of the acridines has contributed to the development of "hybrid"
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Figure 27. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the ethidium bromide derivative set from the 67 Compound Set
[10].
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Figure 27. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the ethidium bromide derivative set from the 67 Compound Set
[10).
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Figure 28. Surflex-Dock (top) and Autodock (bottom) docking scores for the ethidium
bromide derivatives from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.
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Figure 28. Surflex-Dock (top) and Autodock (bottom) docking scores for the ethidium
bromide derivatives from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.
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Figure 29. Surflex-Dock (top) and Autodock (bottom) docking scores for the ethidium
bromide derivatives from the 67 Compound Set, after application of the intercalation
metrics. The results shown are for the intercalation sites in the nucleic acid library.
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Figure 29. Surflex-Dock (top) and Autodock (bottom) docking scores for the ethidium
bromide derivatives from the 67 Compound Set, after application of the intercalation
metrics. The results shown are for the intercalation sites in the nucleic acid library.
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molecules or "threading intercalators", by attaching DNA minor groove binding agents
(such as netropsin) to a molecule with an acridine core scaffold (such as amsacrine) to
impart both intercalation and groove binding properties to a single molecule [106]. The
goal of this approach is to create a high affinity ligand with sequence specificity and
these efforts have been modestly successful [106].

Another member of this class is

amsacrine (also known as m-amsa) which has been shown to bind to topoisomerase II
[124, 127-128]. Another example is BRACO-19 (a 3,6,9 trisubstituted acridine), one of
the most potent G-quadruplex binding ligands discovered to date, consists of an aromatic
acridine scaffold that is thought to end-stack with the G-quadruplex, and three "arms"
that may bind the grooves and provide quadruplex specificity [126, 129].
Application of the groove binding (Figure 30) and intercalation (Figure 31)
metrics shows most of the positive in silico scores present in the intercalation sites,
supporting the known intercalation of the acridines. Interestingly, Autodock also predicts
some triplex groove binding for the aac and ac compounds, which is possible given that
these two compounds possess an aromatic core that can intercalate as well as an extended
substituent that may also occupy available grooves of the nucleic acid. The competition
dialysis data shows the acridines binding predominately to AT and GC rich duplex and
triplex DNA structures and sequences (Figure 32). Surflex predicts intercalation into
duplex, triplex and quadruplex nucleic acids while Autodock predicts intercalation
mostly into triplex DNA and some quadruplex DNA (Figure 31).

For this class of

compounds, the metrics generally successfully predict the mechanism of action with
moderate success in predicting sequence selectivity.
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Figure 30. Surflex-Dock (top) and Autodock (bottom) docking scores for the acridine
derivatives from the 67 Compound Set, after application of the groove binding metrics.
The results shown are for the groove binding sites in the nucleic acid library.
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Figure 30. Surflex-Dock (top) and Autodock (bottom) docking scores for the acridine
derivatives from the 67 Compound Set, after application of the groove binding metrics.
The results shown are for the groove binding sites in the nucleic acid library.
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Figure 31. Surflex-Dock (top) and Autodock (bottom) docking scores for the acridine
derivatives from the 67 Compound Set, after application of the intercalation metrics. The
results shown are for the intercalation sites in the nucleic acid library.
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Figure 31. Surflex-Dock (top) and Autodock (bottom) docking scores for the acridine
derivatives from the 67 Compound Set, after application of the intercalation metrics. The
results shown are for the intercalation sites in the nucleic acid library.
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Figure 32. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the acridine derivative set from the 67 Compound Set
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Figure 32. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the acridine derivative set from the 67 Compound Set
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Aromatic Diamidine Derivatives. Members of the aromatic diamidine family (Figure 26)

of compounds have proven to be effective treatments for many infectious diseases such
as malaria and trypanosomiasis [111, 113]. These compounds have generally been shown
to bind to AT rich DNA sequences and prefer binding to the DNA triplex, poly(dA)[poly(dT)b, which is consistent with the competition dialysis data (Figure 33) [130]. The
crescent shaped structure of many of the compounds initially suggests that the aromatic
diamidines generally bind to the minor groove, and this is true for many molecules in this
family [130]. The crescent shape assists with fitting the compound to the geometry of the
minor groove and allows the aromatic diamidines to form hydrogen bonds at the base of
the groove [113]. Interestingly, however, the position of the terminal imidazoline groups
for all three of the compounds in our test data set (Figures 26) increases the planarity of
the compounds and causes the preferred mode of binding to be intercalation into the
triplex DNA structure [111, 130].
When the groove and intercalation metrics are applied to the aromatic diamidine
derivative set, the scores show some positive scores for the grooves, but mostly positive
scores for the intercalation sites (Figures 34 and 35). This is generally consistent with the
intercalation mechanism of the aromatic diamidines described here. The observation that
there are positive groove scores predicted by the in silico metrics is not entirely
surprising. Subtle changes in the aromatic diamidines (for example the para-para to
meta-meta switch of the terminal groups) can switch the main mode of binding from
groove binding to intercalation, but the compounds still may possess secondary groove
binding interactions. Thus, while the compounds listed here primarily intercalate, they
could easily groove bind with only minimal structural changes. This emphasizes that the
161

Figure 33. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the aromatic diamidine derivative set from the 67 Compound
Set.
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Figure 33. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the aromatic diamidine derivative set from the 67 Compound
Set.
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Figure 34. Surflex-Dock (top) and Autodock (bottom) docking scores for the aromatic
diamidine derivatives from the 67 Compound Set,
metrics. The results shown are for the
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Figure 34. Surflex-Dock (top) and Autodock (bottom) docking scores for the aromatic
diamidine derivatives from the 67 Compound Set, after application of the intercalation
metrics. The results shown are for the intercalation sites in the nucleic acid library.
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Figure 35. Surflex-Dock (top) and Autodock (bottom) docking scores for the aromatic
diamidine derivatives from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.
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Figure 35. Surflex-Dock (top) and Autodock (bottom) docking scores for the aromatic
diamidine derivatives from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.
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experiments here are testing the limits of these software, as subtle chemical changes can
make a significant difference in predicting the mode of binding, using the established
metrics.
The competition dialysis data show that the aromatic diamidines generally bind
triplex DNA and RNA with some binding to quadruplex DNA (Figure 33). The Surflex
data predicts intercalation of these compounds mostly to quadruplex DNA and somewhat
to the triplex DNA (Figure 34).

Autodock predicts intercalation predominately into the

triplex DNA, with minimal quadruplex intercalation (Figure 34). Much lower binding to
the grooves is predicted, although the scores are most positive for AT duplex DNA and
triplex RNA which is where groove binding of many aromatic diamidines occurs in vitro
(Figure 35). The Autodock data in particular closely resembles the sequence specificity
of the aromatic diamidines that was determined by competition dialysis. Overall, these
data suggest that the metrics can generally elucidate the mode of binding of the aromatic
diamidines as well as predict sequence specificity of these compounds.

Cyclic Aromatic Derivatives.

This group of compounds, along with the "Other

Compounds" set represents a diverse group of chemical compounds including
porphyrins, the threading intercalator PIPER, and compounds that possess large, fused,
aromatic chemical groups (Figure 26). As such, it is expected that these compounds
should interact primarily by an intercalative or end-stacking mechanism. The porphyrins
(including tetrakisporphrine and mesotetrakisporphine) are perhaps the best known class
of G-quadruplex binding ligands.

These compounds, in particular the compound

TmPyP4, have been investigated in detail as their structure suggests that the compounds
may preferentially stack and interact with the guanine quartet of quadruplex structures
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[10, 131]. However, the porphyrins have also been shown to interact with the grooves of
the human telomeric quadruplex, AG 3(TTAGGG)3, through an "outside" groove binding
mechanism [132]. Porphyrins also appear to generally suffer from non-specific binding
to many other forms of duplex and triplex DNA and RNA, as has been demonstrated by
competition dialysis [10]. On the other hand, the small molecule NMM, has been shown
to be highly selective for G-quadruplexes over duplex and triplex nucleic acids, although
NMM binds with lower affinity than porphyrins such as TmPyP4 [10]. The aromatic
system of the bis acridine molecule Bisa, also reflects its propensity to intercalate into
DNA as well as possibly act as a threading intercalator in various nucleic acids [133134]. Finally, the last member of this family is PIPER which is reported to bind by endstacking to various G-quadruplex nucleic acids and also possibly interacting by a
threading intercalator mechanism [135].
The in silica Surflex data classifies all of these compounds primarily as
intercalators, as there are no positive groove binding scores (Figure 36), but positive
scores for several intercalation sites (Figure 37). The Autodock results are more diverse
as the metrics predict some of the compounds to be exclusively groove binders
(tetrakisporphine and bisa) while the others to act predominately by intercalation or
endpasting (hoa, mesotetrakisporphine, nmm, piper).

While it is likely that the

porphyrin tetrakisporphine can interact with grooves, gIVen its promIscuouS binding
behavior, it is well known that porphyrins in general can intercalate and endpaste into
nucleic acids. Overall, Surflex appears superior at predicting the mechanism of action of
these compounds compared to Autodock. For structure and sequence specificity, this
group of compounds generally appears to bind with preference to triplex and quadruplex
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Figure 36.

Surflex-Dock (top) and Autodock (bottom) docking scores for the cyclic

aromatic derivatives from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.
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Figure 36. Surflex-Dock (top) and Autodock (bottom) docking scores for the cyclic
aromatic derivatives from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.
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Figure 37. Surflex-Dock (top) and Autodock (bottom) docking scores for the cyclic
aromatic derivatives from the 67 Compound Set, after application of the intercalation
metrics. The results shown are for the intercalation sites in the nucleic acid library.
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Figure 37. Surflex-Dock (top) and Autodock (bottom) docking scores for the cyclic
aromatic derivatives from the 67 Compound Set, after application of the intercalation
metrics. The results shown are for the intercalation sites in the nucleic acid library.
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DNA, as determined by competition dialysis (Figure 38). The intercalator metrics from
Surflex predict that these are also the preferred binding structures of DNA for all of the
compounds (Figure 37). For the predicted intercalators using the Autodock metrics (hoa,
mesotetrakisporphine, nmm, piper), these compounds are generally predicted to bind to
the triplex DNA, except for hoa that is also predicted to bind to quadruplex DNA (Figure
37). In summary, for the cyclic aromatic set, Surflex appears superior to Autodock at
predicting both the binding mechanism and sequence specificity of the compounds and
the predicted data is in reasonable agreement with the data from competition dialysis.
Dibenzophenanthroline Derivatives. The dibenzophenanthrolines (Figure 26) were
designed as small molecules that would intercalate into the triplex DNA poly( dA)[poly(dT)h [136]. The crescent-shaped curvature of the compounds suggests that the
compounds may also bind to the grooves of DNA.

These compounds posses a

pentacyclic ring and are either monosubstituted (mpq2 and mpq3) or bisubstituted
(mmql, mmq3 and moql).

The monosubstitited compounds have reported preferential

triplex binding compared to duplex, while the bisubstituted derivates show promiscuous
binding to both duplex and triplex DNA, which is generally consistent with the
competition dialysis results reported here.

There are also recent reports of

dibenzophenanthrolines suggesting that these molecules bind G-quadruplexes, as the
fused aromatic chemical features provide large It-orbital stacking with the guanine
tetrads of the G-quadruplexes [123, 136-137].
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Figure 38. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the cyclic aromatic derivative set from the 67 Compound Set.
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Figure 38. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the cyclic aromatic derivative set from the 67 Compound Set.
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The

Surflex

in

silica

docking

results

appear

to

generally

segregate

the

dibenzophenanthrolines on the basis of whether they are monosubstituted (mpq2 and
mpq3) or bisubstituted (mmql, mmq3, moql) (Figures 39 and 40). The monosubstituted
ligands have few positive groove binding scores and instead have mostly positive
intercalation site scores, suggesting intercalation is the mechanism of action. On the
other hand, the bisubstituted ligands appear to be classified largely as groove binders
according to the groove binding rules developed with Surflex (Figure 39).

This is

consistent with the more crescent shaped curvature of the bisubstituted ligands which
have substituent locations that would support groove binding. Surflex appears to be able
to modestly elucidate the sequence specificity of the classified mono and bisubstituted
compounds. The groove binding scores that are positive are generally for the duplex AT
rich DNA which the bisubstituted ligands are known to bind, as determined by
competition dialysis (Figure 41).

The intercalation binding scores that are the most

positive are typically for the triplex and quadruplex sites for the monosubstituted
compounds. The Autodock data are less clear, as there are positive scores present for the
grooves and intercalation sites in both the mono and bisubstituted ligands, suggesting that
the Autodock metrics are less successful at classifying the compounds as primarily
groove binders or intercalators (Figure 39 and 40). However, Autodock does appear to
be able to identify the sequence preference for the general class of compounds, as the
highest groove binding scores are found for AT rich duplex DNA and the triplex nucleic
acids (Figure 39). Also, the highest Autodock intercalation scores are found for the
triplex intercalation sites, which were the basis for the original design of these small
molecules (Figure 40). In summary, the metrics have only moderate success at
177

Figure 39.

Surflex-Dock (top) and Autodock (bottom) docking scores for the

dibenzophenanthroline derivatives from the 67 Compound Set, after application of the
groove binding metrics. The results shown are for the groove binding sites in the nucleic
acid library.
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Figure 39. Surflex-Dock (top) and Autodock (bottom) docking scores for the
dibenzophenanthroline derivatives from the 67 Compound Set, after application of the
groove binding metrics. The results shown are for the groove binding sites in the nucleic
acid library.
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Figure 40. Surflex-Dock (top) and Autodock (bottom) docking scores for the
dibenzophenanthroline derivatives from the 67 Compound Set, after application of the
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid
library.
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Figure 40. Surflex-Dock (top) and Autodock (bottom) docking scores for the
dibenzophenanthroline derivatives from the 67 Compound Set, after application of the
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid
library.
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Figure 41. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the dibenzophenanthroline derivative set from the 67
Compound Set.
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Figure 41. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the dibenzophenanthroline derivative set from the 67
Compound Set.

'< ~
-3

'0

"0
c::
;:,

8

0

III

c:

g
~
c::

&
c:

o

U

183

predicting

the

mechanism

of

action

and

sequence

selectivity

of

the

dibenzophenanthroline derivatives. This may be ascribed to the minor chemical changes
among these compounds that can result in a change in the binding mode.
Bis-quinoline Derivatives. There is interest in "bis" intercalators as these compounds

can intercalate into two sites in nucleic acids which allows increased affinity and
specificity of the small molecule for the nucleic acid [121]. Previous results have shown
that some of these compounds preferentially intercalate into triplex and quadruplex DNA
structures [123]. These compounds are unique as they have a long linking chain that
connects the two quinoline derivatives (Figure 26). This chain is capable of binding to
the groove of the nucleic acid and thus these compounds exhibit both intercalation and
groove binding character that may challenge the metrics as described here.
Application of the in silica Surflex metrics shows that positive scores are present
in the groove sites and the intercalation sites, suggesting that these compounds have
substantial groove binding and intercalation character (Figures 42 and 43).

This is

possible given that the planar, aromatic groups intercalate into DNA and the long linker
likely binds in the groove. The most positive scores for the groove sites are with AT rich
DNA, an observation that is generally consistent with the known competition dialysis
data which shows binding to AT rich DNA (Figure 44). The most positive intercalation
scores are for the quadruplex nucleic acids which these ligands are known to interact.
Autodock classifies these ligands exclusively as groove binders as there are only positive
groove binding scores present (Figure 42). This could be due to the particularly long
linker chains between the quinoline groups, which can lie in the groove and dramatically
impact Autodock scores.
184

Figure 42.

Surflex-Dock (top) and Autodock (bottom) docking scores for the bis-

quinoline derivatives from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.
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Figure 42. Surflex-Dock (top) and Autodock (bottom) docking scores for the bisquinoline derivatives from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.
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Figure 43. Surflex-Dock (top) and Autodock (bottom) docking scores for the bisquinoline derivatives from the 67 Compound Set, after application of the intercalation
metrics. The results shown are for the intercalation sites in the nucleic acid library.
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Figure 43. Surflex-Dock (top) and Autodock (bottom) docking scores for the bisquinoline derivatives from the 67 Compound Set, after application of the intercalation
metrics. The results shown are for the intercalation sites in the nucleic acid library.
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Figure 44. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the bis-quinoline derivative set from the 67 Compound Set.
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Figure 44. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the bis-quinoline derivative set from the 67 Compound Set.
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Interestingly, the Autodock results do appear to generally mimic the sequence specificity
of the compounds, as positive groove scores are seen for the AT rich DNA, the RNA and
the quadruplex structures. Overall, however, Surflex again appears best at predicting the
mechanism of action and sequence specificity of the Bis-quinoline derivatives.

It is

worth noting for this class of compound that the size and extended length of these
molecules make these one of the most challenging docking experiments of all of the
compound sets tested.
Amidoanthraquinones (aromatic side chains and non-aromatic side chains).

The

amidoanthraquinones (Figure 26) have been reported to bind to various nucleic acids
depending on the location of the side chains that extend from the central fused aromatic
ring system. The so-called l,4-disubstituted small molecules (tcj74 and tcj62) appear to
bind duplex DNA while the 2,6-disubstituted small molecules (tcj78, telominhl and
telominh5 and tcj69) and the 2,7-disubstituted small molecules (pjp57 and pjp66) prefer
triplex over duplex DNA [123, 138-139]. Additionally, the amidoanthraquinones have
been shown to bind G-quadruplex nucleic acids, as is confirmed by the competition
dialysis data (Figure 45) [140-141]. These compounds have a primary reported
intercalation mechanism of binding with additional "threading" behavior, where the fused
aromatic system intercalates, but the substituents can occupy the grooves of the nucleic
acids [123, 138, 140].
For the amidoanthraquinones with aromatic side chains, the in silico groove
binding metrics for Surflex show positive scores with the AT rich duplex DNA (Figure
46).

However, the scores for the intercalation sites after applying the metrics are

generally higher and suggest that intercalation is the primary mechanism of action, with
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Figure 45. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the amidoanthraquinones (aromatic side chains) derivative set
from the 67 Compound Set.
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Figure 45. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the amidoanthraquinones (aromatic side chains) derivative set
from the 67 Compound Set.
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Figure 46. Surflex-Dock (top) and Autodock (bottom) docking scores for the
amidoanthraquinones (aromatic side chains) derivatives from the 67 Compound Set, after
application of the groove binding metrics. The results shown are for the groove binding
sites in the nucleic acid library.
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Figure 46. Surflex-Dock (top) and Autodock (bottom) docking scores for the
amidoanthraquinones (aromatic side chains) derivatives from the 67 Compound Set, after
application of the groove binding metrics. The results shown are for the groove binding
sites in the nucleic acid library.
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some additional groove binding interactions possible (Figure 47). This is consistent with
the known binding mechanism of action of many of these compounds. Interestingly, the
highest in silica scores are found typically for the triplex and quadruplex intercalation
sites, suggesting that these structures are the preferred intercalation sites, which is
generally consistent with their known structural preference.

The Autodock groove

binding metrics yield less clear information, as there appears to be positive scores for
many ligands to a number of different grooves (Figure 46).

Application of the

intercalation metrics for Autodock shows that many of the amidoanthraquinones actually
appear to prefer to intercalate into the triplex DNA (Figure 47). However, no positive
scores are seen for quadruplex intercalation sites which is somewhat surprising given that
these compounds are generally known to bind quadruplexes.

Generally, the score

distribution for the groove and intercalation sites for Autodock support intercalation as
the primary mechanism of action, with some groove binding behavior evident.
For the amidoanthraquinones with non-aromatic side chains, the Surflex metrics clearly
predict intercalation as the preferred mechanism of action, with some groove binding
possible (Figures 48 and 49). Similar to the results seen with the amidoanthraquinones
with aromatic side chains, both the triplex and quadruplex intercalation sites have the
highest scores, suggesting that these are the preferred structures, which is generally
consistent with the competition dialysis data (Figure 50). Application of the Autodock
metrics classifies these compounds as almost exclusively groove binding in nature, as
almost all of the positive scores seen are in the groove binding sites as opposed to the
intercalation sites (Figures 48 and 49). We believe this may be due to the nature of the
side chain substituents. In this class of compounds, the side chains are non-aromatic
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Figure 47.

Surflex-Dock (top) and Autodock (bottom) docking scores for the

amidoanthraquinones (aromatic side chains) derivatives from the 67 Compound Set, after
application of the intercalation metrics. The results shown are for the intercalation sites
in the nucleic acid library.
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Figure 47.

Surflex-Dock (top) and Autodock (bottom) docking scores for the

amidoanthraquinones (aromatic side chains) derivatives from the 67 Compound Set, after
application of the intercalation metrics. The results shown are for the intercalation sites
in the nucleic acid library.
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Figure 48.

Surflex-Dock (top) and Autodock (bottom) docking scores for the

amidoanthraquinones (non-aromatic side chains) derivatives from the 67 Compound Set,
after application of the groove binding metrics. The results shown are for the groove
binding sites in the nucleic acid library.
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Figure 48.

Surflex-Dock (top) and Autodock (bottom) docking scores for the

amidoanthraquinones (non-aromatic side chains) derivatives from the 67 Compound Set,
after application of the groove binding metrics. The results shown are for the groove
binding sites in the nucleic acid library.

200

Figure 49.

Surflex-Dock (top) and Autodock (bottom) docking scores for the

amidoanthraquinones (non-aromatic side chains) derivatives from the 67 Compound Set,
after application of the intercalation metrics. The results shown are for the intercalation
sites in the nucleic acid library.
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Figure 49.

Surflex-Dock (top) and Autodock (bottom) docking scores for the

amidoanthraquinones (non-aromatic side chains) derivatives from the 67 Compound Set,
after application of the intercalation metrics. The results shown are for the intercalation
sites in the nucleic acid library.
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Figure 50. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the amidoanthraquinones (non-aromatic side chains) derivative
set from the 67 Compound Set.
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Figure 50. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the amidoanthraquinones (non-aromatic side chains) derivative
set from the 67 Compound Set.
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carbon chains, which should actually have supenor groove binding properties as
compared to the aromatic side chains. Thus, the Autodock metrics appear to score these
compounds as having better groove binding character, which is likely consistent with
their binding properties, but comes at the expense of classifying the compounds as
predominately groove binders instead of intercalators. Overall, the results suggest that
Surflex and Autodock are generally able to predict the binding mechanism of action of
these compounds but prediction of sequence and structural specificity

IS

more

challenging.
Naphthoflavones. The flavonoids class of compounds have long been known to exhibit

anti-inflammatory and antiviral properties (Figure 26) [142].

The alpha and beta

naphthoflavone flavonoids included and tested here are known to intercalate into triplex
DNA with high specificity, with little or no perceived binding to other nucleic acid
structures [123, 142].

This binding behavior has also been seen in the competition

dialysis data that was acquired on these compounds (Figure 51).
The Surflex and Autodock metric data for this class of compounds is perhaps the
best out of all of the classes of compounds that were tested in silico with respect to
differentiating groove binders versus intercalators. There are no positive scores present
for either Surflex or Autodock with respect to the groove binding sites (Figure 52).
Surflex has the most positive scores in the quadruplex intercalation sites while Autodock
has the most positive scores in the triplex intercalation sites (Figure 53).

This is

important in several respects. First, both software predict exclusive intercalation of these
compounds, with no discemable groove binding. This is entirely consistent with the
reported literature and is expected given the planar, aromatic structure of the
205

Figure 51. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the naphthoflavone derivative set from the 67 Compound Set.

206

Figure 51. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the naphthoflavone derivative set from the 67 Compound Set.
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Figure 52. Surflex-Dock (top) and Autodock (bottom) docking scores for the
naphthoflavone derivatives from the 67 Compound Set, after application of the groove
binding metrics. The results shown are for the groove binding sites in the nucleic acid
library.
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Figure 52. Surflex-Dock (top) and Autodock (bottom) docking scores for the
naphthoflavone derivatives from the 67 Compound Set, after application of the groove
binding metrics. The results shown are for the groove binding sites in the nucleic acid
library.
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Figure 53. Surflex-Dock (top) and Autodock (bottom) docking scores for the
naphthoflavone derivatives from the 67 Compound Set, after application of the
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid
library.
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Figure 53 . Surflex-Dock (top) and Autodock (bottom) docking scores for the
naphthoflavone derivatives from the 67 Compound Set, after application of the
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid
library.
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naphthoflavones. Second, this is an example of where Autodock appears superior to
Surflex as Autodock predicts preferential binding to triplex DNA which is what occurs in
vitro while Surflex predicts binding to quadruplex structures. The success in this class of

compounds may also be due to their small size and few rotatable bonds.

Smaller

compounds with fewer rotatable bonds are typically much easier to dock compared to
larger molecules because of the fewer degrees of freedom of the smaller compounds [63].
These results suggest that the metrics for both Surflex and Autodock have potential for
successfully classifying ligands based on mechanism of action and structural preference.
AmidoJluorenone Derivatives. The synthesis of the amidofluorenones (Figure 26) came

largely out of the observed success of the anthraquinones at binding to G-quadruplexes
and inhibiting the enzyme telomerase. The fluorenones were designed with the goal of
achieving similar inhibitory potencies but with fewer cytotoxic side effect of the
anthraquinones [143]. Modeling studies have suggested that these compounds can bind to
nucleic acids by intercalation or end-stacking [143 -144]. The side chains also suggest
some groove binding occurs, imparting a "threading" type of intercalation binding
behavior to these compounds.
Both the Surflex and Autodock metrics appear to have some positive scores
particularly for the triplex nucleic acid grooves, suggesting that the amidofluorenones
have groove binding character (Figure 54). However, the majority of the positive scores
for Surflex are in the intercalation sites, supporting intercalation as the primary
mechanism of action, with some groove binding behavior present (Figure 55). The in
silico Surflex data generally predicts that intercalation to quadruplex structures is
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Figure 54.

Surflex-Dock (top) and Autodock (bottom) docking scores for the

amidofluorenone derivatives from the 67 Compound Set, after application of the groove
binding metrics. The results shown are for the groove binding sites in the nucleic acid
library.
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Figure 54. Surflex-Dock (top) and Autodock (bottom) docking scores for the
amidofluorenone derivatives from the 67 Compound Set, after application of the groove
binding metrics. The results shown are for the groove binding sites in the nucleic acid
library.
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Figure 55. Surflex-Dock (top) and Autodock (bottom) docking scores for the
amidofluorenone derivatives from the 67 Compound Set, after application of the
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid
library.

215

Figure 55. Surflex-Dock (top) and Autodock (bottom) docking scores for the
amidofluorenone derivatives from the 67 Compound Set, after application of the
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid
library.
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Figure 56. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the amidofluorenone derivative set from the 67 Compound Set.
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Figure 56. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the amidofluorenone derivative set from the 67 Compound Set.
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preferred over triplex, while the competition dialysis data generally shows comparable
binding of these compounds to both triplex and quadruplex structures (Figure 56). In
contrast, the Autodock data suggests that these compounds bind exclusively by groove
binding, as there are only positive scores present for the groove sites (Figure 54) and no
positive scores for the intercalation sites (Figure 55).

The Autodock results are not

overly surprising given that similar problems were observed with the structurally related
amidoanthraquinones.

For this class of compounds, Surflex appears superior to

Autodock at predicting the mechanism of binding as well as structural specificity.
Other Compounds. Compounds that did not fall into any other chemical group have

been included in the "Other Compounds" category and possess a large amount of
structural diversity and nucleic acid binding specificity (Figure 26).

The known

mechanism of binding and sequence selectivity of these compounds is described briefly
here. The competition dialysis data suggests that many of these compounds appear to
favor triplex DNA, as well as interactions with quadruplex DNA and AT B-DNA to a
lesser extent (Figure 57). Berberine has been shown to bind to predominantly triplex and
quadruplex nucleic acids by intercalation or end-stacking [112, 145-147]. A preference
for AT base pairs is notable for berberine [147]. Ditercalinium acts as a bis-intercalator
with the linker sequence binding in the major groove of duplex DNA [148-149]. The
interactions with the major groove are noteworthy as most small molecules interact with
the minor groove [149]. Additionally, there have been reports of ditercalinium favoring
Guanine-Cytosine over Adenine-Thymine sequences [149].

DODC has been identified

as preferentially binding AT rich triplex DNA and to a lesser extent, quadruplex DNA
structures [10,39, 150]. The ligand appears to interact with different grooves of different
219

Figure 57. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the Other Compound set from the 67 Compound Set.
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Figure 57. Competition Dialysis data showing the concentration of ligand bound to each
nucleic acid structure for the Other Compound set from the 67 Compound Set.
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quadruplexes [150]. Less significant interactions have been reported with minor groove
interactions in duplex DNA [150].

Hycanthone is recognized as an intercalator that

appears to prefer AT sequences over GC sequences [151]. This molecule is a particularly
interesting "non-classical" intercalator, as it lacks a charge on the cyclic ring [151].
Methylene blue and Methyl green are unique compounds and have been included here as
they may interact with the major groove of DNA.

These compounds may be

inappropriate for classification based on the metrics developed here as the developed
metrics identify molecules that bind to the minor groove, as this is the prefereable site of
interaction on nucleic acids for most small molecules.

Methylene blue is also an

intercalator, but is unique in that at different ionic conditions, it may also interact with the
major groove of AT rich DNA [112, 122]. Methyl green has been shown to prefer AT
rich sequences and bind to the major groove of many different sequences of DNA[l22,
152]. The compound pjp407 is a 2-phenylnapthalene derivative that has structure
supporting intercalation [153]. Compound pjp72 appears similar in structure to some of
the amidofluorenones that were previously discussed which suggests it possesses an
intercalation or threading intercalation binding mechanism.
suggesting either groove binding or intercalation [121].

Pm008 has a structure

Quinacrine has long been

utilized as an anti-malarial drug and is thought to act predominantly by intercalation.
Sampangine is another anti-malarial and anti-fungal drug and the fused ring structure
suggests it binds by classical intercalation [154-155].
The Surflex metrics appear to classify many of the compounds as exclusively
intercalators, as there are many positive scores observed for the intercalation sites with
few positive scores for the groove binding sites (Figures 58 and 59). Interestingly,
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Figure 58.

Surflex-Dock (top) and Autodock (bottom) docking scores for the Other

Compound set from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.
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Figure 58. Surflex-Dock (top) and Autodock (bottom) docking scores for the Other
Compound set from the 67 Compound Set, after application of the groove binding
metrics. The results shown are for the groove binding sites in the nucleic acid library.

3.0

<'s ~
<'0
'S
.

8

C/)

o

S

Q)

~

.lC

1·0

g

"0

o

"5

~

224

Figure 59. Surflex-Dock (top) and Autodock (bottom) docking scores for the Other
Compound Set from the 67 Compound Set, after application of the intercalation metrics.
The results shown are for the intercalation sites in the nucleic acid library.
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Figure 59. Surflex-Dock (top) and Autodock (bottom) docking scores for the Other
Compound Set from the 67 Compound Set, after application of the intercalation metrics.
The results shown are for the intercalation sites in the nucleic acid library.
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ditercalinium and methylgreen are predicted to have some positive groove scores,
suggesting groove binding is also involved in their mode of binding which is consistent
with known data. While Surflex successfully predicts many of these compounds to be
intercalators, it does a marginal job of predicting structural preference, as many of the
compounds bind triplex DNA, while duplex and quadruplex intercalation sites are the
preferred in silico binding sites. Autodock shows many of the compounds having some
groove binding character to different nucleic acids, which is not surprising given the
structural diversity.

However, almost all of the compounds also are predicted to

intercalate into triplex nucleic acids (Figure 59). This finding is significant, as it is most
consistent with the mechanism of action of many of these ligands as well as the structural
specificity. In total, these results suggest that even for a heterogeneous group of ligands
such as those shown here, Surflex and Autodock can generally successfully predict the
binding mechanism and sometimes predict structural preference of the ligands.
Comparison and Limitations of Surjlex and Autodock Performance and Metrics. The
data presented here allow some comparisons to be made between Surflex and Autodock
about the performance of these docking programs as well as limitations of the software.
For both programs, the metrics that were developed were able to generally differentiate
groove binding small molecules (Pentamidine and Distamycin) from intercalators
(Daunorubicin and Ellipticine) in the Positive Control set.

A similar finding was

observed when performing robustness testing in the Validation and 67 Compound library
sets (Table 8). Moreover, in some cases, even sequence and structural selectivity were
successfully predicted in silico and generally mimic the actual in vitro competition
dialysis data. Perhaps the best example of the success of the metrics are the triplex
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Table 8. Comparison of Software for the Prediction of Compound Binding Mechanism
After Application of the In Silico Metrics
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Table 8. Comparison of Software for Predicting Binding Mechanism After Application of the In Silica Metrics

selective naphthoflavones, whose behavior was generally accurately predicted by the in
silica metrics. We generally found Surflex to outperform Autodock with respect to
predicting the binding mechanism while both programs had modest success at predicting
sequence selectivity of the compounds.

The success with Surflex was somewhat

surprising, as Surflex is not parameterized for DNA and operates largely by-shaped based
complementarity. On the other hand, Autodock has been used previ6usly for targeting
DNA and is specifically parameterized for nucleic acids [34]. This may explain the
ability of Autodock in some cases to outperform Surflex when predicting sequence
selectivity of some classes of compounds in the 67 compound library such as the
Naphthoflavones.

Our general findings, however, support the use of Surflex for further

study as a molecular docking tool to use to target nucleic acid for small molecule
discovery.
Based on the results from this study, there were several limitations of these
software that require further elaboration. In general, the docking programs appeared to
have a more difficult time predicting sequence and structural selectivity rather than
predicting the binding mechanism, based on the in silica metrics developed here. We
suspect that this is likely because even small structural changes can dramatically impact
sequence and structural selectivity of a small molecule for nucleic acids. The docking
programs also appear to have the most difficult time predicting the binding mechanism of
larger molecules that bind by both intercalation and groove binding mechanisms. An
example are the bis-quinolines which possess aromatic core scaffolds that can intercalate
as well as a linker chain that bind into the grooves of the nucleic acids. Additionally,
some molecules such as methylene blue bind to atypical sites such as the major groove of
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duplex DNA instead of the mmor groove.

The metrics as developed here may be

inappropriate for classification of these few compounds as the metrics focus on predicting
molecules that bind to the minor groove which is typically where small molecules
interact with DNA. Finally, we emphasize here that the array of nucleic acids is by no
means all encompassing but was merely used as this is the same array used for the
competition dialysis assay and facilitated the comparison of the 67 compound library in
silica and in vitra results. The array as constructed here is just a starting point. In the

future, structures can be added to the in silica array as they become available that will
hopefully add more diversity and power to this in silica approach.
Conclusions

Predicting how small molecules can interact with nucleic acids is crucial to
discovering new compounds that target biologically relevant nucleic acids. BourdouxheHousiaux et at. outline three criteria that can profoundly impact the biological activity of
compounds that interact with DNA; (1) mechanism of ligand interaction with nucleic
acids; (2) sequence specificity and (3) kinetics of association and dissociation [106]. We
address points (1) and (2) here by inventing a novel approach to predict in silica how
small molecules interact with nucleic acids. In silica rules were developed based on the
docking of four small molecules (Daunorubicin,

Distamycin, Ellipticine and

Pentamidine) to an array of nucleic acids that allowed for the classification of these small
molecules as either intercalators or groove binders.

These metrics were tested for

robustness on several compounds that our lab has discovered as well as a 67 compound
library, for which extensive competition dialysis exists. The results of the testing with
the 67 compound library confirmed that the Surflex and Autodock metrics are generally
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more successful at predicting binding mechanisms rather than sequence selectivity. A
logical extension of this work is to utilize the metrics for the discovery of novel
compounds that bind by a known mechanism to a specific nucleic acid. We envision that
this would be accomplished by large scale virtual screening of millions of compounds to
a nucleic acid target of interest. Top hits could then be screened against the in silica
array of nucleic acids to check for unwanted binding and the metrics could be applied to
elucidate the binding mechanism. As Surflex is approximately 10 times faster than
Autodock under the conditions tested here, we describe in the next chapter of this work
the use of Surflex with integrated selectivity metrics for the purposes of discovering new
small molecules that bind nucleic acids.
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CHAPTER IV

DISCOVERY OF NOVEL TRIPLE HELICAL DNA INTERCALATORS BY AN
INTEGRATED VIRTUAL AND ACTUAL SCREENING PLATFORM

This chapter describes the use of ligand-based and structure-based virtual
screening approaches for the purposes of discovering new small molecules that can
specifically bind to triplex DNA. Our previous results in Chapters II and III supported
the use of the virtual screening software Surflex for predicting the mechanism of action
of small molecules that interact with nucleic acids. In this chapter, we use metrics to
virtual screen millions of compounds to discover small molecules that specifically
interact with triplex DNA by the mechanism of intercalation. My contribution to this
work was the virtual screening experimental design and execution. Patricia Ragazzon,
Ph.D. was responsible for the biophysical characterization experiments. The results of
this work were published by P.A. Holt et al [64].
Virtual screening is an increasingly attractive way to discover new small
molecules with potential medicinal value. We introduce a novel strategy that integrates
use of the molecular docking software Surflex with experimental validation by the
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method of competition dialysis. This integrated approach was used to identify ligands
that selectively bind to the triplex DNA poly(dA)-[poly(dT)h.

A library containing

approximately 2 million ligands was screened to identify compounds with chemical and
structural similarity to a known triplex intercalator, the napthylquinoline MHQ-12.
Further molecular docking studies using compounds with high structural similarity
resulted in the discovery of two compounds that were then demonstrated by competition
dialysis to have a superior affinity and selectivity for the triplex nucleic acid than MHQ12. One of the compounds has a different chemical backbone than MHQ-12, which
demonstrates the ability of this strategy to "scaffold hop" and to identify small molecules
with novel binding properties.

Biophysical characterization of these compounds by

circular dichroism and thermal denaturation studies confirmed their binding mode and
selectivity.

These studies provide a proof-of-principle for our integrated screening

strategy, and suggest that this platform may be extended to discover new compounds that
target therapeutically and physiologically relevant nucleic
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acid morphologies.

DISCOVERY OF NOVEL TRIPLE HELICAL DNA INTERCALATORS BY AN
INTEGRATED VIRTUAL AND ACTUAL SCREENING PLATFORM

Patrick A. Holt, Patricia Ragazzon, Lucjan Strekowski, Jonathan B. Chaires and John O.
Trent. Discovery of Novel Triplex Helical DNA Intercalators by an Integrated Virtual
and Actual Screening Platform. Nucleic Acids Res. 2009 Mar; 37 (4):1280-7. Epub 2009
Jan 9.
Introduction

Triple helical nucleic acid forming sequences have become a source of increasing
interest as a way to interfere with DNA transcription and modulate gene expression [5657, 156]. Several approaches attempt to use triplex nucleic acids to interfere with the
transcription of genes, through either inducing the formation of triplex or stabilizing
existing triplex nucleic acids. The former approach is the so-called "anti-gene" approach
and involves the administration of triplex forming oligonucleotides (TFOs), which are
short sequences of nucleic acids that can bind to the major groove of duplex nucleic acids
in genes and promote the formation of triplex structures [58, 157]. TFOs have already
been successful in reducing transcription of the c-myc oncogene that is located in the
promoter site of genes [58, 158]. However, there are currently significant challenges
associated with the use of TFOs and triplex structures in general.

First, TFOs have

significantly lower activity in cell-based systems, compared to in vitro systems [159].
This has been ascribed to many factors including improper cellular localization,
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degradation of the oligonucleotide, or lack of accessilibity to chromatin wrapped DNA
[159-160]. A second limitation is the inherent low stability of many triplex structures
[161-162]. The latter limitation is the focus of this work where we demonstrate the use
of a novel virtual and actual screening platform for identifying several compounds that
can selectively bind to and stabilize a triplex nucleic acid structure.

These newly

identified small molecules could be used to target triplex structures in several ways.
First, the small molecule could stabilize pre-existing triplex structures in vivo. The small
molecules could be used in an adjuvant setting with TFOs to increase stability, or
alternatively the small molecules can be linked to TFOs to enhance the stability of newly
formed triplex structures [160]. Either of these approaches could be used to control gene
expression. These capabilities make these small molecules potentially clinically relevant
for treating cancer and other diseases that are closely linked with abnormal gene
expressIOn.
Several small molecules are known to intercalate into and stabilize triplex nucleic
acids including coralyne, benzo[ e]pyridoindoles (BePI), benzo[g]pyridoindoles (BgPI),
dibenzophenanthrolines, and anthraquinones [136, 162-165]. One of the most selective
and extensively studied classes are the napthylquinolines, which have been shown to
intercalate into the TAT DNA triplex, poly(dA)-[poly(dT)h [166-168]. Chaires et al.
performed an extensive study that characterized the selectivity and affinity of 14
napthylquinoline derivatives [44]. The ligand MHQ-12 emerged from that study as the
compound with the highest affinity and greatest selectivity for the poly(dA)-[poly(dT)h
triplex. While this approach for the discovery of triplex-selective ligands was successful,
it is a laborious and time-consuming process. We propose a novel alternative approach
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for finding ligands that target a particular structure in which virtual screening is used to
identify promising ligand candidates followed by validation using competition dialysis.
We demonstrate here that this approach can identify small molecules that intercalate into
po1y(dA)-[po1y(dT)h with higher selectivity and affinity than MHQ-12. A significant
result of this approach is that a small molecule with a substantially different molecular
scaffold was identified that has superior affinity and selectivity for triplex DNA
compared to MHQ-12.

This strategy thus provides a new platform for identifying

promising small molecule drugs against nucleic acid targets.
Virtual screening using molecular similarity and docking methods is becoming an
increasingly important and economical approach to identify small molecules drug
candidates [24]. While there are numerous studies using such screening methods for
targeting proteins, far fewer virtual screening efforts have been performed targeting
nucleic acids. The few studies that have been performed targeting nucleic acids have
produced promising results. They have shown that screening methods can accurately
reproduce crystallographic structures of ligand-nucleic acid complexes using a variety of
docking programs including DOCK, Autodock and Surflex [33-34, 63]. Our virtual
screening approach uses both ligand and structure-based discovery principles to select
ligands from a commercially available library that bind to po1y(dA)-[po1y(dT)h with
higher affinity and selectivity than MHQ-12. Initial virtual screening is performed with
Surflex-Sim, which is a ligand similarity-based software program that has superior
performance compared to most traditiona12D similarity methods [169]. This program is
an effective tool to rapidly prescreen large virtual compound libraries to enrich for
structurally similar ligands [169]. Surflex-Sim maximizes 3D morphological similarity
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and alignment of a test ligand to the control ligand, which in this work was MHQ-12
[169-171]. The quantitative metric that is used for evaluating Surflex-Sim results is the
Surflex-Sim score, which embodies an all atom comparison and alignment of the test
ligand with the control ligand.

The top ranked Surflex-Sim results were used for

structure-based docking studies to dock the ligand to the intercalation site and the three
grooves (major-major, major-minor and minor) of the triplex structure using the docking
program Surflex-Dock [44].

Surflex-Dock performs docking of test ligands to a

"protomol" or idealized representation of the binding site on the nucleic acid target. The
ligands are docked to the target and the poses are ranked by a Surflex Raw Score (SRS)
which consists of an affinity score of the ligand for the target [171]. This sequential
combination of Surflex-Sim followed by Surflex-Dock produced several ligands that had
hypothesized higher binding affinity and selectivity for the triplex intercalation site,
compared to MHQ-12.
A critically important step after virtual screening is validation by experimental
testing of the top candidates. To accomplish this, competition dialysis was employed
because of its extensive use to determine the selectivity and affinity of a small molecule
for single stranded, duplex, triplex and quadruplex nucleic acid targets [7, 10, 130, 164,
172-179].

The advantage of competition dialysis is that it is not limited to the target

sequence, or a simple comparison with one other form of DNA, but with as many nucleic
acid forms as are included in the assay. Competition dialysis involves dialyzing solutions
of an array of nucleic acid sequences and structures against a common solution
containing a test ligand [10]. The solution is allowed to reach equilibrium, and the
amount of ligand that is bound to each nucleic acid is measured using either fluorescence

238

or absorbance [10]. Comparison of the total and relative amounts of ligand bound to each
nucleic acid assesses the affinity and selectivity, respectively, of the ligand for any
included nucleic acid. Competition dialysis testing is used here to validate the affinity
and selectivity of the top virtual screening hits.

Circular dichroism and thermal

denaturation were used for further characterization of the triplex binding of the top virtual
screening candidate hits.
By using this integrated approach we have identified small molecules that have
higher selectivity and affinity for triplex poly(dA)-[poly(dT)h than the original molecule,
MHQ-12, and which are among the most selective and tightest triplex binding molecules
reported to date.

Materials and Methods

Virtual Library Construction. The triplex-selective ligand MHQ-12 was constructed and

hydrogen atoms were added using Macromodel (version 7.0).

The ligand was

energetically minimized using a sequential combination of 2000 iterations of a Steepest
Descent algorithm followed by 2000 iterations of a Polak-Ribier Conjugate Gradient
(PRCG) algorithm. AMBER ligand atom types were assigned using Sybyl (version 7.3).
The program Antechamber in the software suite Amber (version 8) was used to calculate
AMI-BCC charges for the ligand and to convert to a MOL2 file format. A virtual set of
1.962 million ZINC compounds in MOL2 format were obtained from the ZINC 2007
"all-purchasable" subset of ligands from the University of California San Francisco
(UCSF) [180].

The triplex nucleic acid structure poly(dA)-[poly(dT)h with an

intercalation site was constructed using B-type parallel triplex with X-ray structural
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intercalation site backbone fragments [Protein Data Bank entry Ip20.ent] and minimized
holding the heavy atoms fixed [181].
Surflex Methods. The program Surflex (version 2.11) containing both the Surflex-Sim

molecular similarity and the Surflex-Dock molecular docking programs was run on 30
AMD Opteron 246 processors (2.0 GHz) running the Linux Red Hat operating system for
all virtual screening experiments. Surflex-Sim experiments were performed using the
"align_list" function to compare the MHQ-12 triplex selective ligand against 1.962
million compounds in the ZINC library.

The top 350 ligands, ranked according to the

highest Surflex-Sim score, were selected as candidates for Surflex-Dock studies and were
extracted as individual MOL2 files from the library files using in house PERL scripts.
For the Surflex-Dock experiments, four protomols were generated to cover the majormajor groove, major-minor groove, minor groove and intercalation sites of the triplex
nucleic acid, using the same methods previously described [63]. The "proto_bloat"
function was set to accommodate all reasonable interactions of the protomols with the
triplex target sites. Docking of the ligands to the target was performed using a whole
molecule approach, as described previously [60, 63, 171].

The Surflex-Dock

experiments involved docking each of the ligands to all four protomols individually, in
separate experiments. Surflex-Dock was operated with parameters "Multi start 5" and
"Random 5," which we have previously shown returned accurate top ranked docked
poses for a set of small molecules to their respective nucleic acid targets [63]. The
Surflex-Dock poses were ranked according to the highest Surflex Raw Score [97].
Surflex-Sim and Surflex-Dock poses were visualized using AutoDockTools (version
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1.4.6). The properties of compounds 1 and 2 used in the QSAR analysis were generated
with QikProp [105].

Compounds for Biophysical Testing. The highest ranked candidates identified by virtual
screening were the ligands with ZINC identification numbers 632255 and 4623551,
which will be referred to hereafter as compound 1 and compound 2, respectively.
Compound 1, is 4-(4-methylpiperazino-2-(2-naphthyl)quinoline and was obtained from
Sigma-Aldrich (Milwaukee, WI). Compound 2 is 1-phenyl-4-pyrrolidino-2,3-dihydro1/H/-pyrrolo[2,3-/b/]quinoline and was obtained from Chemical Block (N.D. Zelinsky
Institute of Organic Chemistry, Moscow, Russia). As positive controls, the known triplex
selective ligands MHQ-15 and OZ-85H were synthesized as previously described [44].

Competition Dialysis Method. Competition dialysis experiments were done as previously
described [7, 44, 173, 182]. The array of oligonucleotides used is given in Table 9. The
buffer used consisted of Na2HP04 (6 mM), NaH 2P04 (2 mM), NaCI (185mM), EDTA
(0.1 mM), pH 7.

All nucleic acid samples were of identical concentration of 75

~,

expressed in terms of monomeric unit (base pairs for duplex DNA, triplets for triplex
DNA and tetrads for quadruplex DNA). At the end of the dialysis equilibration period,
ligand concentrations were determined by fluorescence. A volume of 180 III of each
sample was carefully transferred into one well of a 96-well microtiter plate (Costar® cat#
3915; Coming Inc., Coming, NY).

To each sample, 20 III of a 10% (w/v) sodium

dodecyl sulfate (SDS) stock solution was added to give a final concentration of 1% (w/v)
SDS, sufficient to dissociate the ligand from the DNA structure and ensure that there are
no complexities arising from differences in the optical properties of free and bound
.ligands. The total ligand concentration (el ) within each dialysis well was determined
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Table 9. Oligonucleotide Array for Competition Dialysis.
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Table 9. Oligonucleotide Array for Competition Dialysis

Conformation

Nucleic
acid

Nomenclature

A(nm)

Single-stranded DNA

poly (dA)

dA

257

8600

Nucleotide

Single-stranded DNA

poly (dT)

dT

264

8520

Nucleotide

Double-stranded

Clostridium

C. perf.

260

12476

base pair

natural DNA

Perfiingens (GC

C.T.

260

12824

base pair

M.lys.

260

13846

base pair

E

(M-1cm- 1)

Monomeric
unit

31%)
Double-stranded

Calf thymus (GC

natural DNA

42%)

Double-stranded

Microccocus

natural DNA

Iysodeiktus (GC

72%)
Double-stranded DNA

Z-DNA

Z-DNA

254

16060

base pair

Double-stranded DNA

poly (dAdT)

dAdT

260

12000

base pair

Double-stranded DNA

poly (dAdT)-

dAT

262

13200

base pair

dGC

254

16800

base pair

(dAdT)
Double-stranded DNA

poly (dGdC)(dGdC)

Double-stranded RNA

poly (rArU)

rArU

260

14280

base pair

DNA-RNA hybrid

poly (rAdT)

rAdT

260

12460

base pair

Triplex DNA or RNA

poly(dA)-

dAdTdT

260

17200

Triplet

TG 4T

260

12672

Quartet

[poly(dT)],
Quadruplex DNA

TG 4 T
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using a fluorescence standard curve for each tested ligand. Appropriate corrections were
made for the small dilution resulting from the addition of the SDS stock solution. The
free ligand concentration (Cr) was determined from an aliquot of the dialysate solution,
which typically did not vary significantly from the initial 1 IlM concentration.
Fluorescence measurements were made using a Safire microplate reader (Tecan US,
Durham, NC), with the following parameters: excitation and emission bandwidth, 10 nm,
gain: 100. Compound OZ-85H: excitation/emission 260/494 nm, compound MHQ-15:
excitation/emission 260/437 nm, compound

1 excitation/emission 260/490 nm,

compound 2: excitation/emission 348/446 nm. The bound ligand concentration (Cb) was
then determined by:
(7)
Binding constants, specificity sums (SS) and the ratio Cb/SS were calculated as follows
[183].

Apparent binding constants for each structure or sequence, K app , may be

calculated by:
(8)

where Cb is the amount of ligand bound, Cf is the free ligand concentration and Stota] is
the total nucleic acid concentration. By virtue of the experimental design used in the
competition dialysis experiment, Cf = 1 IlM and Stota]
monomeric unit of the nucleic acid.

=

75 11M, expressed in terms of the

The specificity sum, SS, is the sum of the

normalized amounts bound to each nucleic acid species, i:

ss= I
i

Cb,i
C max

(9)
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where Cb,i is the amount bound and Cmax is the maximum amount bound to any species.
The index i ranges from 1 to 13 in the current assay, corresponding to the 13 different
nucleic acids. A SS value of 1 indicates absolute selectivity for one structure whereas a
value of 13 indicates lack of selectivity. Information about compound binding affinity is a
function of Cmax . Thus, the ratio Cmax/SS represents affinity and selectivity. If SS
the maximal value of Cmax/SS will be obtained and if SS
result.

=

= 1,

13, the minimal value is the

A high value of the Cmax/SS ratio is representative of compounds with high

binding affinity and selectivity.
CD Titration and Thermal Denaturation Methods.

CD titrations were done as

previously described, using a Jasco 810 spectropolarimeter. Instrument settings were:
wavelength range (220-500 nm), scan rate (100 nm min-I), averaging time (0.125 s),
bandwidth (1 nm), number of scans (2), temperature (20 DC) [184]. The effect of ligands
on the thermal denaturation of triplex DNA was studied using the exact protocol
described previously [183].

Results and Discussion

Virtual Screening. The initial step in virtual screening was performing Surflex-Sim to

determine which of the ligands in the library were most structurally similar to the known,
triplex selective intercalator MHQ-12. Of the approximately 2 million ligands screened
for similarity against MHQ-12, 350 ligands had a Surflex-Sim score of greater than 0.70
(range: 0.875 - 0.704) and were selected for Surflex-Docking studies. A cutoff SurflexSim score of 0.70 was selected based on previous studies which suggested that this is the
lowest score where the ligand structure-function relationship is typically maintained [97].
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The next step in the virtual screening process involved perfonning Surflex-Dock studies
with the top 350 ranked Surflex-Sim ligands using the intercalation site and the three
grooves (major-major, major-minor and minor) of the triplex as individual docking
targets. Interestingly, MHQ-12 has the top Surflex Raw Score out of all 350 ligands that
were docked to the intercalation site, which directly supports the ability of Surflex-Dock
to successfully dock and rank a known selective triplex intercalator. We propose a new
metric to evaluate the Surflex-Dock results, the "Nonnalized Surflex Raw Score
(NSRS)". The rationale behind the nonnalization of the Surflex Raw Score is that the
score for a ligand binding to a single site on a target measures only the interaction with
that one site. However, a ligand may have multiple interaction sites on a particular target.
Therefore for selectivity for a particular mode of binding, it is crucial to detennine the
binding of the ligand to the site of interest relative to the binding to other potential sites
on the target.

Since ligands interact with nucleic acids typically through either the

groove-binding or intercalation, protomols were constructed at the three grooves and the
intercalation site [75]. Binding of the ligand to the intercalation site relative to binding in
the three grooves embodies the "nonnalized" affinity and specificity of the ligand for
triplex intercalation. The following metric, which was first developed in Chapter III of
this work, detennines the NSRS for the intercalation site for each of the top 350 SurflexDock results:

NSRSintercalate site

=

SRSintercalate site - Maximum SRSmajor-major site, major-minor site, minor site
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(10)

Ranking of the 350 intercalation site Surflex-Dock results by NSRS shows that only three
ligands have a higher NSRS score than MHQ-12 (NSRS of 6.8) (Figure 60A). The
ligands are LS-08 (Figure 60B), compound 1 (Figure 60E) and compound 2 (Figure 60F)
and have NSRS values of 7.03, 7.34 and 7.39, respectively (Figure 60) [185].
Interestingly, LS-08 (Figure 60B) which was identified by our virtual screening
methodology, was previously tested by Chaires et ai. and shown to be highly triplex
selective, which adds validity to our virtual screening approach used to identify triplex
selective ligands [44,183]. Based on the NSRS values, compounds 1 (Figure 60E) and 2
(Figure 60F) were hypothesized to have superior affinity and selectivity for binding to the
triplex nucleic acid, and were tested by competition dialysis.

Two known triplex

selective compounds, MHQ-15 (Figure 60C) and OZ-85H (Figure 60D) served as
positive controls, as these compounds have been extensively studied and characterized
[44].

Biophysical characterization was performed by circular dichroism and thermal

denaturation to assess the ability of the compounds to intercalate into the DNA triplex.
Competition Dialysis. The results of the competition dialysis experiments are shown in

Figure 61. It is visually apparent that compounds 1 and 2 have a much higher affinity for
the TAT triplex than the two positive control reference compounds, MHQ-15 and OZ85H. The competition dialysis results for MHQ-12 have previously been described in
detail, and this compound has a SS of 1.32 and a Cmax/SS ratio of 8.93 [44].
Determination of the SS (Table 10) for compounds 1 and 2 demonstrates superior triplex
selectivity compared to OZ-85H but slightly less selectivity than MHQ-12 and MHQ-15.
However, the significantly higher binding affinities of compounds 1 and 2 translates to
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Figure 60. Chemical structures of the ligands used in virtual screening and competition
dialysis Experiments.

(A) MHQ-12, (B) LS-08, (C) MHQ-15, (D) OZ-85H, (E)

compound 1 and (F) compound 2.
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Figure 60. Chemical structures of the ligands used in virtual screening and competition

E

F
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Figure 61. Competition dialysis results for MHQ-15, OZ-85H, compound 1 and
compound 2. The concentration of bound ligand to each nucleic acid structure in the
array is shown.
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Figure 61. Competition dialysis results for MHQ-15, OZ-85H, compound 1 and

compound 2.
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Table 10. Competition dialysis metric results for the positive controls, MHQ-15, OZ85H, and the virtual screening top results, compounds 1 and 2.
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Table 10. Competition dialysis metric results.

Test Ligand
MHQ-15
OZ-85H
Compound 1
Compound 2

Cb
(J.l.M)
10.7
17.6
24.2
30.0

Kapp/lO!l
(M- 1)
1.7
3.1
4.8
6.7
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SS
1.66
3.69
2.30
1.92

C max / SS
(J.l.M)
6.44
4.77
10.47
15.63

much higher Cmax/SS values than MHQ-12, MHQ-15 or OZ-85H. The Cmax/SS ratio
for compounds 1 and 2 is significant as it suggests that compounds 1 and 2 have a
superior combination of binding affinity and selectivity compared to the reference
compounds. These results validate the virtual screening approach, and show that the
method can be used to identify compounds with high affinity and selectivity for a target
nucleic acid, in this case the DNA TAT triplex.

Circular Dichroism. The interaction of compounds 1 and 2 with DNA was studied by
circular dichroism (Figure 62).

Both compounds show pronounced induced circular

dichroism (ICD) in the presence of triplex DNA. The ICD is in a spectral range where
the compounds absorb light but the DNA does not. This ICD is unambiguous proof of
the ligand binding to triplex DNA. For both compounds 1 and 2, the ICD is negative in
sign, and relatively weak in magnitude. Such behavior is consistent with an intercalative
binding mode, although the mode of binding can only be definitively established by highresolution experimental structural analysis [186].

Thermal denaturation studies. Figure 63 shows the effects of compounds 1 and 2 on the
thermal denaturation of the TAT triplex. In the absence of added ligand, two transitions
are seen, corresponding to the melting of the third strand
70°C).

(~

30°C) and the duplex

(~

Titration with both ligands results in a clear elevation of the first transition,

indicating stabilization of the triplex. The effect is maximal at saturating concentrations
of ligand (1: 1, ligand:triplet), where melting of the triplex coalesces with duplex melting.
Melting of the triplex is stabilized by ~ 40°C indicating tight binding of both compounds.
Neither compound I nor compound 2 alter the transition temperature of the duplex form

254

Figure 62. Induced Circular Dichroism results for (A) compound 1 and (B) compound 2.
(A) Spectra are shown for a ligand concentration of 45

~

in the presence of triplex

DNA ranging from 5 11M to 450 11M triplets. (B) Spectra are shown for a ligand
concentration of22.5 11M in the presence of triplex DNA ranging from 2.25 11M to 225
11M triplets.
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Figure 62. Induced Circular Dichroism results.
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400

450

Figure 63. Thermal Melting results for (A) compound 1 and (B) compound 2. Derivative
melting curves were obtained using 32 JlM triplex DNA and ligand concentrations
ranging from 0 - 16 JlM (A) or 0 -32 JlM (B). The peak near 30°C is for the melting of
the third stand, while that near 70°C is for melting of the duplex.
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Figure 63. Thennal Melting results.
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to any appreciable extent, an observation that is fully consistent with the weak binding to
duplex seen in competition dialysis experiments (Figure 61).

Validation ofQSAR. In the previous study of naphthyl quinoline binding to triplex DNA
[44], a QSAR was derived from competition dialysis binding data. The best three-term
QSAR to emerge was:

logKcw =O.OO264(±OJXXl65)S4S4 -0.693(±O.125)E4 -0. 196(±O.02)HBa
-t4.66(±O.44)

(11)

N =14;R=0.959;RM5E=0.13O;F=49.84;P=0.OOOI
In this relationship, log Kapp is the logarithm of the apparent binding constant (Table 10),
SASA is the total solvent accessible surface area in

A2 , EA is electron affinity in eV and

HBa is the number of hydrogen bond acceptors.

The physical meaning of this is as

follows. As SA SA increases, log Kapp increases in magnitude, indicating higher affinity
for triplex DNA. Increases in the magnitudes of EA and HBa result in decreasing binding
affinity. Increasing the solvent accessible surface areas of naphthyl quinoline compounds
results in higher affinity for the triplex. Greater electron affinity and more hydrogen
bond acceptors reduce the affinity of naphthylquinolines for triplex DNA.
Binding data obtained for compounds 1 and 2 in this study validate the published
QSAR. The molecular descriptors SASA, EA and HBa were calculated using QikProp,
and substituted into equation (11).

For compound 1, log Ka

=

5.07 was predicted,

compared to a measured value of log Kobs = 5.68. For compound 2, log K values of5.18
and 5.82 were calculated and observed, respectively. The differences in calculated and
observed values correspond to a factor of about 4 in binding constants, an acceptable
agreement for predictions from a QSAR.
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Conclusion

This work demonstrates a novel strategy for discovering small molecules that can
selectively bind to the triplex nucleic acid, poly(dA)-[poly(dT)b-

Through the

combination of virtual screening by Surflex and experimental validation by competition
dialysis, compounds 1 and 2 were discovered. These compounds have the highest overall
affinities and selectivities reported for triplex binders as determined by competition
dialysis. Further biophysical characterization by circular dichroism and thermal melting
confirmed the mechanism of action of these new compounds and verified the predictive
nature of the virtual screening methodologies. Several aspects of the virtual screening
results are noteworthy. First, the combination of a ligand-based (Surflex-Sim) with a
structure-based approach (Surflex-Dock) proved to be a powerful and highly
computationally efficient way to identify triplex selective small molecules, as SurflexSim is two orders of magnitude faster than Surflex-Dock. Second, our development of
the NSRS metric, which can predict a particular mode of binding of triplex selective
ligands with both similar and different (scaffold hopping) chemical scaffolds. This is
significant as it has the potential to identify new classes of small molecules that may have
much higher affinity and selectivity for a given nucleic acid target. Future work will
focus on extending this integrated virtual and actual screening platform to target other
nucleic acid structures that may hold medicinal value and physiological relevance.
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CHAPTER V

DISCOVERY OF A G-QUADRUPLEX NUCLEIC ACID BINDING SMALL
MOLECULE BY IN SILleo SCREENING AND MOLECULAR MODELING

This chapter describes the utilization of the validated software Surflex and Autodock for
the purpose of discovering novel small molecules that can bind to G-quadruplex DNA
structures. The targeting of G-quadruplex nucleic acids by virtual screening approaches
remains vastly underexplored despite the potential anti-neoplastic use of small molecules
that bind specifically to G-quadruplexes. We report here the development of a novel,
structure-based virtual screening approach that uses the molecular docking software tools
Surflex and Autodock to screen over 6.6 million compounds for their binding to a
specific site within the human telomeric G-quadruplex AGGG(TT AGGGh A novel
compound with a scaffold unlike any previously reported was discovered in silico. The
compound was demonstrated by spectroscopic and fluorescent biophysical methods to
interact with the G-quadruplex by the specific mechanism predicted by the in silico
screen. Models of the newly discovered compound interacting at various end-pasting
sites on the human telomeric quadruplex were constructed which provides insights to the
important ligand-nucleic acid interactions necessary for targeting quadruplex structures.
The virtual screening approach as presented here may be applied to any number of
nucleic acid targets to discover new compounds that may have medicinal benefit.
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DISCOVERY OF A G-QUADRUPLEX NUCLEIC ACID BINDING SMALL
MOLECULE BY IN SILleo SCREENING AND MOLECULAR MODELING

Patrick A. Holt, Robert Buscaglia, Jonathan B. Chaires, John o. Trent

Introduction

Discovering small molecules that bind to nucleic acids using high throughput in
silico virtual screening continues to be a largely untapped area of computational research

and drug discovery. Indeed, nucleic acid focused therapeutics currently represent only a
few percent of marketed drugs, with the vast majority focused on protein targets [1].
This initial neglect of nucleic acids as viable targets appears partially due to the failure to
appreciate the structural diversity and functional significance of nucleic acids.

With

advances in the understanding of the diverse structures of nucleic acids, there is now an
increasing list of nucleic acid targets with physiological and in vivo relevance [8].
Among the most attractive nucleic acid targets are the G-quadruplexes, which are found
in the human telomeric region of chromosomes and consist of the motif (TT AGGG)n.
These G-quadruplex nucleic acid structures have a novel mechanism of potentially
inhibiting cancer cells replication [39, 53, 187]. Over 85% of cancer cells overexpress
telomerase which allows cancer cells to maintain the ends of human telomeres and is
ultimately responsible for cancer cell immortality [54]. G-quadruplex structures have
been shown to destabilize telomerase from the telomere, resulting in decreasing cancer
cell life [55]. Thus, these quadruplexes have become a source of great interest for the
identification of small molecules that may bind and stabilize the structures in vivo, and
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inhibit telomerase activity. Efforts to discover quadruplex binding small molecules have
so far been modestly fruitful, and highlighted by the movement of Quarfloxin (owned by
Cylene

Pharmaceuticals)

into

humans

III

planned

clinical

trials.

In addition to G-quadruplex in the human telomeric region of chromosomes, Gquadruplexes also exist with increased frequency in the promoter regions of many genes.
It appears that oncogene promoter regions contain potential quadruplex-forming

sequences at a statistically significant increased rate, such as c-myc, bcl-2 and VEGF
[188-189]. The c-myc promoter in particular has gained attention as its overexpression is
strongly associated with cancer development. There is increasing evidence suggesting
that G-quadruplexes play a role in the regulation and modulation of oncogene
transcription and the G-quadruplexes have increasingly been the focus of small molecule
targeted approaches. In the case of c-myc, the small molecule TmPyP 4 has been shown to
stabilize quadruplex structures located in the nuclease hypersensitivity element III1
(NHE) area of the promoter, which controls >80% of c-myc gene transcription [188].
Ultimately, TmPyP4 is able to effectively inhibit gene transcription by stabilizing the
quadruplex [108, 189]. This emphasizes that G-quadruplexes in promoters as well as in
the human telomeric region are attractive structures for small molecule targeting.
In spite of the promise of small molecules that may bind to G-quadruplex targets,
in particular the human telomeric G-quadruplexes, there are very few published reports of
large scale in silico molecular docking approaches to discover new small molecules that
can bind to these targets [34, 36-37]. The studies that have been performed appear to
screen only limited numbers of compounds, typically on the order of thousands of
compounds [190]. A significant number on the order of tens of millions of in silico small
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molecules that are currently available that may bind to these targets have yet to be
explored. The lack of computational structure-based small molecule discovery in this
research area exists for several reasons.

First, while the human telomeric sequence

AGGG(TTAGGG)3 is of intense interest and has been studied in depth in vitro, there
remains great controversy as to the actual structure that this sequence adopts under
physiologically relevant solutions in K+. A number of structures and sequence variants
have been reported which emphasizes the unique polymorphism of the human telomeric
and other closely related sequences [191]. Published X -ray crystallographic structures
suggest this sequence forms an all-parallel "propeller" shape [191-193]. However, an
increasing body of evidence suggests that in fact, this structure may not represent the
"correct"

structure(s)

under

physiological

conditions

in

solution

[194-195].

Unfortunately, an NMR solution structure of the 22mer human telomeric sequence has
not been published although a number of variant sequences containing this human
telomeric sequence suggest that the human telomere adopts a so-called Hybrid or
paralleVanti-parallel structure under physiological relevant conditions [193-194, 196197].
Another reason for the lack of in silico structure-based targeting of the human
telomeric quadruplex is that molecular docking software in large part has been
developed, parameterized and validated almost exclusively for protein targets, and may
not appropriately consider the unique properties of nucleic acids.

Also, previous

computational studies have focused on rationalizing known data, which is an important
but different type of experiment than using the software to discover new nucleic acid
binding small molecules with novel scaffolds [34, 63]. Additionally, it remains to be
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seen whether large scale virtual screening of millions of small molecules to nucleic acid
targets in silica is computationally feasible and whether the small molecules that are
discovered possess the binding activity that was predicted in vitro.

A rigorous in vitro

validation is necessary to validate the predictive nature of computational approaches.
A final reason that in silica approaches have been ignored for targeting the human
telomeric quadruplex appears to the focus of many research groups on "rational" drug
discovery by derivatizing known quadruplex binding small molecules, such as TMPyP4
and other small molecules, to enhance binding to the human telomeric quadruplex
structure [198-200]. Unfortunately, attempts to discover new small molecules with truly
novel scaffolds that interact with G-quadruplexes by in silica based approaches have been
severely limited. As a result, the ability of computational approaches to explore the full
chemical space for new small molecule discovery remains underappreciated and
underutilized.

While these are only some of the challenges associated with targeting of

quadruplex structures, two in particular are the main foci of this chapter. First, is how to
select a relevant or representative human telomeric G-quadruplex structure for structurebased virtual screening. Second, is to determine if an integrated in silica molecular
docking and in vitro testing platform can successfully discover and validate the binding
of new small molecules to the human telomeric G-quadruplex structure.
An important issue that arises when targeting the human telomeric G-quadruplex
is the choice of a representative structure to use for structure-based virtual screening.
While there are known small molecules that appear to bind to the human telomeric
sequence, the solved crystal structure to which these small molecules are bound may not
be the "relevant" solution structure of the human telomeric quadruplex. For example,
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structures are available of small molecules bound to the "propeller" shaped all-parallel
quadruplex even though the Hybrid type quadruplex structure is largely considered to be
the "relevant" structure in solution [194-195, 201]. The lack of relevant solution
structures with small molecules bound with this specific DNA structure has undoubtedly
limited structure-based drug discovery approaches [202]. Small molecules are known to
interact with the AGGG(TT AGGG)3 quadruplex in three ways:

first by groove

interactions, second by intercalation between consecutive guanine tetrads and third by
end-pasting, where the ligand is bounded on one side by the guanine quartet and on the
other side by the loops of the quadruplex (Figure 64A) [203].

The end-pasting

mechanism is of intense interest, as it is thought to confer selectivity for quadruplexes
over other nucleic acid structures by taking into account both guanine quartet and loop
interactions. Small molecules that interact in this manner are thought to stabilize Gquadruplexes, prevent replication by telomerase and result in decreased cancer cell
proliferation [55]. We were interested in performing virtual screening experiments to
discover small molecules that may end-paste on the AGGG(TTAGGG)3 structure.
However, a difficulty is identifying an in silico G-quadruplex structure in the RSCB PDB
with a "representative" end-pasting site for targeting in which a small molecule is bound.
For our purposes, it is preferable to use a virtual structure in which ligands are complexed
as the ligands can be easily removed by computational methods and docking experiments
performed without perturbing the nucleic acid structure. As we will show, the nucleic
acid structure that was identified possesses an end-pasting site with strikingly
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Figure 64. (A) A G-quadruplex structure (PDB ID 2JPZ) that contains the human
telomeric repeat and shows potential ligand interaction sites in the grooves, intercalation
sites and end-pasting sites. (B) The G-quadruplex (PDB ID INZM) with the sequence
(TTAGGT)4 with a Guanine-Adenine end-pasting site that was initially used for virtual
screening with Autodock and Surflex. The RHPS4 ligand that is positioned in the
end-pasting site is removed for clarity. Blue = Thymine, Red = Adenine, Green =
Guanine and Purple = K+ cations.
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Figure 64. (A) A G-quadruplex structure (PDB ID 2JPZ) that contains the human
telomeric repeat. (B) The G-quadruplex (PDB ID INZM) with the sequence
(TTAGGT)4 with a Guanine-Adenine end-pasting site that was initially used for virtual
screening with Autodock and Surflex.

B

A
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similar properties of the human telomeric end-pasting site and this end-pasting site served
as the target for the virtual screening of millions of compounds.
After selection of a G-quadruplex nucleic acid structure for structure-based virtual
screening, the next challenge is how to perform the molecular docking experiments. The
use of molecular docking software to target nucleic acids has generally been limited
almost entirely to proteins.

However, our recent evidence suggests that two virtual

screening software in particular, Surflex and Autodock, have great potential for
molecular docking small molecules to nucleic acid targets [34, 63, 204]. We previously
reported that both of these software accurately reproduced the crystal structures of a set
of small molecules that interact with nucleic acids by both groove binding and
intercalation [63]. However, the question remains whether the software can be used for
virtual screening of millions of compounds to discover new small molecules that bind to a
desirable target.

Our previous results suggested that the accuracy of both software at

reproducing known structures is comparable (under conditions previously tested), but
Surflex is approximately 10 fold faster than Autodock and requires less file preparation
for virtual screening [63].

Because of the complementary docking and scoring

algorithms of Surflex and Autodock, however, we also investigate combining the power
of both of these software into a single platform that is capable of novel small molecule
discovery through a virtual screening strategy that is detailed below.
Even given these challenges, we report here the successful development of a high
throughput in silica molecular docking platform that discovered a human telomeric
quadruplex binding small molecule with a chemical scaffold unlike any reported to date
in the literature. A quadruplex with the sequence (TT AGGGT)4 that is complexed with a
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small molecule intercalated between a guanine-adenine tetrad was used as an in silico
basis for the representative "end-pasting" site contained in the human telomeric
quadruplex AGGG(TTAGGG)J. A new virtual screening strategy is described that was
successful and computationally plausible for screening millions of small molecules
against a nucleic acid target. The top nine hits gleaned from the virtual screening studies
were tested using spectroscopic and fluorescence based assays to validate the predicted in

silico activity by in vitro testing. Finally, we computationally generated all possible endpasting sites in two in silico RSCB PDB structures containing the human telomeric Gquadruplex AGGG(TT AGGG)3 repeat and docked the newly discovered compound to the
sites to assess nucleic-acid and small molecule interactions. The results show that the
virtual screening platform, as described here, is predictive and capable of discovering
new small molecules with a specific mechanism of interacting with G-quadruplex nucleic
acids.

Experimental and Computational Methods

In silico Ligand Database and Nucleic Acid Target Preparation. A ZINC database
consisting of approximately 6.6 million virtual small molecules was used for initial
virtual screening studies against the nucleic acid (TTAGGGT)4. These small molecules
were the "Reference" subset of the 2008 "Drug-Like" dataset and are freely available for
download from the University of Cali fomi a, San Fransisco [180]. The ligands have been
named "Drug-Like" because of their adherence to Lipinski's rule of 5 to increase the
chances that any hits will have higher oral bioavailability [31].

The small molecules

were downloaded and used without any further modification from the initial procedures
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perfonned by UCSF which included protonation based on a pH 7 reference, 3D
coordinate generation and partial charge assignment from AMSOL semi-empirical
quantum calculations.

The NMR detennined G-quadruplex (TTAGGGT)4 with PDB ID

1NZM was downloaded from the RSCB Protein Data Bank in PDB file fonnat for use in
the virtual screening in silica experiments. Sybyl v8.1 (Tripos, Inc.) was used to assign
AMBER atom types and convert the file to MOL2 fonnat in preparation for initial
Surflex-Dock screening. The RHPS4 complexed ligand was removed prior to molecular
docking experiments using Sybyl. All in silica virtual screening studies were perfonned
on our server of 440 computers consisting of 2.66GHz Intel(R) Xeon(R) E5430
processors and required approximately 3 days to complete the Surflex-Dock experiments
and 2 days to complete the Autodock experiments.
SurJlex and Autodock Virtual Screening Methods. We have previously validated the
use of Surflex-Dock and Autodock for targeting nucleic acids and these software are a
logical choice for the discovery of new ligands against novel targets [63]. The endpasting site on the nucleic acid (TTAGGGT)4 was considered a model of the end-pasting
site on the human telomeric quadruplex AGGG(TTAGGG)3 and was targeted for
molecular docking using both Surflex-Dock v2.2 (Tripos, Inc.) and Autodock v4.0
(Scripps). The end-pasting cavity was specified for Surflex-Dock v2.2 docking using a
ligand-based approach. This involves using the existing RHPS4 ligand that was bound
inside the (TTAGGGT)4 end-pasting site to generate a Surflex-Dock "protomol" which
guides the molecular docking of the in silica ligand library to the end-pasting site. The
"protomol" was constructed by altering the "proto_bloat" and "proto_thresh" functions
and visualized in Sybyl to ensure reasonable interactions in the end-pasting site. The
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significance of the protomol and the Surflex-Dock docking and scoring functions have
been described in detail previously [60]. Briefly, the "protomol" consists of a series of
small chemical fragments that model important forces in the nucleic acid pocket,
including steric effects and hydrogen bond acceptor and donor groups. Each of the
ligands in the in silica virtual library is fragmented, aligned against the protomol, and
subsequently scored based on the interactions in the binding site. Surflex-Dock was
performed using default options which in our previous experience is appropriate for
rapidly screening databases of small molecules against nucleic acid targets.
The utilization of Autodock to target nucleic acid structures has also been
previously described [34, 63-64, 204]. Autodock works by precomputing energy grids
for a target [205]. A genetic algorithm such as the Lamarkian Genetic Algorithm is used
to assess the interactions of the ligand with the pre-calculated energy grids until typically
a specific number of energy evaluations is reached. The final top "pose" returned by
Autodock is the computed lowest energy docked structure of the ligand with respect to
the target.

The highest scoring pose of the top 1% of ranked Surflex-Dock hits

(approximately 66,000 small molecules) were extracted in MOL2 format and converted
to PDBQT file format using the Python scripts included with Autodock.

The G-

quadruplex nucleic acid (TTAGGGT)4 was prepared for Autodock by using
AutoDockTools to convert the MOL2 to PDBQT file format. The extent of the Autodock
grid maps was 66,64,40 points (X,Y,Z) with grid spacing distance of0.375A, and the grid
centered on the end-pasting site. Autodock docking was performed by setting the number
of docking runs to 5 and energy evaluations to 20 million energy evaluations, as we
previously found these parameters to be optimal for docking of small molecules to
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nucleic acids [63]. After completion of Autodock docking, the Surflex and Autodock
results were re-ranked using a Ranked Consensus Scoring (RCS) function as follows
[206]:
'C'l"t

ReS = ~t=1.

Rt

N

(12)

The rank-by-rank strategy (RCS) is used to assign an average rank for each of the top
66,000 compounds from the two available scoring functions in Autodock and Surflex.
The following example illustrates how this scoring function works. If the small molecule
ranks 1 by Autodock and 3 by Surflex, than the consensus ranking score is 2, using
equation 12 above [207]. The RCS is performed for all 66,000 compounds to develop a
consensus ranked list of compounds.

Oligonucleotide and Small Molecule Preparation. The G-quadruplex oligonucleotide
AGGG(AGGGTT)3, also referred to here as the "K+ 22mer," was obtained from
Integrated DNA technologies (IDT, Coralsville, IA) and prepared for experiments by
dialysis and annealing. Dialysis was performed against KPEK buffer, which is composed
ofK2HP0 4 (6mM), KH ZP04 (2mM), KCI (185mM), EDTA (O.lmM), pH 7, using Pierce
(Rockford, IL, USA) 3500 Da molecular weight cutoff dialysis cassettes.

The

oligonucleotides were annealed by heating at 90 °C for 2 minutes, cooling to room
temperature overnight and left at 4 °C for 48 hours prior to use, as previously described
[10,64]. The oligonucleotide (with

E =

228,500 LI(mole cm) for the single-strand form)

was characterized structurally by Circular Dichroism (CD) spectroscopy and the resulting
spectrum was consistent with previously reported results for this structure (Figure 65)
[132, 208]. All oligonucleotides used for the quadruplex melting studies were also
obtained, annealed and characterized using the methods described and
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Figure 65. CD Spectrum (A) and CD Melt (B) of the K+ 22mer G-Quadruplex. Both
spectra are consistent with published structural data for this nucleic acid.
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Figure 65. CD Spectrum (A) and CD Melt (B) of the K+ 22mer G-Quadruplex.
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previously [10, 64]. The top nine small molecules with the best ranked consensus scores
were purchased for testing.

The molecule described in detail here has ZINC

identification number 8927810, was purchased from InterBioScreen (Moscow, Russia)
under the catalog number STOCK1S-61623 and is described chemically as 1-methyl-4[5-( 1-methyl-4-quinolylidene)-3-phenyl-penta-1 ,3-dienyl]-quinoline. This small molecule
will be hereafter described as "Compound 1." Compound 1 was weighed and a stock
solution was created by dissolved the weighed compound in DMSO (Sigma, St. Louis,
MO, USA) prior to testing.
Biophysical Testing Methods. UV /Vis Absorption titration experiments were performed
on a Tecan Safire 96 well microplate reader (Durham, NC, USA) in duplicate and
measured five times at 1nm step intervals between 550nm and 950nm, consistent with
previously described procedures [203].

The percent hypochromicity for the UV/Vis

absorption titrations was determined from the shift in the absorbance at no added DNA
(650nm) and maximal added DNA (659nm) by the formula:

(13)
Both the UVNis Absorbance and CD experiments were performed using procedures
previously described [184, 203, 209]. All CD experiments were performed on a Jasco J810 spectropolarimeter (Easton, MD, USA). CD scanning experiments for the purposes
of K+ 22 mer quadruplex DNA characterization were performed at a concentration of

3.51lM (strand) from 320nm to 220nm with a data interval of 1nm, band width of 1nm,
response of 1 second, scanning speed of 200 nrn/minute and a total of four accumulated
scans.

Induced CD experiments were performed from 900nm to 550nm with a data

interval of lnm, band width of lnm, response of 2 seconds, scanning speed of 200
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nrn/minute and a total of three accumulated scans. For induced CD experiments, the
Compound I concentration was fixed at 11.6JlM and separate solutions were prepared
with increasing ratios of K+ 22 mer quadruplex DNA. CD melting experiments with the
K+ 22mer were performed at a DNA concentration of 3.5JlM from 20°C - 98 °C with a
scanning speed of I °C/minute.
The Thiazole Orange Fluorescent Intercalation Displacement Assay (TO-FID)
was performed using procedures previously described [40].

Thiazole Orange was

obtained from Anaspec, Inc (San Jose, CA, USA) and dissolved in DMSO. Using a K+
22mer quadruplex concentration ofO.25JlM (strand) and a Thiazole Orange concentration
of 0.50JlM, increasing amounts of Compound 1 test ligand are added to the solution and
the fluorescence of Thiazole Orange is monitored. All TO-FID fluorescence readings
were performed in duplicate and measure 5 times on a Tecan Safire 96 well microplate
reader with Excitation at 501nm, Emission from 52lnm to 750nm, Emission maximum
at 535nm, lnm step size, Excitation and Emission Band Widths of 9nm and a Gain of
130. All spectroscopic and TO-FID testing was performed in a buffer solution consisting
of KPEK and 5% DMSO. The absorbance of Compound 1 is in the region of 550nm 900nm and does not interfere with reading TO fluorescence at 535nm.
The quadruplex melting studies were performed in a 96-well plate format on an
Applied Biosystems StepOnePlus Real-Time PCR System (Carlsbad, CA, USA) adapted
for use in thermal melting experiments.

The K+ 22mer quadruplex was labeled with a

FAM-TAMRA Fluorescence Resonance Energy Transfer (FRET) pair to selectively
monitor the K+ 22 mer quadruplex melting in the presence of competing DNA solutions.
For the FAM -TAMRA labeled K+ 22mer quadruplex compound melting saturation
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experiments, increasing concentrations of Compound I were added to a fixed solution
containing 250 nM FAM-TAMRA labeled K+ 22mer quadruplex (Sigma, St. Louis, MO,
USA) and melting experiments were performed. The temperature range for the melting
range was 20°C - 98°C with data measurements taken every 0.2°c. The FAM-TAMRA
labeled quadruplex was monitored using a fluorescence filter that quantifies emission at
520 nm.

Melting curves were fit in Mathematica v6.0.2.1 (Wolfram Research) and

melting temperatures calculated as previously described [210-211].

For the DNA

competition experiments, a stock solution of250 /-lM ofFAM-TAMRA labeled K+ 22mer
quadruplex was made by weighing the quadruplex, dissolving in a solution of tetrabutyl
ammonium phosphate and adjusting the pH to 7.0 with tetrabutyl ammonium hydroxide.
The stock solution ofFAM-TAMRA labeled K+ 22mer quadruplex was diluted to a final
concentration of 150 nM using KPEK buffer for all melting experiments. Competing
DNA solutions were added to the wells containing the FAM-TAMRA labeled K+ 22mer
quadruplex such that the final concentration of competing DNA was 20 fold higher (3
/-lM) than the concentration of the FAM-TAMRA labeled K+ 22mer quadruplex (150
nM). Finally, Compound 1 was added such that the concentration ratio of Compound 1
to FAM-TAMRA labeled K+ 22mer quadruplex was 40/1 (final Compound 1
concentration of 6 /-lM). All melting studies were performed in a buffer consisting of
KPEK + 5% DMSO. Oligonucleotides concentrations were based on a monomeric unit
(nucleotide for duplex DNA, triplet for triplex DNA and quartet for quadruplex DNA) as
previously described [172-173].

Hybrid-l and Hybrid-2 Quadruplex Modeling and Docking Methods. The nucleic acids
that are representative of the Hybrid-l (PDB ID: 2HY9) and Hybrid-2 (PDB ID: 2JPZ)
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structures that are present in the K+ 22mer quadruplex sequence were downloaded from
the Protein Data Bank in PDB file format and prepared for molecular docking
experiments as described above. Both of these structures contain the human telomeric
repeat

sequence

(TT AGGG)n

with

Hybrid-l

consisting

of

the

sequence

AAAGGG(TTAGGG)3AA and Hybrid-2 consisting of the sequence (TTAGGG)4TT.
There are four possible end-pasting sites in these two structures to which Compound I
was docked using both Surflex and Autodock. In each of these two structures, endstacking sites are present at both the 3' and 5' ends and occupy the space between the
terminal guanine tetrad and accompanying loop structures. Unfortunately, Surflex v2.2
has yet to include and have receptor flexibility validated for use with targeting nucleic
acids. Therefore, an alternative strategy was employed to "open up" the external Gquartet and surrounding bases that comprise the end-pasting site to allow for molecular
docking to proceed. To expose the end-pasting sites, we built a virtual ligand consisting
of a quaterpurine, a largely planar, aromatic, small molecule that would stack well upon
the terminal guanine quartet. This virtual ligand was appropriately named because it
consists of four purines that are connected together in a cyclic arrangement (Figure 66).
Using Macromodel, the quaterpurine was initially positioned between the terminal Gtetrad and loop region for each of the possible four endpasting sites. The nucleic acid
was initially energetically minimized holding the ligand fixed using a Steepest Descent
algorithm for 1000 iterations. The nucleotides comprising the end-pasting site including
the terminal G-quartet and loop nucleotides were designated as flexible while the
remaining nucleic acid bases were held rigid and fixed. Further structural minimizations
were performed by 500 iterations of the Polak Ribier Conjugate Gradient Method. This
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Figure 66. The structure of the Quaterpurine small molecule used to "open-up" the
Hybrid-l and Hybrid-2 End Pasting sites.
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Figure 66. The structure of the Quaterpurine small molecule used to "open-up" the
Hybrid-l and Hybrid-2 End Pasting sites.
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approach successfully opened the end-pasting sites for Surflex and Autodock molecular
docking experiments.

The docking of Compound 1 to the two end pasting sites in

Hybrid-l and the two end pasting sites in Hybrid-2 using Surflex and Autodock was
performed based on our previously published results validating the use of these software
to target small molecules that bind to nucleic acids [63]. For Surflex, the "Multi start 5"
option was enabled and with Autodock, the number of dockings was set to 5 and the
number of energy evaluations was set to 20 million (2E7) [63]. The "protomol" used by
Surflex was generated using the position of the quaterpurine ligand occupied in the end
pasting sites. The Autodock procedures for grid map preparation and grid parameters
used for docking have been previously described (Table 11) [63].

These molecular

modeling studies of Compound 1 with the human telomeric structures were performed on
a single computer consisting of 2.66GHz Intel(R) Xeon(R) E5430 processor and required
an average of approximately 2.2 minutes and 31.8 minutes to complete each of the four
Surflex and Autodock experiments, respectively.

Results and Discussion

The (TTA GGTh Quadruplex has a Representative End-Pasting Site for Virtual
Screening. The discovery of small molecules that are able to bind to the end-pasting
region of the human telomeric sequence AGGG(TTAGGG)3 (K+ 22mer) are of great
interest as they can potentially stabilize the quadruplex in vivo and may possess anticancer activity [55]. A search of the online RSCB PDB database showed over 120
quadruplex structures that had been deposited as of December 2009.

Surprisingly,

however, there are conflicting published reports about the "correct" structure of the K+
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Table 11. Autodock Docking Parameters used for In silico Targeting of the End-Pasting
Sites in Hybrid-I and Hybrid-2.
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Table 11. Autodock Docking Parameters used for In silica Targeting of the End-Pasting
Sites in Hybrid-l and Hybrid-2.

Autodock Target

Dimensions of Grid

Grid Center

(X, Y, Z)
Hybrid 1 End Paste 1

66 X 46 X 70

-0.034 X 7.176 X 0.032

Hybrid 1 End Paste 2

70X64X66

-0.01 X 4.819 X 0.036

Hybrid 2 End Paste 1

50 X 40 X 50

-0.099 X 7.303 X 0.059

Hybrid 2 End Paste 2

68 X 38 X 56

0.089 X 3.91 X -0.018
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22mer under physiologically relevant conditions, even though there are mUltiple small
molecules that are thought to interact with the human telomeric quadruplex by endpasting binding [191, 202]. Increasing evidence is suggesting that the K+ 22mer exists as
a "hybrid" structure, but there have yet to be any NMR structures published with small
molecules bound to this structure [191,193-194]. This is unfortunate, as the ligand could
be easily removed computationally and the nucleic acid used for structure-based virtual
screening. Instead, however, structures that possess the human telomeric repeat must be
computationally altered prior to molecular docking to allow docking to the end-pasting
region of the quadruplex.
An alternative approach that we propose is selection of a G-quadruplex structure
(with a small molecule complexed) which we believe possesses similar properties of the
K+ 22mer end-pasting including a terminal guanine quartet with flanking Adenine
containing residues. Interestingly, the quadruplex (TTAGGGT)4 with PDB ID INMZ
appears to possesses many properties that makes it a representative end-pasting site of the
K+ 22mer G-quadruplex structure.

While the small molecule that is found in the

(TTAGGGT)4 quadruplex site lies in an end-pasting site with adenine and guanine
quartets (Figure 64B), we believe that this arrangement of nucleotides is remarkably
similar to an end-pasting site that is present in the K+ 22mer (Figure 64A) and thus makes
(TTAGGGT)4 a suitable choice for virtual screening experiments. The small molecule
RHPS4 that is found in the end-pasting site of (TTAGGGT)4 is easily removed
computationally and allows the nucleic acid structure to be used with minimal alterations
for virtual screening experiments. In this sense, the (TTAGGGT)4 structure represents
the in silica structure that is perhaps singularly most representative of an end-pasting site
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found in the K+ 22mer. We prefer this strategy over previously reported approaches
which typically involve breaking bonds of the target nucleic acid structure to generate an
artificial site for docking as our approach preserves the fidelity of the in silico structure
without manipulation or perturbation [212].

Importantly, this also demonstrates an

approach for circumventing structure-based in silico screening problems when the target
site is not entirely available from the in silico structure.

Virtual Screening Discovery of a Novel Quadruplex Binding Ligand.

The

(TTAGGGT)4 structure with the representative pseudo end-pasting site was the basis for
the virtual screening efforts to discover new quadruplex binding small molecules. The
next challenge is the selection of molecular docking programs that are suitable for
screening millions of compounds against a nucleic acid target. Our recent validation of
two popular protein molecular docking programs, Autodock and Surflex, for use with
nucleic acids demonstrated that these software can accurately reproduce multiple small
molecule crystal structures of small molecules that interact with DNA by several
mechanisms [34, 63]. The docking results showed that while both docking programs
were accurate at reproducing the crystal structures, Autodock required approximately 10
fold greater time for docking experiments compared to Surflex, under conditions reported
previously [63]. This difference in docking speed is particularly important when the in

silico library screened here is greater than 6.6 million small molecules. The question
remains whether these two structure-based docking software can be combined in an in

silico platform to target the (TTAGGGT)4 pseudo end-pasting site.
While one possibility for virtual screening was to perform experiments using only
Surflex, this would neglect the validated use of Autodock, as well as the fact that
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Autodock implements different scoring and docking algorithms than Surflex, which may
complement the Surflex approach [60, 205]. An alternative strategy that we developed is
to use Surflex to pre-screen the entire in silico library and subsequently perform
Autodock docking on only the top 1% of ranked Surflex hits (Figure 67). This approach
balances both the computational efficiency and accuracy of Surflex with the power of
Autodock in a single, integrated, virtual screening platform. The top ranked hits (66,000
compounds) for both programs were subsequently re-ranked using a rank-by-rank
consensus scoring function that is preferable over a single scoring function and has
previously been shown to increase success with virtual screening experiments [206-207].
In this case, a consensus approach is preferred as there is yet to be developed a
"universal" scoring function that is suitable for either nucleic acids or proteins. Because
each scoring function has distinct advantages and disadvantages, the adoption of a
consensus-based approach increases the probability of discovering novel small
molecules, while minimizing false positives that commonly occur in virtual screening
studies of large numbers of in silico compounds [207, 213]. The virtual screening
approach outlined in Scheme 1 was used for the selection of nine small molecules with
hypothesized K+ 22mer end-stacking binding.

Unfortunately, eight of the nine

compounds were excluded from biophysical testing in the assays described herein due to
such problems as solubility limitations or lack of a suitable chromophore for testing.
However, one small molecule in particular, Compound 1 (Figure 68), possessed suitable
properties for biophysical experiments and was tested to determine if the hypothesized
activity that was identified through the in silico screen could be demonstrated in vitro.
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Figure 67. The virtual screening strategy used to dock the in silico library of compounds
to the (TTAGGT)4 quadruplex and determine the best hits for biophysical testing.
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Figure 67. The virtual screening strategy used to dock the in silica library of compounds
to the (TT AGGT)4 quadruplex and determine the best hits for biophysical testing.

Surflex-Dock Pre-Screening

D

-Dock 6.6 million compounds

Autodock on Top 1% Surflex Hits

D

-Dock 66,000 compounds

Ranked Consensus Scoring (RCS)

D

I

-RCS on 66,000 compounds

Biophysical Testing of Top 9 Hits
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Figure 68. The newly discovered small molecule, Compound 1, from the in silico virtual
screening experiments.
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Figure 68. The newly discovered small molecule, Compound 1, from the in silica virtual
screening experiments.
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These experiments were crucial to determine if the virtual screening strategy developed
in Scheme 1 can not only discover new compounds, but also predict the specific site of
binding of the compound to the quadruplex.
Biophysical Validation of the Predicted In silico Activity of Compound 1. While our in
silico approach successfully discovered multiple ligands with hypothesized K+ 22 mer Gquadruplex binding activity, the question remains whether the computational methods are
truly predictive of small molecule nucleic acid interactions in vitro. To address this
concern, we present biophysical testing that suggests that our molecular docking
approach as outlined in Scheme 1 successfully identifies a small molecule that not only
interacts with the K+ 22mer quadruplex as predicted in silico, but also binds by the
hypothesized end-stacking mechanism to the external guanine quartet.
UVlVis Absorbance Titrations and CD Spectroscopy. UV/Vis absorption titrations and
Circular Dichroism (CD) are powerful techniques that for our purposes can be used to
confirm our in silico predictions of the interaction of Compound 1 with the K+ 22mer.
The UV/Vis absorption experiments involve adding an increasing amount of K+ 22mer
DNA to a solution of fixed ligand concentration while monitoring the absorbance
spectrum of the ligand. Because the absorption spectrum of the ligand (550 nm - 900
nm) is unique from that of the DNA «300 nm), changes in the monitored ligand spectra
are indicative of specific interactions with the DNA.

These spectra data show

unambiguously that Compound 1 binds to the K+ 22mer. In the case of Compound 1, as
increasing concentrations of K+ 22mer DNA are added to the solution, there is marked
hypochromicity that occurs at 650nm as well as an appearance of a new peak at 827nm
(Figure 69). The amount ofhypochromicity and relative wavelength shift can be used as
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Figure 69. UV/Vis Absorption Titrations at increasing Quadruplex/Compound 1 ratios
demonstrating the G-quadruplex interaction of Compound 1 with the K+ 22mer
quadruplex, AGGG(TTAGGG)3.
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Figure 69. UVN is Absorption Titrations at increasing Quadruplex/Compound 1 ratios
demonstrating the G-quadruplex interaction of Compound 1 with the K+ 22mer
quadruplex, AGGG(TT AGGG)3.
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indicators to determine the DNA binding mode [214]. The amount of hypochromicity
observed here (>38.2%) is consistent with ligands such as TmPyP4 that can interact with
the K+ 22mer by both end-stacking and intercalation [132]. However, intercalation of
ligands such as TmPyP4 is typically characterized by a bathochromic, red shift of> 15
nm, while reports for ligands that interact by end-stacking such as Berberine are in the
range of 8 - 12 nm [132, 146, 203, 209, 215]. Additionally, it has been reported that
intercalation is energetically less favorable than terminal end-stacking due to the
challenge of quadruplexes accommodating ligands stacked between existing guanine
quartets [209]. In the case of Compound 1, in addition to the observed hypochromicity at
650 nm, an estimated 9 nm red shift occurs from 650 nm to approximately 659 nm,
suggesting that Compound 1 may interact with the K+ 22mer quadruplex by end-stacking.
A consideration here is that the amount of hypochromicity and red-shift appears to be
somewhat ligand-and quadruplex dependent, and the amount to which the quadruplex
loop interactions are involved can substantially impact these values [209]. Nonetheless,
the UV/Vis absorption data support an interaction of Compound 1 with the K+ 22mer
quadruplex and suggest an end-stacking interaction with the external G-tetrads of the K+
22mer quadruplex.
Circular Dichroism was also employed to determine if Compound 1 interacts with the K+
22mer quadruplex by the in silica predicted end-stacking mode. Circular Dichroism is
useful for studying small molecule-nucleic acid interactions as ligands typically lack a
CD signal, but upon binding to DNA, an "induced" CD (lCD) effect may be observed.
Importantly, the magnitude and sign of the ICD signal typically allows for the
classification of the ligand binding mechanism as either groove binding (a positive
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signal) or intercalation (a negative signal) [184]. The CD results are consistent with the
other data presented thus far and clearly show an interaction of Compound 1 with the K+
22mer quadruplex. At low Quadruplex/Compound 1 ratios (0.1 - 0.25), Figure 70A
shows the presence of both a positive peak in the region of 625nm and a negative peak in
the region of 665nm. The spectroscopic signature, with the presence ofbisignate positive
and negative peaks, is likely the so-called "exciton" effect. The exciton effect is
significant as it may indicate the presence of multimers or aggregates of Compound 1 that
impart this unique spectroscopic signal [184]. At higher Quadruplex/Compound 1 ratios
(2 - 5), there is a progressive negative inducible CD that is observed as well as shift from
approximately 675 nm - 700 nm. This behavior is generally consistent with Compound
1 interacting with the quadruplex by intercalation or end-stacking (Figure 70B). The shift
of the CD spectral minimum from 675 to 700 nm could exist for several reasons. First,
there may exist multiple end-pasting sites with variable affinity for the ligand. This sitedependent variable affinity binding behavior has been seen previously with other K+
22mer binding small molecules such as TmPyP4 [203]. Additionally, because the K+
22mer DNA sequence typically consists of a heterogeneous mixture of species, there may
be interactions with multiple, unique G-quadruplex end-pasting sites [194]. It is also
possible that the ligand may interact primarily by end-stacking and by intercalation, as
this dual type of binding behavior has been previously reported with other G-quadruplex
binding ligands [131]. In total, however, the appearance of an induced CD signal as seen
here is consistent with other biophysical data and supports the end-stacking of Compound
1 to the K+ 22mer quadruplex.
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Figure 70. Induced CD Spectroscopy at increasing QuadruplexlCompound 1 ratios
showing the G-quadruplex interaction of Compound I with the K+ 22mer quadruplex,
AGGG(TTAGGG)J. (A) and (B) show the spectroscopic profile at lower and higher
QuadruplexlCompound 1 ratios, respectively.
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Figure 70. Induced CD Spectroscopy at increasing Quadruplex/Compound 1 ratios
showing the G-quadruplex interaction of Compound 1 with the K+ 22mer quadruplex,
AGGG(TT AGGGh (A) and (B) show the spectroscopic profile at lower and higher
Quadruplex/Compound 1 ratios, respectively.
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Thiazole Orange Fluorescence Intercalation Displacement (TO-FID).

The TO-FID

assay is a complementary assay to the UVNis absorbance and CD spectroscopic studies
and is another method to determine if Compound I interacts with the K+ 22mer
quadruplex by end-stacking. One of the advantages of this assay is that only the
fluorescence ofthiazole orange (TO) is monitored, so the tested ligand need not have any
fluorescent or absorbance properties. The assay requires no specialized equipment and
less training than other techniques that have been used to assess DNA-small molecule
interactions such as ESI-MS and SPR [40]. Finally, the assay is amenable to a 96 well
microplate format; a property that is desirable for high-throughput testing of ligands that
may be discovered by virtual screening and other computational methods. Successful
operation of the TO-FID assay relies on the known binding of TO to the end-pasting
region of the human telomeric quadruplex K+ 22mer which has been previously well
characterized [40, 216-217]. Thiazole Orange is unique as it typically has a reported
several hundred to thousand fold increase in fluorescence when it is bound to DNA and
an insignificant fluorescence when displaced from DNA and unbound in solution [217219]. The assay is performed by initially saturating the K+ 22mer DNA with TO and
subsequently adding increasing amounts of the ligand to the solution. If the ligand binds
to the quadruplex end-stacking region with sufficiently high affinity, TO will be
displaced and the fluorescence will be quenched.

This assay can thus confirm both

binding of the ligand to the quadruplex and the probable site of binding. Indeed, the
quenching of TO fluorescence upon addition of Compound 1 suggests that it dissociates
TO from the end-pasting region of the K+ 22mer (Figure 71). The testing of Compound 1
was successful and avoided the limitations of the assay, which are as follows. First, if the
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Figure 71. TO-FID results showing the displacement of Thiazole Orange (TO) from the
K+ 22mer quadruplex and subsequent TO fluorescence quenching at increasing
concentrations of the ligand Compound 1. The inset shows the structure of TO. Black
squares
triangles

=
=

TO + DNA + buffer.

Red circles

=

TO + DNA + Compound 1.

Green

TO + Compound 1. Data plotted are the average of experiments in duplicate.

Error bars represent ± one standard deviation.
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Figure 7l. TO-FID results showing the displacement of Thiazole Orange (TO) from the
K+ 22mer quadruplex and subsequent TO fluorescence quenching at increasing
concentrations of the ligand Compound 1. Data plotted are the average of experiments in
duplicate. Error bars represent ± one standard deviation.
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ligand is of weak affinity (or has a binding constant lower than that of TO), it may not be
sufficient to displace TO. Second, the ligand may bind the quadruplex at a different site,
the grooves for example, instead of the end sites, and this binding would elude detection
by the FID method as described here. Third, the ligand of interest may have overlapping
spectroscopic behavior with Thiazole Orange which can confound the results of the
assay. Compound 1 circumvents these limitations as it clearly displaces and lacks any
spectral overlap with the TO probe, allowing an assessment of the binding properties of
Compound 1. It is conceivable that Compound 1 may also interact with the K+ 22mer by
additional mechanisms at distinct sites on the K+ 22mer that may complicate the observed
fluorescent quenching curve. However, in total, the TO-FID data are consistent with the
UV/Vis and CD data and support the initial in silico based hypothesis that Compound 1
likely interacts with the end-pasting sites on the human telomeric K+ 22mer quadruplex.

Selective Recognition and Thermal Stabilization of the

JC 22mer Quadruplex.

Melting experiments were performed to determine whether Compound 1 can thermally
stabilize the K+ 22mer quadruplex in the absence and presence of competing DNA
structures. Many of the most studied quadruplex binding ligands have been shown to
increase the quadruplex melting temperature (Tm) [220]. It is worth mentioning that the
melting temperature of the K + 22mer quadruplex (as tested here) occurs at approximately

noc

which is far above physiological temperature (37°C) and may not reflect what

occurs under more biologically representative conditions [221].

However, the assay

provides further unambiguous proof of binding of a compound to the quadruplex target.
As Figure

n

shows, the addition of increasing amounts of ligand to the K+ 22mer results
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Figure 72. Effect of Compound 1 on the Melting Temperature of the FAM-TAMRA
labeled K+ 22mer G-Quadruplex.
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Figure 72. Effect of Compound 1 on the Melting Temperature of the FAM-TAMRA
labeled K+ 22mer G-Quadruplex. Data plotted are the average of experiments performed
in triplicate. Error bars are ± one standard deviation.
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in an increase in the Tm of the quadruplex of approximately 10°C at the highest levels of
Compound 1 tested.
Competition experiments were performed to determine if Compound 1 prefers the
K+ 22mer over other DNA structures.

Under the conditions tested, Compound 1

stabilizes the K+ 22mer from approximately 73°C (- cmpd 1) to 79.5°C (+ cmpd 1). The
addition of 20 fold excess competitor quadruplex (T2 G20T2 , bcl-2, VEGF, Rb, C-myc)
relative to the K+ 22mer can generally decrease the Tm of the K+ 22mer which suggests
that these structures are successfully competing for binding to Compound 1 (Figure 73).
The VEGF quadruplex appears to be most successful at competing for Compound 1 as is
evidenced by the greatest decrease in K+ 22mer Tm. However, the addition of dAdT and
dGdC does not effect the Tm, which suggests that Compound 1 selectively prefers the K+
22mer quadruplex compared to these DNA structures.

Taken in total, these results

further validate the binding of Compound 1 to the K+ 22mer quadruplex and also suggest
that Compound 1 offers some selectivity for quadruplex compared to duplex DNA
structures.

Molecular Docking of Compound 1 to Hybrid-l and Hybrid-2.

With the initial

discovery of Compound I and subsequent biophysical testing to demonstrate binding
activity to the K+ 22mer G-quadruplex, the next goal was to develop possible models for
how Compound 1 can interact with the external G-quartet that is present in the K+ 22mer
quadruplex.

These models could provide valuable insights into the possible interaction

of Compound 1 with the terminal G-quartets and loop regions that are present in the
human telomeric quadruplex structure. The K+ 22mer is polymorphic and is known to
adopt several so-called Hybrid structures (Hybrid-l and Hybrid-2) in vitro [146].
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Figure 73: Effect of a 20 fold Excess of Competitor DNA on the Ability of Compound 1
to Thermally Stabilize the FAM-TAMRA labeled K+ 22mer G-Quadruplex.
triplex and quadruplex nucleic acids were used as competitor DNA structures.
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Duplex,

Figure 73: Effect of a 20 fold Excess of Competitor DNA on the Ability of Compound I
to Thermally Stabalize the FAM -TAMRA labeled K+ 22mer G-Quadruplex. Duplex,
triplex and quadruplex nucleic acids were used as competitor DNA structures.
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Structures for the Hybrid-l (PDB ID 2HY9) and Hybrid-2 (PDB ID 2JPZ) quadruplexes
are available in silico and were selected for modeling studies as they contain the human
telomeric K+ 22mer repeat [196-197, 222], but have unique flanking sequences. These
two structures each have two external G-quartet end-stacking sites for a total of four
possible end-pasting sites. Interestingly, while the common conserved feature among
these sites is the presence of the G-quartet, each of these sites has unique loop topologies
that may confer ligand-binding specificity. Unfortunately, a limitation of these structures
is that neither of these structures has a complexed ligand present in the end-pasting zone.
An alternative approach is to computationally "open-up" the end-pasting site prior to
docking of Compound 1. This was accomplished by constructing a planar, aromatic
small molecule ligand, manually placing the ligand in the four possible end-pasting sites
and energetically minimizing the nucleic acid structure around the ligand (Figure 66).
This procedure was sufficient to open up the end-pasting site for molecular docking for
the purposes of modeling the fit of Compound 1 in the putative end-pasting sites.
Molecular docking of Compound 1 to all four end-pasting sites was successfully
performed with Autodock and Surflex using a validated docking procedure previously
described for nucleic acids [63].

The top poses of Compound 1 for these docking

software are shown in Figure 74 with the resulting scores shown in Table 12. Based on
our previous experience with these programs, the Autodock and Surflex scores for all
docked complexes are comparable. Generally, Compound 1 appears to dock and fit well
in all four of the end-pasting sites. A closer view of the top poses without the nucleic
acid present (Figure 75) reveals that the top ranked poses for Surflex and Autodock
appear to have a higher amount of overlap for the two Hybrid 1 end-pasting sites
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Figure 74. The top ranked poses for Compound 1 docked using Surflex (Gold) and
Autodock (Cyan) to the following G-quadruplex nucleic acid structures: (A) Hybrid-l
End Paste Site 1 (B) Hybrid- 1 End Paste Site 2 (C) Hybrid-2 End Paste Site 1 and (D)
Hybrid-2 End Paste Site 2. The nucleic acid structures are shown in white except for the
small molecule interacting terminal guanine tetrads which are shown in green.
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Figure 74. The top ranked poses for Compound I docked using Surflex (Gold) and
Autodock (Cyan) to the following G-quadruplex nucleic acid structures: (A) Hybrid-l
End Paste Site 1 (B) Hybrid- 1 End Paste Site 2 (C) Hybrid-2 End Paste Site 1 and (D)
Hybrid-2 End Paste Site 2.
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Table 12. The scores for the top-ranked pose from
possible end-pasting sites in Hybrid-l and Hybrid-2.
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A~todock

or Surflex for the four

Table 12. The scores for the top-ranked pose from Autodock or Surflex for the four
possible end-pasting sites in Hybrid-l and Hybrid-2.

Hybrid Structure /
PDBID
Hybrid-l /2HY9
End Paste site 1
Hybrid-l /2HY9
End Paste site 2
Hybrid-2 /2JPZ
End Paste site 1
Hybrid-2 /2JPZ
End Paste site 2

Surflex-Dock Score

14.29

Autodock Score
(kcal/mol)
-11.45

15.19

-11.77

14.98

-12.71

13.56

-12.57

(-I02(K.J) )
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Figure 75. The top ranked poses for Compound 1 docked using Surflex (Gold) and
Autodock (Cyan) to the following G-quadruplex nucleic acid structures: (A) Hybrid-l
End Paste Site 1 (B) Hybrid-l End Paste Site 2 (C) Hybrid-2 End Paste Site 1 and (D)
Hybrid-2 End Paste Site 2. The file format for the Autodock poses is PDBQT with
merging of non-polar hydrogens.
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Figure 75. The top ranked poses for Compound 1 docked using Surflex (Gold) and
Autodock (Cyan) to the following G-quadruplex nucleic acid structures: (A) Hybrid-l
End Paste Site 1 (B) Hybrid-l End Paste Site 2 (C) Hybrid-2 End Paste Site 1 and (D)
Hybrid-2 End Paste Site 2.
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compared to Surflex and Autodock top ranked poses for the end-pasting sites of Hybrid2. Visual inspection of the top ranked pose is necessary to evaluate ligand interactions
with the guanine quartet and the loop regions. Indeed, in all four of the end-pasting
models, Compound 1 appears to stack well on the guanine quartet. This type of binding
behavior is in agreement and consistent with that of many largely aromatic compounds
such as TMPyP4 that bind G-quadruplex structures by either end-pasting or intercalation
[202]. What is typically more difficult to interpret, but albeit equally important, is the
interaction of Compound 1 with the various terminal loop structures. In contrast to the
Guanine tetrad, the loop arrangements appear much more flexible and conformationally
heterogeneous.

The models certainly suggest that Compound 1 can interact with the

various loops to different extents, which could potentially modulate selective binding and
stabilization of quadruple x structures. In fact, compounds that bind by end-stacking as
well as preferentially to specific quadruplex loops and accompanying grooves are
currently a source of great interest as this is thought to confer quadruplex discriminatory
capability to small molecules.

Of interest here is the modeling data suggesting both

guanine quartet interactions as well as potential loop interactions with the four possible
end-pasting sites of the Hybrid-l and Hybrid-2 quadruplex structures. These models also
suggest that Compound 1 may serve as a lead compound for derivatization experiments
to increase preferential loop and or groove binding to impart specific quadruplex
discrimination.
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Conclusions

The discovery of novel G-quadruplex nucleic acid small molecules using in silico virtual
screening was investigated. This work details the development of an in silico virtual
screening approach using the end-pasting site from the quadruplex (TTAGGGT)4 as a
representative pseudo end-pasting site for the K+ 22mer quadruplex.

The software

Surflex and Autodock were used to dock over 6.6 million small molecules to the pseudo
end-pasting site and resulted in the discovery of a novel G-quadruplex binding small
molecule with a completely novel scaffold.

Biophysical testing by spectroscopic and

fluorescence based assays validated our virtual screening approach and demonstrated that
the strategy was predictive and capable of discovering small molecules that bind
quadruplexes specifically by an end-pasting mechanism. Furthermore, four molecular
models were developed demonstrating the interaction of the newly discovered compound
with the guanine tetrad and loop regions of the end-pasting sites present in structures
containing the K+ 22mer. These results suggest that the in silico platform presented here
can be utilized to discover new small molecules that have G-quadruplex binding activity
and may serve as lead compounds for further modification to optimize quadruplex
binding and discriminatory properties.
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CHAPTER VI
CONCLUSIONS

The use of molecular docking and virtual screening has gained widespread use for
the discovery of novel small molecules for targeting proteins.

However, these

computational approaches have historically neglected the targeting of nucleic acid
structures. With the increase in the understanding of nucleic acid structure and in vivo
function, nucleic acids have garnered increased attention as relevant and good targets.
This is particularly true of the G-quadruplex nucleic acids which can inhibit telomerase
activity in vivo and decrease cancer cell proliferation. While small molecules have been
discovered that bind to G-quadruplexes, many such as TmPyP4 suffer from poor
selectivity and bind to many other nucleic acid structures. With the general landscape of
"druggable" targets expanding to include nucleic acids such as the G-quadruplexes, there
is a critical need to determine if computational resources can be utilized and customized
for the discovery of new small molecules that interact with nucleic acid targets
selectively and by a known binding mechanism.
The initial goal of this research was determining if the docking software
Autodock and Surflex can be used for targeting nucleic acids.

We demonstrated

conclusively in Chapter II that both software packages can accomplish this goal. The
next focus was to determine if in silica rules can be developed to predict the mechanism
of action and structural selectivity of small molecules that are known to
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interact with nucleic acids.

The answer was affirmative, and in silico rules for

distinguishing intercalator from groove binders were obtained. This was largely based on
the rationalization of known competition dialysis binding data of several sets of small
molecules to an array of heterogeneous nucleic acid structures. Finally, the knowledge
from this early work was utilized for the discovery of novel triplex and quadruplex
binding compounds that may have in vivo significance.

Importantly, the predicted in

silico binding behavior of the newly discovered triplex and quadruplex binding
compounds was rigorously validated using a combination of spectroscopic, calorimetric
and thermodynamic assays. This demonstrates the practical application of the research
that is described in this work. This work also provides, for perhaps the first time, an
integrated, computational and experimental platform for drug discovery for nucleic acids.
The first set of experiments involved the validation of the molecular docking
software Autodock and Surflex for targeting nucleic acid structures.

This was

accomplished by selecting several minor groove binders (distamycin and pentamidine)
and intercalators (daunorubicin and ellipticine) as these ligands have solved in silico
nucleic acid - ligand structures. Using molecular docking techniques, the software were
found to be able to successfully reproduce the in silico complexes to a high degree of
accuracy.

Surflex was discovered to be of comparable accuracy to Autodock but

approximately an order of magnitude faster for the molecular docking experiments,
which made this software particularly relevant for virtual screening applications. The
"optimal" software parameters for virtual screening were determined which served as the
basis for the use of these software for the remaining work in this dissertation.
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After the establishment of the feasibility of using Autodock and Surflex to target
nucleic acids, the next focus was on whether in silica rules could be developed to
specifically predict the mechanism of action and nucleic acid sequence and structural
selectivity of small molecules. Using the four small molecules from the initial validation
study (daunorubicin, distamycin, ellipticine and pentamidine), molecular docking
experiments were performed for each of the small molecules against an in silica array of
nucleic acids. Based on these results, in silica metrics were developed for Autodock and
Surflex to classify each of the small molecules on the basis of their binding mechanism
(groove binder or intercalator) and nucleic acid structural and sequence preference. The
in silica rules were further tested and validated on multiple triplex and quadruplex
binding compounds that our lab has discovered as well as an extensive 67 compound
library set of compounds for which detailed competition dialysis data exists using the
identical array of nucleic acids used for the in silica molecular docking experiments. The
results supported the use of the metrics for generally successfully predicting the
mechanism of action of ligand. Prediction of sequence and structural selectivity of the
small molecules generally appeared to be more challenging, especially for some of the
larger molecules that were tested.
The development of the in silica metrics set the stage for application of the
metrics

III

large scale virtual screening experiments for the discovery of new small

molecules that can target physiologically significant nucleic acid structures. A combined
ligand and structure based virtual screening approach was utilized for the discovery of
novel triplex binding small molecules. After screening several million small molecules
and applying the in silica metrics, two small molecules were tested using a combination
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of biophysical techniques and were demonstrated to bind selectively to the triplex
structure, as predicted by the in silico screen. These findings were a critical validation of
the use of the in silico metrics for the discovery of new scaffolds of ligands that may have
therapeutic value.
Finally, the last set of experiments describes the use of structure-based molecular
docking approaches to identify new quadruplex binding small molecules.

Over 6.6

million small molecules were docked into a quadruplex end-pasting site that we
hypothesized to be structurally representative of the end-pasting site of the human
telomeric G-quadruplex AGGG(TTAGGGk A rank-by-rank consensus scoring function
was used to re-rank the top hits from both Autodock and Surflex into a single top hit list.
A single novel compound was discovered to bind to the human telomeric quadruplex by
the in silico hypothesized end-pasting mechanism using a combination of biophysical
techniques.

This compound has a scaffold unlike any reported to date in the literature

and represents a good lead for future derivatization experiments to further optimize the
binding behavior of the compound.
The work presented has laid the foundation for future research investigating how
small molecules interact with nucleic acids. We envision several areas in which this
research can be well utilized.

While the initial focus of this research was on the

prediction of binding behavior of "pure" groove binders or classical intercalators, we
believe this research can be extended to the field of "non-classical" intercalators, which
are typified structurally by unfused polyaromatic ring systems and consist of a mixedmode action with both groove binding and intercalation character. Compounds that bind
by "non-classical intercalation" have garnered great interest recently because of their
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prevalence in the phannaceutical industry. In fact, it was recently detennined that as
many as 26 out of 50 currently marketed drugs demonstrated surprising clastogenicity
and these compounds were surprisingly mutagenic. This may be partly ascribed to the
majority of these ligands having atypical, non-standard intercalator structures [223].
While there is software including DEREK, TOPKAT and MeASE that is used to
estimate the toxicity of phannaceutical compounds, these software have been largely
unsuccessful at predicting the toxicity of non-classical intercalators [223]. It would be
particularly valuable to extend the work perfonned here to the field of non-classical
intercalators to detennine if this binding mechanism can also be predicted by in silico
based approaches.
The research here also has particular additional relevance in the field of
quadruplex nucleic acids. A logical extension of our work is to develop metrics that can
be used to discover small molecules that selectively discriminate between various
quadruplex structures. Finding small molecules that can selectively bind to a specific Gquadruplex morphology has largely been elusive in the literature. The development of
targeted metrics for predicting this behavior could be immensely powerful as virtual
screening could potentially be used to identify new scaffolds of ligands that bind to a
quadruplex of interest.
The research presented investigates the prediction of small molecule -nucleic acid
interactions by in silico molecular docking and metric development.

A unique facet of

the work is the empirical validation of the in silico results using a number of
spectroscopic, calorimetric and other techniques.

This emphasizes that the work as

described here has practical applications for the clinical discovery of new small

321

molecules with therapeutic indications. There continues to be an increasing need to find
new drugs to treat many types of disease. The research as outlined here provides a novel
approach to discover small molecules to meet this need.
The combined approach of virtual screening and empirical validation of hits
continues to identify many compounds with medicinal benefit. Our most recent work and
our current focus is on investigating the potential anti-cancer properties of over 20
compounds that we have recently identified. Preliminary testing of these compounds has
demonstrated that all of these compounds bind to the K+ 22 mer human telomeric
quadruplex and several compounds significantly stabilize the quadruplex, suggesting they
may also inhibit telomerase and suppress tumor cell growth. The labs of Drs Trent and
Chaires are now focused on rigorously testing these hits using a combination of
spectroscopic, calorimetric and other biophysical techniques as well as multiple assays to
measure cellular inhibition of telomerase (TRAP assay) and tumor cell proliferation
(MTT assay). This is a practical application of our research and demonstrates that the
integrated discovery and testing strategy we described here has led to the discovery of
multiple novel small molecules with possible anti-cancer activity.
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